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ABSTRACT 
The development and validation of accurate and reliable analytical methods using 
techniques such as capillary electrophoresis, liquid chromatography, UV-spectrophotometry, 
spectrofluorimetry and mass spectrometry for separation and determination of some selected 
drugs in different matrices are presented in the first three chapters.  The developed methods were 
applied to the determination of these compounds in their dosage forms and/or in biological fluids 
such as human plasma. The stability indicating characteristics including the analysis and 
separation of certain drugs from their alkaline, acidic, oxidative, thermal or photolytic 
degradation products along with the study of the degradation kinetics were also investigated. The 
first chapter focuses on the liquid chromatographic methods and the second chapter covers the 
capillary electrophoretic methods whereas the third chapter includes the UV-spectrophotometric 
and spectrofluorimetric methods. On the other hand, the fourth chapter shows how functionalized 
silica nanoparticles can be used in achieving enhanced electrophoretic separations of selected 
groups of acidic and basic drugs. Finally, the fifth chapter of this dissertation presents a library of 
fluorescently labeled-silica nanoparticles that can be used in certain hydrophobicity-based 
detection applications such as fingerprint detection. 
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1 SEPARATION AND DETERMINATION OF SELECTED PHARMACEUTICAL 
COMPOUNDS USING LIQUID CHROMATOGRAPHY 
1.1 Introduction 
Mechanism of action for the majority of the approved drugs in the market are mediated in 
one way or another through affecting the normal biological function of some endogenous 
peptides such as angiotensinogen, angiotensin I, angiotensin II, renin or biogenic amines such as 
noradrenaline, serotonin, histamine…etc. Some examples of these drug classes include protease 
inhibitors, angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, renin 
inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, signal transduction inhibitors (protein 
tyrosine kinase inhibitors), incretin hormone glucagon-like peptide-1 (GLP-1) agonists, α 
agonists, α blockers, β agonists, β blockers, some antidepressants, some antipsychotics, some 
anti-parkinsonism, antihistaminics and H1 receptor antagonists 1. Therefore, it is important to 
develop and apply precise, accurate and advanced analytical techniques including capillary 
electrophoresis, liquid chromatography, spectrophotometry, spectrofluorimetry and mass 
spectrometry for determination of drugs such as valsartan, azilsartan moexipril and aliskiren 
hemifumarate that affect endogenous peptides as well as drugs affecting biogenic amines such as 
atenolol in different matrices including dosage forms and biological fluids.  
It proved useful for elucidating the stability indicating characteristics of some of these 
methods.  In addition, these developed methods were validated according to the proper validation 
guidelines. 
High-pressure (high-performance) liquid chromatography (HPLC) is a separation 
technique based on a liquid or solid stationary phase and a liquid mobile phase. Depending upon 
the type of stationary phase used, separations are achieved by adsorption, partitioning, or ion-
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exchange processes. The elution time of a compound is better to be described by the capacity 
factor K', which depends on the nature of the analyte, the mobile phase composition, and the 
surface area and structure of the stationary phase. Only compounds holding different capacity 
factors can be separated by HPLC. Column length is also an important determinant of resolution.  
2. 
Based on sales volumes and the scientific importance of HPLC, this is the most popular 
analytical method. Its present popularity results from its effective separation of a wide range of 
samples, ease of use, speed, and nanomolar detection levels 3. 
Five major types of HPLC can be mentioned based on its purposes: normal phase 
chromatography, reversed phase chromatography, size exclusion chromatography, ion exchange 
chromatography and bioaffinity chromatography. Reversed phase HPLC (RP-HPLC) consists of 
an aqueous, moderately polar mobile phase and a non-polar stationary phase. Silica is a common 
stationary phase which was treated with RMe2SiCl, where R is a straight chain alkyl group such 
as C8H17 or C18H37. The retention time is therefore longer for non-polar molecules, allowing 
polar molecules to elute faster. Retention time is decreased by the addition of a hydrophobic 
solvent to the mobile phase and increased by the addition of a more polar solvent 4.  
Structural features of the analyte molecule play a crucial role in its retention behavior. In 
general, an analyte with a more hydrophobic nature results in a longer retention time as it 
increases the molecule's non-polar surface area, which interacts less with the polar component of 
the mobile phase. On the other hand, polar groups result in a shorter retention time as they 
interact well with water. Very large molecules, however, can result in a poor interaction between 
the ligands alkyl chains and the large analyte surface, and can have problems accessing the pores 
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of the stationary phase. Branched chain compounds elute faster than their corresponding linear 
isomers because the overall surface area is lower 3. 
Different applications of HPLC on the analysis of drugs in dosage forms and biological 
matrices have been investigated extensively. The applications of HPLC in the field of 
pharmaceutical analysis are expected to continue to grow mainly supported by the recent 
advances in instrumentations. Improvements made in HPLC include changes in packing 
material, hyphenated detection systems, automation, and computer-assisted optimization. These 
improvements facilitate its introduction into high assay volume situations such as clinical 
laboratories and quality control 5-9. 
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1.2 Stability-Indicating RP-LC Method for Determination of Azilsartan medoxomil and 
Chlorthalidone in Pharmaceutical Dosage Forms: Application to Degradation 
Kinetics 
Copyright © Springer-Verlag Berlin Heidelberg 2014 
Analytical and Bioanalytical Chemistry (2014) 406:6701–6712 
DOI 10.1007/s00216-014-8085-0 
 
A RP-LC method was developed and validated for simultaneous determination of the 
active components, azilsartan medoxomil (AZL) and chlorthalidone (CLT), in their 
antihypertensive combined recipe. The chromatographic separation was achieved on Eclipse 
XDB-C18 (4.6 x 150 mm, 5 µm) column using a mobile phase consisting of methanol: 
potassium hydrogen phosphate buffer (pH 8, 0.05 M) (40:60, v/v) in isocratic mode. The flow 
rate was maintained at 0.8 mL min-1 at ambient temperature. Detection was carried out at 210 
nm.  The method was validated according to ICH guidelines. Linearity, accuracy and precision 
were satisfactory over the concentration range of 5.0–50.0 and 2.5-25.0 µg mL-1 for AZL and 
CLT, respectively (r2 = 0.9999). LODs for AZL and CLT were 0.90 and 0.32 µg mL-1 whereas 
LOQs were 2.72 and 0.98 µg mL-1, respectively. Both drugs were subjected to forced 
degradation studies under hydrolysis (neutral, acidic and alkaline), oxidative and photolytic 
extensive stress conditions. The proposed method is stability-indicating by the resolution of the 
investigated drugs from their degradation products. Moreover, the kinetics of the acidic 
degradation of AZL as well as the kinetics of the alkaline degradation of CLT were investigated. 
Arrhenius plots were constructed and the apparent first-order rate constants, half-life times, 
shelf-life times and the activation energies of the degradation processes were calculated. The 
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method was successfully applied for the determination of the studied drugs simultaneously in 
their co-formulated tablet. The developed method is specific and stability indicating for the 
quality control and routine analysis of the cited medications in their pharmaceutical preparations.   
1.2.1 Introduction 
Azilsartan medoxomil (AZL), is chemically designated as ((5-Methyl-2-oxo-1,3-dioxol-
4yl) methyl 2-ethoxy-1-((2`-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl)-
1H-benzimidazole-7-carboxylate), (Fig. 1.2.1a). Azilsartan, the active metabolite of AZL, is a 
novel non-peptide angiotensin II type 1 (AT1) receptor blocker (ARB), was recently approved for 
treatment of hypertension 10. It has a superior ability to control systolic blood pressure relative to 
other widely used ARBs. Greater antihypertensive effects of AZL might be due in part to its 
unusually potent and persistent ability to inhibit binding of angiotensin II to AT1 receptors 
11. 
Preclinical studies have indicated that AZL may also benefit cellular mechanisms of cardio-
metabolic disease and insulin sensitizing activity 12. There is only one reported method 13 for 
determination of AZL alone and it was applied to its analysis in plasma. Chlorthalidone (CLT), 
(2-chloro-5- (1-hydroxy-3-oxoiso-indolin-1-yl) benzenesulfonamide), (Fig. 1.2.1b), is an orally 
taken thiazide-like diuretic for controlling hypertension and edema, including that associated 
with heart failure 14. CLT has been determined in different matrices either alone or in 
combination with other medications using LC 15, 16, LC-MS/MS 17, HPTLC 18, 19, 
chemiluminometry 20, spectrophotometry 21 and CE 22 techniques.  Binary combination therapies 
of AZL and CLT  proved to induce significant reductions in systolic and diastolic blood pressure 
in patients with mild to severe hypertension 23. Regarding simultaneous determination of CLT 
and AZL, there is only one LC reported method  24, done on a symmetry C18 column with a 
mobile phase consisting of methanol: Water: Acetonitrile: 0.1% o-phosphoric acid (30:35:15:5, 
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v/v/v/v) at λ of 251 nm.  To the best of our knowledge, the present study is the first reported 
stability-indicating LC method for the determination of AZL and CLT in tablets. The parent drug 
stability test guideline Q1A (R2) issued by International Conference of Harmonization (ICH) 25 
suggests that, stress studies should be carried out on a drug to establish its inherent stability 
characteristics. Accordingly, the aim of the present study was to establish the inherent stability of 
AZL and CLT through stress studies under a variety of ICH recommended test conditions, and to 
develop the first stability-indicating assay method for their determination in their commercially 
available tablets. In the present work, AZL and CLT were subjected to forced degradation 
studies under an extensive stress testing. These studies included the effects of hydrolysis 
(neutral, acidic and alkaline), oxidation and photolysis. The currently developed LC method 
effectively separated the two investigated drugs from their degradation products (DPs). 
Furthermore, the proposed LC method was applied to study the degradation kinetics of AZL and 
CLT under acidic and alkaline degradation stress conditions, respectively. Arrhenius plots were 
constructed and the apparent first-order rate constants, half-life times, shelf-life times and the 
activation energies of the degradation processes were calculated. The described method 
demonstrates its novelty and pros by combining several advantages in one method: the limit of 
detections for AZL and CLT were as low as 0.9 and 0.3 µg mL-1, respectively. The method was 
able to simultaneously determine the two drugs in their pharmaceutical preparation. Moreover, 
the present work was designed to detect and analyze AZL and CLT in presence of their potential 
DPs using a stability indicating accurate, inexpensive and simple procedure. Another added 
advantage of the current method resides in its ability to study the kinetics of degradation 
processes of AZL and CLT which were obtained by subjecting them to acidic and alkaline stress 
conditions, respectively.  
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1.2.2  Experimental 
1.2.2.1  Instruments 
Separations were performed using Agilent HPLC system 1200 chromatograph (USA) 
equipped with a quaternary pump G1311A and a Rheodyne injector valve with a 20 μL loop and 
a G1315D MWD detector. Mobile phases were degassed using a G1322A solvent degasser. 
Agilent Chemstation for LC systems [Rev.B.03.01-SR1 (317)] PC program was used for the 
instrument control, data analysis and acquisition. A SympHonly (SB20) pH-meter (Thermo 
Orion, MA, USA) was used for pH adjustment. Nano pure water was prepared using a Barnstead 
NANO pure DIamond Analytical ultrapure water system (Fischer Scientific, NJ, USA). Fisher 
Biotech UV fluorescent lamp, model FBUVLS-80 dual wavelength (254/366) was used in the 
photo-stability studies (Fisher Scientific, PA, USA). The LC–MS studies was performed using 
an Agilent 1200 ultra-high pressure liquid chromatography system (USA) consisting of a binary 
pump (G1312A) with a degasser, autosampler (G1329A) and a DAD (Agilent 1100, G1315B) 
using a mobile phase composed of water and methanol (20: 80, v/v)   coupled to a 3200 Q TRAP 
mass spectrometer (AB Sciex; CA, USA) fitted with a TurboV ion source operating in negative 
and positive electrospray ionization (ESI) mode. The data were acquired and processed using 
Analyst® 1.6.1 Software (AB Sciex; Ontario, Canada). MS source parameters were set at: 
desolvation temperature (TEM): 200 °C, high voltage: -4500 V (ESI -), 4500 V (ESI +), curtain 
(CUR) and nebuliser (GS1 and GS2) gases: nitrogen; 20, 40, and 50 psi; respectively, nitrogen 
collision gas pressure: 5 mTorr.  
1.2.2.2 Materials and reagents 
All the chemicals used were of Analytical Reagent grade, and the solvents were of HPLC 
grade. AZL (certified to contain 98%) was supplied by D-L Chiral Chemicals, LLC., NJ 08540 
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USA. CLT (certified to contain 98%) was supplied by Ark Pharm. Inc., IL 60048 USA. 
Edarbcyclor® 40-25 mg tablets; batch # NDC 64764-0994-30 (Takeda Pharmaceutical Company 
Limited, Tokyo, Japan) each labeled to contain 42.68 mg of azilsartan kamedoxomil (equivalent 
to 40 mg AZL) and 25 mg CLT were purchased from commercial sources in the local market. 
Sodium hydroxide, potassium hydroxide, acetic acid and dipotassium hydrogen orthophosphate 
were obtained from J.T. Baker, NJ, USA. Orthophosphoric acid 85%, hydrochloric acid and 
ammonium acetate (Fisher Scientific, NJ, USA) were also used. Methanol and hydrogen 
peroxide (30% w/v) (Sigma-Aldrich, MO, USA).  
1.2.2.3 Chromatographic conditions 
A mixture of methanol: dipotassium hydrogen phosphate buffer (PBS) (pH 8±0.1, 
0.05M) (40:60, v/v) was prepared. Flow rate was maintained at 0.8 mL min-1. All analyses were 
performed at ambient temperature. The system was equilibrated and saturated with the mobile 
phase for 30 min before the injection of the solutions. Quantification was achieved with UV 
detection at 210 nm based on peak area. Twenty L of the solutions were injected with a 50 l 
Agilent analytical syringe in triplicates. 
1.2.2.4  Standard solutions 
Ten mg of each of AZL and CLT were accurately weighed and transferred in to 10 mL 
volumetric flasks separately. Then, they were dissolved and made up to volume with methanol to 
give final concentrations of 1000 g mL-1 for each. The solutions were stable for at least 14 days 
without alteration when kept in the refrigerator at 4 ◦C and protected from light. 
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1.2.2.5 Procedures 
1.2.2.5.1 Construction of the calibration graphs 
Accurate aliquots from the standard solutions were transferred separately into a series of 
10 mL Fisherbrand disposable tubes. Then, the volumes were completed to the mark with the 
mobile phase so that the final concentrations were in the range of 5.0-50.0 and 2.5-25.0 µg mL-1 
for AZL and CLT, respectively. Aliquots of 20 µL were injected (triplicate) and eluted with the 
mobile phase under the optimum chromatographic conditions using UV detection at 210 nm. The 
average peak area versus the final concentration of the drug in µg mL-1 was plotted. 
Alternatively, the corresponding regression equations were derived. 
1.2.2.5.2 Preparation of the laboratory prepared mixtures 
Accurate aliquots of AZL and CLT standard solutions were transferred into a series of 10 
mL Fisherbrand disposable tubes keeping the medicinally recommended ratio of 1.6:1 for 
AZL/CLT mixture to give final concentrations of 8, 16, 24 µg mL-1 for AZL and 5, 10, 15 µg 
mL-1 for CLT. The above procedure described under “section 2.5.1” was then applied. The 
recovery percentage was calculated using the corresponding regression equation. 
1.2.2.5.3 Analysis of the studied drugs in their pharmaceutical preparation 
Ten tablets of Edarbcyclor® 40-25mg were weighed, finely pulverized and thoroughly 
mixed. After calculating the average tablet weight, amounts of powder equivalent to 40 and 25 
mg of AZL and CLT, respectively, were accurately weighed and transferred into a 25 mL 
measuring flask. Twenty milliliters of methanol were added and the solution was sonicated for 
30 min then completed to volume with the same solvent. The solution was filtered through a 
Whatman filter paper and then filtered again using 0.2µm a Whatman inorganic membrane filter. 
For analyses, different aliquots from the prepared sample solutions were chromatographed using 
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the same procedure described under “section 2.5.1”. The recovery percentage was calculated by 
referring to the corresponding regression equations. 
1.2.2.5.4 Procedures for the extensive stress stability studies 
1.2.2.5.4.1 Stress degradation by hydrolysis under acidic and alkaline conditions 
Aliquots of AZL and CLT standard solutions equivalent to 500 and 400 μg, respectively, 
were transferred separately into Fischerbrand disposable tubes; treated with 2 mL of 0.1 M 
NaOH or 0.1M HCl and heated at 80 and 100 oC for 1 h, respectively. After the specified time, 
the contents of each tube were cooled and neutralized to pH 7.0 with 0.1 M HCl or 0.1 M NaOH, 
respectively. The solutions were then transferred into 10-mL volumetric flasks. Five milliliters 
methanol were added to each flask and completed to the volume with Nano pure water. Two 
milliliters of the resulting solutions were then transferred into Fischerbrand disposable tubes and 
diluted to 4 mL with the mobile phase (final concentrations were 25 and 20 µg mL-1 as 
equivalent to AZL and CLT, respectively, before degradation) and filtered before injection into 
the column. The above procedure described under “section 2.5.1” was then applied. 
1.2.2.5.4.2 Procedure for oxidative and wet heat induced degradations 
Aliquots of AZL and CLT standard solutions equivalent to 500 and 400 μg, respectively, 
were transferred separately into Fischerbrand disposable tubes; 2 mL aliquots of 6% H2O2 or 
Nano pure water were added and heated at 80 and 100 oC for 1 h for AZL and CLT, respectively. 
After the specified time, the resulting solution was cooled and transferred into 10-mL volumetric 
flasks. Five milliliters methanol were added to each flask and completed to the volume with 
Nano pure water. Two milliliters of the resulting solutions were then transferred into 
Fischerbrand disposable tubes and diluted to 4 mL with the mobile phase (final concentrations 
were 25 and 20 µg mL-1 as equivalent to AZL and CLT, respectively, before degradation) and 
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filtered before injection into the column. The above procedure described under “section 2.5.1” 
was then applied. 
1.2.2.5.4.3 Procedure for photolytic degradation 
The photo degradation study was performed by subjecting 4 mL from each of AZL (100 
μg mL-1) and CLT (80 μg mL-1), prepared in methanol and placed in 1-cm stoppered quartz cells 
to direct UV radiation (UV lamp set at 254 nm) at room temperature for 24 h at a distance of 10 
cm. Protected samples, wrapped in aluminum foil in order to protect them from light, were 
submitted to identical conditions and used as control.  One milliliter of the resulting solutions 
were then transferred into Fischerbrand disposable tubes and diluted to 4 mL with the mobile 
phase (final concentrations 25 and 20 µg mL-1 as equivalent to AZL and CLT, respectively, 
before degradation) and filtered before injection into the column. The above procedure described 
under “section 2.5.1” was then applied. 
1.2.2.5.5 Kinetics investigation 
1.2.2.5.5.1 Study of the acidic induced degradation of AZL at different temperatures 
Aliquots of AZL standard solution (equivalent to 500 μg) were transferred into 
Fischerbrand disposable tubes. Two milliliters of 0.1 M HCl were added for each tube. The tubes 
were heated at different temperatures (50, 60, 70, 80 oC) for different time intervals (15–60 min). 
At the specified time interval, the contents of each tube were cooled and neutralized to pH 7.0 
with 0.1 M NaOH. The solutions were then transferred into 10-mL volumetric flasks. Five 
milliliters methanol were added to each flask and completed to the volume with Nano pure 
water. Two milliliters of the resulting solutions were then transferred into Fischerbrand 
disposable tubes and diluted to 4 mL with the mobile phase (final concentration was 25 μg mL-1 
as equivalent to AZL before degradation) and filtered before injection into the column. The 
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above procedure described under “section 2.5.1” was then applied. The concentration of the 
remaining drug was calculated for each temperature and time interval. Data were further 
processed and degradation constants were calculated for each temperature to construct the 
Arrhenius plot. An Arrhenius plot was constructed and the apparent first-order rate constants, 
half-life times, shelf-life times and the activation energy of the degradation process were then 
calculated. All solutions were filtered through 0.2 µm membrane filters and degassed for 5 min 
before injection to the LC system. 
1.2.2.5.5.2 Study of the alkaline induced degradation of CLT at different temperatures 
Aliquots of CLT stock solutions (equivalent to 400 μg) were transferred into 
Fischerbrand disposable tubes. Two milliliters of 0.1 M NaOH were added for each tube. The 
tubes were heated at different temperatures (70, 80, 90, 100 oC) for different time intervals (30–
120 min). At the specified time interval, the contents of each tube were cooled and neutralized to 
pH 7.0 with 0.1 M HCl. The solutions were then transferred into 10-mL volumetric flasks. Five 
milliliters methanol were added to each flask and completed to the volume with Nano pure 
water. Two milliliters of the resulting solutions were then transferred into Fischerbrand 
disposable tubes and diluted to 4 mL with the mobile phase (final concentration was 20 μg mL-1 
as equivalent to CLT before degradation) and filtered before injection into the column. The 
above procedure described under “section 2.5.1” was then applied. The concentration of the 
remaining drug was calculated for each temperature and time interval. Data were further 
processed and degradation constants were calculated for each temperature to construct the 
Arrhenius plot. An Arrhenius plot was constructed and the apparent first-order rate constants, 
half-life times, shelf-life times and the activation energy of the degradation process were then 
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calculated. All solutions were filtered through 0.2 µm membrane filters and degassed for 5 min 
before injection to the LC system. 
1.2.3 Results and discussion 
The proposed method permitted the separation and quantitation of the studied drugs in a 
short time <9 min. Furthermore, the suggested procedure was applied for the quality control of 
commercial dosage form (Fig. 1.2.2). The proposed LC method allows the separation of AZL 
and CLT from all possible degradation products. Fig. (1.2.3b-f) as well as (1.2.4b-f) show good 
resolution of AZL and CLT from each of its alkaline, acidic, oxidative, thermal (wet heat) and 
photolytic degradation products, respectively. The stability studies for the acidic degradation 
kinetics of AZL as well as the alkaline degradation kinetics of CLT were successfully conducted. 
1.2.3.1 Optimization of experimental conditions 
Several trials were carried out to achieve the best chromatographic conditions for the 
simultaneous determination of AZL and CLT as well as their separation from their degradation 
products. Three columns were tested for performance investigation, including: Ultrasphere ODS 
column (4.6 mm ×250 mm, 5 μm particle size), Beckman, Fullerton, CA, USA, Eclipse XDB-
C18 column (4.6 x 150mm, 5 µm) Agilent, East Windsor, NJ, USA and Spherex 10 phenyl 
column (250 mm x 2.0 mm i.d.), Phenomenex, CA, USA. The experimental studies revealed 
that, the second column was the most suitable one since it produced symmetrical peaks with high 
resolution and within a reasonable analytical run time. AZL is practically insoluble in water, 
freely soluble in methanol, dimethylsulfoxide, soluble in acetic acid, slightly soluble in acetone, 
and acetonitrile and sparingly soluble in tetrahydrofuran and 1-octanol 13. Methanol and 
acetonitrile were examined as the organic modifiers and acetonitrile was found to cause splitting 
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for the peak of AZL due to its poor solubility in that solvent so methanol was chosen as the 
organic modifier in this study. Water, 1% acetic acid, ammonium acetate buffer (pH 5.5; 0.05 M) 
and PBS (pH 8; 0.05 M) were tested as the aqueous component in the mobile phase. The use of 
buffer is necessary in this method in order to enhance the ionization of the analytes, obtain 
proper separation and increase the sharpness of peaks. Both ammonium acetate buffer and PBS 
are able to achieve proper separation. PBS was selected as it was able to produce sharper and 
more symmetric peaks than ammonium acetate buffer. Then, effect of pH on the separation of 
the analytes was studied. The higher the pH of the used buffer the lower the retention time with 
sharp and symmetric peak for AZL so pH 8 was selected as it achieved satisfactory separation at 
a reasonable run time (<9 min) and with satisfactory resolution between all of the analytes, (Fig. 
1.2.2). Ratio of aqueous to organic component in the mobile phase system was also studied and a 
ratio of (60:40, v/v) was selected.  Increasing the ratio of the aqueous component will produce 
significant delay and broadening of peaks meanwhile increasing the ratio of the organic 
component will cause overlap between the studied analytes. Different flow rates were studied as 
it affects both resolution and shape of peaks and flow rate of 0.8 mL min-1 was selected. Proper 
choice of the detection wavelength is crucial for sensitivity of the method. Quantitation was 
achieved with UV-detection at 210 nm based on good peak area for each of the analyzed drugs. 
System suitability tests were used to verify that the conditions of the chromatographic system 
were adequate for the separation and hence for the analysis 26, (Table 1.2.1).  
1.2.3.2  Method validation 
The validity of the proposed LC method was assessed according to ICH guidelines in 
terms of linearity, range, limit of detection, limit of quantification, accuracy, precision, 
robustness, specificity and stability 26.  
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1.2.3.2.1 Linearity and range 
Under the above described experimental conditions, linear relationships were established 
by plotting the peak area versus the corresponding concentration in μg mL-1. The graphs were 
found to be rectilinear over the concentration ranges cited in table 1.2.2. Statistical analysis of 
the data gave high value of the correlation coefficient (r) of the regression equation, small values 
of the standard deviation of residuals (Sy/x), of intercept (Sa), and of slope (Sb), and small value 
of the percentage relative standard deviation and the percentage relative error, (Table 1.2.2). 
These data indicated the linearity of the calibration graphs. 
1.2.3.2.2 Limit of quantitation (LOQ) and limit of detection (LOD) 
 LOQs and LODs were calculated according to ICH Q2 (R1) recommendations using the 
following equation 26:  LOQ = 10 Sa /b and LOD = 3.3 Sa /b, where Sa = standard deviation of the 
intercept and b = slope of the calibration curve. Results are given in (Table 1.2.2).  
1.2.3.2.3 Accuracy and precision 
The satisfactory recovery results for the assay of AZL and CLT in their laboratory 
prepared mixtures indicate the accuracy of the method, (Table 1.2.3). Repeatability (intraday) 
and intermediate precision (inter-day) were assessed using three concentrations and three 
replicates of each concentration. The relative standard deviations were found to be very small 
indicating reasonable repeatability and intermediate precision of the proposed method (Table 
1.2.4).   
1.2.3.2.4 Stability of standard solutions and mobile phase 
Stability of the standard solutions of AZL and CLT stored at 4 ◦C, were evaluated at 
various time points over one month. The concentrations of freshly prepared solutions and those 
aged for one month were calculated by the method developed and the difference between them 
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was found to be non-significant (% RSD <2%). Similarly, the stability of the mobile phase was 
checked for two weeks. The results obtained in both cases proved that the samples solutions and 
mobile phase used during the assay were stable for the specified durations, when kept in the 
refrigerator at 4 ◦C. 
1.2.3.2.5 Robustness of the method 
Minor deliberate changes in different experimental parameters such as flow rate (±0.1 
mL min-1), pH (±0.1) and ratio of mobile phase components (±2%) did not significantly affect 
resolution of the analyzed compounds indicating that the proposed method is robust, (Table 
1.2.5). 
1.2.3.2.6 Specificity 
 The specificity is the ability of the analytical method to assess unequivocally the analyte 
in the presence of components which may be expected to be present. The specificity of the 
method was investigated by observing any interference encountered from common tablet 
excipients and it was confirmed that the signals measured was caused only by the analytes. The 
inactive ingredients in Edarbcylor® are: mannitol, microcrystalline cellulose, fumaric acid, 
sodium hydroxide, hydroxypropyl cellulose, crospovidone, magnesium stearate, hypromellose 
2910, talc, titanium dioxide, ferric oxide red, polyethylene glycol 8000, and printing ink gray F1. 
It was found that the excipients did not interfere with the results of the proposed method. As 
shown in (Fig. 1.2.2) the chromatograms of the combined formulations did not show any 
additional peaks when compared with the chromatograms of the laboratory prepared mixtures 
which confirm the specificity of the developed method. Specificity of the method was also 
confirmed by its ability to measure AZL and CLT in the presence of all of their degradation 
products, as revealed by the results of the stability study (Fig. 1.2.3b–3f and 1.2.4b-4e).  
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1.2.3.3 Application of the proposed method for quality control of AZL and CLT in their 
combined commercial dosage form 
The proposed method was applied to determine AZL and CLT in their commercially 
available tablets. Satisfactory recoveries were obtained and the results are given in (Table 1.2.3).  
1.2.3.4 Forced degradation studies 
AZL and CLT were subjected to forced decomposition by alkali, acidic, wet heat, light 
and oxidation, as suggested in the International Conference on Harmonization (ICH) Q1A (R2) 
and (Q1B) guideline 25, (Fig. 1.2.4). 
1.2.3.4.1 Alkaline Induced Degradation 
AZL showed high stability to alkaline degradation. Only 3.1 % degradation was observed 
as evidenced by the decrease in the parent drug peak area upon the addition of 2 mL 0.1 M 
NaOH to the drug and boiling at 80 oC for 1 h, (Fig. 1.2.3b). On the contrary, CLT was found to 
undergo alkaline degradation very readily after addition of 2 mL 0.1 M NaOH to the drug and 
boiling at 100 oC for 1 h. 69.0 % degradation was observed as evidenced by the decrease in the 
parent drug peak area, and the appearance of two major DPs with peaks at 3.8 min and 4.9 min, 
(Fig. 1.2.4b).  
1.2.3.4.2 Acid induced degradation 
AZL was found to undergo acid degradation very readily upon the addition of 2 mL 0.1 
M HCl to the drug and boiling at 80 oC for 1 h. 94.7 % degradation was observed as evidenced 
by the decrease in the parent drug peak area, (Fig. 1.2.4c) and the appearance of one major DP 
peak at 2.7 min, (Fig. 1.2.3c). On the contrary, CLT was found to show high stability to acidic 
degradation upon the addition of 2 mL 0.1 M HCl to the drug and boiling at 100 oC for 1 h. Only 
3.6 % degradation was observed as evidenced by the decrease in the parent drug peak area, (Fig. 
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1.2.4c). 
1.2.3.4.3 Hydrogen Peroxide and thermal (wet heat) induced degradation: 
Oxidative and thermal (wet heat) degradation of AZL and CLT were also studied. AZL 
was found to show certain stability to oxidative and thermal (wet heat) degradation upon the 
addition of 2 mL of 6% H2O2 or water, respectively, to the drug and boiling at 80 
oC for 1 h. 
Only 19.2 and 2.6 % degradation was observed as evidenced by the decrease in the parent drug 
peak area, (Fig. 1.2.3d, 3e). Also, CLT showed certain stability to oxidative and thermal (wet 
heat) degradation upon the addition of 2 mL of 6% H2O2 or water, respectively, to the drug and 
boiling at 100 oC for 1 h. Only 7.7 and 0.7 % degradation was observed as evidenced by the 
decrease in the parent drug peak area, (Fig. 1.2.4d, 4e).   
1.2.3.4.4 Photolytic degradation 
The effect of UV-light on the stability of AZL and CLT were studied. It was found that 
99.1% and 96.1% degradation was observed after exposure of the drug to 254 nm light for 1 day 
at room temperature, respectively, (Fig. 1.2.3f, 4f).  
1.2.3.5  Identification of the potential acid degradation product for AZL 
As shown in scheme 1.2.1, the LC-MS total ion chromatograms (negative mode) for the 
intact AZL and its acidic induced degradation after 1 h boiling at 80 °C, a predominant DP was 
found to be present with a molecular ion at m/z 539. It is postulated that the drug degraded 
through cleavage of the ether linkage attached to the benzodiazole moiety. This DP showed a 
fragment at m/z 427 due to cleavage of the ester bond. Then, further fragmentation occurred 
through opening of the oxadiazole ring and losing CO2 molecule to give a fragment at m/z 383. 
This anticipation was supported by the disappearance of the peaks at δ= 1.3 and 4.6 of the ethyl 
group in the 1H NMR spectrum (400 MHz, DMSO) of AZL DP and by the appearance of new 
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peaks at δ= 5.5 and 11.4 of the resonating iminol group in the benzdiazole ring. 
1.2.3.6 Identification of the potential alkaline degradation product for CLT 
The LC-MS total ion chromatogram (negative mode) for the intact CLT and its alkaline 
degradation after 1 h boiling at 100 °C revealed some distinguishable molecular ion peaks at m/z 
375, 339, 356, 294 and 258 from that of the ion chromatogram of the intact drug. Also, it showed 
many peaks for dimer adducts. As demonstrated in scheme 1.2.2, we have two anticipated 
pathways for the alkaline induced degradation of CLT. The first one is through hydrolytic 
cleavage of the amide bond in the isoindole ring with a molecular ion at m/z 356 followed by 
removal of the ammonia group to form a stable benzophenone derivative with m/z at 339. 
Further fragmentation of that DP was proposed to be via decarboxylation to give a fragment at 
m/z 294. The second pathway is through direct opening of the isoindole ring to form amido 
benzophenone derivative at m/z 339. Further fragmentation of that DP was through removal of 
sulphonamide moiety to form a fragment at m/z 258. The second anticipated pathway was 
supported by the disappearance of the peaks at δ= 8.1 and 9.4 of the hydroxyl and the secondary 
amino groups in the 1H NMR spectrum (400 MHz, DMSO) of CLT DP and by the appearance of 
a new peak at δ= 6.1 of the amide group. 
1.2.3.7 Degradation kinetics for AZL and CLT 
The experimental investigation of the possible breakdown of the drugs is usually studied 
to produce more stable preparations and to assist the pharmacists and physicians regarding the 
proper storage and handling of the medicinal agents. Degradation reaction rates are affected by 
temperature, as suggested by the Arrhenius equation 27: 
𝐿𝑜𝑔 𝐾 = 𝐿𝑜𝑔 𝐴 −
𝐸𝑎
2.303
 
1
𝑅𝑇
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Where:  K = specific reaction rate at temperature T, A = Arrhenius factor (collision 
factor) constant, Ea = energy of activation (the minimum kinetic energy a molecule must possess 
in order to undergo reaction), R = gas constant, and T = absolute temperature in Kelvin.   
In this study, the constant A and Ea were evaluated by determining K for the acid 
degradation of 25 µg mL-1 of AZL in 0.1 M HCl at different temperatures (50, 60, 70, and 80 oC) 
as well as for the alkaline degradation of 20 µg mL-1 of CLT in 0.1 M NaOH at different 
temperatures (70, 80, 90, and 100 oC). As shown in Fig. 1.2.5 the degradation was found to be 
temperature dependent. 
The apparent first order degradation rate constant, half-life time (t1/2), shelf-life (t90) and 
the activation energy Ea were calculated (Table 1.2.6). By plotting log Kobs values versus 1/T, 
Arrhenius plot was obtained (Fig. 1.2.6) and the resulting lines were extrapolated at room 
temperature to obtain 𝐾25
𝑜 , which is used as a measure of the stability of the drug under ordinary 
shelf conditions. Arrhenius equations 27 were found to be: (Log K = 11.482 + 4.5441 x 103/T) 
for AZL as well as  (Log K = 10.235 + 4.4562 x 103/T) for CLT. Where; K is the specific 
reaction rate, T is the absolute temperature. 
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Table 1.2.1 System Suitability data for the RP-LC Method 
Item AZL CLT 
N 4422 4185 
K` 2.63 1.89 
T 1.19 1.22 
R 3.88 
α 1.26 
(N: number of theoretical plates; K`: capacity factor; R: resolution factor; T: tailing factor; : 
relative retention time) 
 
 
 
Table 1.2.2 Characteristics and Results of the Proposed RP-LC Method 
Item AZL CLT 
Limit of detection, LOD (µg mL-1) 0.90 0.32 
Limit of quantitation, LOQ (µg mL-1) 2.72 0.98 
Intercept (a) -189.71 -72.54 
Slope (b) 175.78 193.75 
Correlation coefficient (r) 0.9999 0.9999 
S.D. of residuals (Sy/x) 61.09 24.24 
S.D. of intercept (Sa) 47.84 18.99 
S.D. of slope (Sb) 1.71 1.36 
 % Error 1.02 0.83 
% RSD 2.27 1.86 
Linearity range (µg/mL) 5.00-50.00 2.50-25.00 
Mean %recovery ± S.D. 100.83 ± 2.29 99.48 ± 1.85 
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Table 1.2.3 Assay results for the determination of the studied drugs in their laboratory prepared 
mixtures and dosage forms 
Ratio Compound Laboratory prepared mixtures Dosage form 
  
Amount 
taken 
(g mL-1) 
Amount 
found 
(g mL-1) 
% 
Found 
 
Amount 
taken 
(g mL-1) 
Amount 
found 
(g mL-1) 
% 
Found 
(A
Z
L
:C
L
T
) 
(1
.6
:1
.0
) 
AZL 8.00 8.10 101.25 8.00 8.22 102.75 
 16.00 15.98 99.88 16.00 16.19 101.19 
 24.00 23.93 99.71 24.00 24.10 100.42 
Mean 
recovery% 
  100.28   101.45 
± %RSD   0.84   1.17 
       
CLT 5.00 5.04 100.80 5.00 5.06 101.20 
 10.00 10.03 100.30 10.00 9.99 99.90 
 15.00 14.60 97.33 15.00 15.28 101.87 
Mean 
recovery% 
 
  99.48   100.99 
± %RSD   1.88   0.99 
Each result is the average of three separate determinations.  
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Table 1.2.4 Assay results for the determination of the studied drugs in their laboratory prepared 
mixtures and dosage forms 
AZL CLT 
Conc. of 
AZL (g mL-1) 
Intra-day 
assay 
Inter-day 
assay Conc. of 
CLT (g mL-1) 
Intra-day 
assay 
Inter-day 
assay 
Recovery % ± 
%RSD a 
Recovery % ± 
%RSD a 
Recovery % ± 
%RSD a 
Recovery % ± 
%RSD a 
12.50 100.48 ± 0.96 101.50 ± 1.25 7.50 100.65 ± 0.75 101.59 ± 0.88 
25.00 98.87 ± 1.22 100.17 ± 1.25 12.50 98.67 ± 1.08 99.61 ± 1.75 
40.00 100.32 ± 0.94 101.55 ± 1.05 20.00 98.12 ± 0.61 99.03 ± 0.96 
Mean  
recovery% ± 
%RSD 
99.89 ± 0.89 101.07± 0.77 
Mean  
recovery% ± 
%RSD 
99.15 ± 1.34 100.08± 1.34 
a Mean and relative standard deviation of three determinations 
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Table 1.2.5 Results of the robustness study 
Parameter Drug 
Standard 
Method 
Flow rate  
(mL min-1) 
pH Mobile phase Composition 
0.7 0.9 7.9 8.1 
PBS : Methanol 
(62:38) 
PBS : Methanol 
(58:42) 
Retention time 
(min) 
AZL 7.0 8.1 6.4 7.3 6.8 5.7 8.8 
CLT 5.6 6.4 5.0 5.7 5.5 4.8 6.5 
Resolution CLT/AZL 3.7 3.8 3.7 3.9 3.7 2.7 4.9 
 
 
Table 1.2.6 Kinetics data of AZL and CLT degradation 
Drug Temperature (°C) K x 10-4 (min-1) t1/2 (min) t90 (min) Ea (k cal mol-1) 
A
Z
L
 i
n
 0
.1
N
 H
C
l 
50 27.64 250.8   
60 89.82 77.2   
70 158.91 43.6   
80 476.72 14.5   
Value at 25 °C 1.96 - 537.8 35.34 
      
C
L
T
 i
n
 0
.1
N
 N
aO
H
 
70 16.12 429.9   
80 55.27 125.4   
90 115.15 60.2   
100 177.33 39.1   
Value at 25 °C 0.22 - 4834.9 20.39 
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Figure 1.2.1 The structural formulae of the studied drugs; (a) azilsartan medoxomil (AZL), and 
(b) chlorthalidone (CLT) 
 
 
 
 
 
Figure 1.2.2 A typical LC chromatogram for Edarbcyclor® tablets: 24 µg mL-1 AZL (6.9 min), 
and 15 µg mL-1 of CLT (5.5 min) under the descried chromatographic conditions 
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Figure 1.2.3 LC chromatograms of 25 µg mL-1 AZL under different stress degradation 
conditions: (a) control, (b) alkaline (0.1N NaOH), (c) acidic (0.1N HCl), (d) oxidative (6% H2O2, 
w/v), (e) thermal (wet heat) and (f) photolytic (254 nm) using the described degradation and 
chromatographic conditions 
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Figure 1.2.4 LC chromatograms of 20 µg mL-1 CLT under different stress degradation 
conditions: (a) control, (b) alkaline (0.1N NaOH), (c) acidic (0.1N HCl), (d) oxidative (6% H2O2, 
w/v), (e) thermal (wet heat) and (f) photolytic (254 nm) using the described degradation and 
chromatographic conditions 
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Figure 1.2.5 Percentage of degradation of 25 µg mL-1 of AZL and 20 µg mL-1 of CLT under 
different stress degradation conditions 
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Figure 1.2.6 Effect of different heating times with 0.1 M HCL and 0.1 M NaOH on the rate of 
degradation of (a) AZL (25 µg mL-1) and (b) CLT (20 µg mL-1), respectively 
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Figure 1.2.7 Arrhenius plots for AZL (25 µg mL-1) and CLT (20 µg mL-1) 
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Scheme 1.2.1 Proposed structure for the acid induced degradation product of AZL 
 
 
 
 
Scheme 1.2.2 Proposed structures for the alkaline induced degradation products of CLT  
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A reversed phase high performance liquid chromatography method was developed for 
simultaneous determination of the diuretic, hydrochlorothiazide, along with six drugs 
representing most commonly prescribed antihypertensive pharmacological classes such as 
atenolol, a selective β1 blocker, amlodipine besylate, a calcium channel blocker, moexipril 
hydrochloride, an ACE inhibitor, valsartan and candesartan cilexetil which are angiotensin II 
receptor blockers and aliskiren hemifumarate, a renin inhibitor, using irbesartan as an internal 
standard. The chromatographic separation was achieved using acetonitrile: sodium phosphate 
dibasic buffer (0.02 M, pH 5.5) at a flow rate of 1 mL min-1 in gradient elution mode at ambient 
temperature on a stationary phase composed of Eclipse XDB-C18 (4.6 x 150 mm, 5 µm) column. 
UV detection was carried out at 220 nm. The method was validated according to ICH guidelines. 
Linearity, accuracy and precision were satisfactory over the concentration ranges of 2-40 µg mL-
1 for hydrochlorothiazide and candesartan cilexetil, 20-200, 10-160, 5-40, 20-250 and 5-50 µg 
mL-1 for atenolol, valsartan, moexipril hydrochloride, aliskiren hemifumarate and amlodipine 
besylate, respectively. The method was successfully applied for the determination of each of the 
studied medications in their combined formulations with hydrochlorothiazide. The developed 
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method is suitable for the quality control and routine analysis of the cited drugs in their 
pharmaceutical dosage forms.   
1.3.1 Introduction 
Hydrochlorothiazide (HCZ) is an orally potent diuretic which inhibits active chloride 
reabsorption and thus increases the excretion of sodium chloride and water 28. It is chemically 6-
chloro-1, 1-dichloro-3, 4, dihydro-2H-1, 2, 4-benzoliadiazine-7-sulphanomide1, 1-dioxide 
(Fig.1.3.1a). Atenolol (ATN), (2-[4-[(2RS)-2-hydroxy-3-[(1-methylethyl) amino] propoxy] 
phenyl] acetamide (Fig. 1.3.1b), is a cardioselective β1 blocker used in the management of 
hypertension, angina pectoris, cardiac arrhythmias, and myocardial infarction 29. It may also be 
used in the prophylactic treatment of migraine 30. Valsartan (VAL), (S)-N-valeryl-N-([2'-(1H-
tetrazol-5-yl)biphenyl-4-yl]-methyl)-valine (Fig. 1.3.1c), and candesartan cilexetil (CND), ± (1-
cyclohexyloxycarbonyloxy) ethyl-2-ethoxyl ([20-(1H-tetrazol-5-yl) biphenyl-4-yl]-methyl)-1H-
benzimidazole-7-carboxylate (Fig. 1.3.1d),  are potent, highly selective, and orally active non 
peptide antagonist on AT1-receptor subtype 
31. Angiotensin receptor blockers (ARBs) are a 
major class of antihypertensive therapies due to their powerful lowering effects on blood 
pressure and excellent tolerability. Recent clinical trials have shown the added benefits of ARBs 
in hypertensive patients (reduction in left ventricular hypertrophy, improvement in diastolic 
function, decrease in ventricular arrhythmias, reduction in microalbuminuria, and improvement 
in renal function), and cardioprotective effect in patients with heart failure 32.  Moexipril 
hydrochloride (MXP), (3S)-2-[(2S)-2-{[(1S)-1-(ethoxycarbonyl)-3-phenyl-propyl]amino}-1-
oxopropyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride (Fig. 
1.3.1e), is a new potent orally active non-sulfhydryl angiotensin-converting enzyme (ACE) 
inhibitor for the treatment of hypertension and congestive heart failure 33. Aliskiren 
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hemifumarate (ALS), (2(S), 4(S), 5(S), 7(S)-N-(2-carbamoyl- 2- methylpropyl) -5-amino-4-
hydroxy 2,7 diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy) phenyl] octanamide 
hemifumarate) (Fig 1.3.1f) is the first direct renin inhibitor suitable for oral administration. By 
achieving more complete renin–angiotensin system inhibition, direct renin inhibitors may afford 
greater protection from hypertensive complications 34. Present evidence indicates that ALS 
reduces baseline systolic and diastolic blood pressure and that it is as effective as other first-line 
antihypertensive agents. Extra advantages can be reached when it is used in combination therapy 
34. Amlodipine besylate (AML), (3-Ethyl 5-methyl (4RS)-2-[(2-aminoethoxy)methyl]-4-(2-
chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate) (Fig. 1.3.1g) 
is a long acting dihydropyridine calcium channel blocker that prevents the transmembrane influx 
of calcium ions into vascular smooth muscles and cardiac muscles 35. Also, it is a direct 
peripheral arterial vasodilator that reduces peripheral vascular resistance and hence lowers blood 
pressure 36. Binary combination therapies of HCZ with each of ATN 37, MXP 38 and CND 39 
induce significant reductions in systolic and diastolic BP from in patients with mild to severe 
hypertension. Also, triple combination therapies of ALS, AML and HCZ 40 as well as VAL, 
AML and HCZ 41 proved to be effective and well tolerated in treatment of hypertensive high-risk 
patients. So, it is necessary to develop a validated analytical method for assay of the cited drugs 
in combination with HCZ in their pharmaceutical preparations. Literature review revealed some 
published methods for simultaneous determination of one or more of the studied drugs in 
combination with HCZ using different analytical techniques such as LC-UV: ATN 42-44, VAL 45-
52, MXP 53, 54, ALS  51, 55-58, AML 48, 50, 52, 55, 56, 58, CND 49, 59-62, LC/MS/MS: ATN 63, VAL 63, 64, 
CND 65, UV-spectrometry: ATN 44, 66, 67, VAL 44, 68, 69, MXP 70, ALS 71, AML 66, 68, 69, CND 72, 73 
and  CE: ATN 74, VAL 75, ALS 76, CND 75. To the best of our knowledge there is no method was 
35 
 
developed to separate the cited seven drugs. Thus, the aim of this method was to develop and 
validate an analytical method using the most preferable RP-LC technique for the simultaneous 
determination of the well-known diuretic HCZ, along with commonly prescribed 
antihypertensive drugs from different pharmacological classes as mentioned before, namely; 
ATN, VAL, MXP, ALS, AML and CND. Irbesartan (Fig. 1.3.1h) was used as an internal 
standard in this method. This method is characterized by simplicity, accuracy, preciseness 
besides its wide range of applications as it can be used for routine analysis and quality control of 
the cited drugs separately or in combinations in more than 17 combined therapies, (Table 1.3.1). 
Also, this method is able to separate the seven analytes along with IS in a short run time of about 
12 minutes in agreement with system suitability parameters.  
1.3.2 Experimental  
1.3.2.1  Materials and reagents 
All the chemicals used were of analytical reagent grade, and the solvents were of HPLC 
grade. HCZ (certified to contain 99.93%) and CND ((certified to contain 99.95%) were supplied 
by AstraZeneca - Cairo - Egypt. Pharmaceutical grade VAL USP was supplied by Zydus, batch 
No.: VSK1MK A02B (certified to contain 99.40%).  ALS (certified to contain 99.51%) was 
supplied by Novartis Pharmaceuticals Corporation East, New Jersey, USA, 07936. AML 
(certified to contain 99.75%) was kindly supplied by Global Nabi Co., (Giza -Egypt). ATN 
(certified to contain >98%), MXP (certified to contain >98%), sodium 1-heptanesulphonate and 
acetonitrile were obtained from (Sigma-Aldrich, MO, U.S.A).  Amturnide® 300-10-25 mg 
tablets; batch # NDC 0078-0614-15 (Novartis Pharmaceuticals Corporation East, New Jersey, 
USA 07936) each labeled to contain 332 mg ALS, 13.9 mg AML and 25 mg HCZ,  Exforge 
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HCT® 160/10/12.5 mg tablets; batch # NDC 0078-0614-15 (Novartis Pharmaceuticals 
Corporation,  East Hanover, NJ, 07936 USA) each labeled to contain 160 mg VAL, 13.9 mg 
AML and 12.5 mg HCZ, Uniretic® 15/12.5 mg tablets; batch # NDC 68462-0206-01 
(SCHWARZ PHARMA, LLC a subsidiary of UCB, Inc. Smyrna, GA 30080, USA) each labeled 
to contain 15 mg MXP and 12.5 mg HCZ, and Atacand HCT® 16/12.5 mg tablets; batch # NDC 
60505-3758-09 (AstraZeneca - Cairo, - Egypt) each labeled to contain 16 mg CND and 12.5 mg 
HCZ were purchased from commercial sources in the local market. Sodium hydroxide, sodium 
phosphate dibasic and o-phosphoric acid 85% (Fisher Scientific, NJ, USA) were used. 
1.3.2.2  Instrumentation  
Separations were performed using Agilent HPLC system 1200 chromatograph (USA) 
equipped quaternary pump G1311A and with a Rheodyne injector valve with a 20 μL loop and a 
G1315D MWD detector. Mobile phases were degassed using G1322A solvent degasser. Agilent 
chemstation for LC systems [Rev.B.03.01-SR1 (317)] PC program was used for the instrument 
control, data analysis and acquisition. Separation and quantitation were made on Agilent Eclipse 
XDB-C18 (4.6 x 150mm, 5 µm) column. A SympHonly (SB20) pH-meter (Thermo Orion 
Beverly, MA, U.S.A) was used for pH measurements. Deionized water was prepared using a 
Barnstead NANO pure DIamond Analytical (USA) ultrapure water system. The mobile phase 
was filtered through 0.2 µm Anatop 25 Whatman inorganic membrane filter (Maidstone, 
England) and degassed using Branson Ultrasonic 5510 degasser (Danbury, CT, U.S.A).  
1.3.2.3 Chromatographic conditions 
A mixture of sol-A: sodium phosphate dibasic buffer (pH 5±0.1, 0.02M): sol-B: 
acetonitrile in gradient elution mode (0-3 min. sol-A: 95-65; 3-6 min. sol-A: 65-65; 6-10 min. 
sol-A: 65-20; 10-15 min. sol-A: 20-95) was used. Flow rate was maintained at 1 mL min-1. All 
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determinations were performed at ambient temperature. The system was equilibrated and 
saturated with the mobile phase for 30 min before the injection of the solutions. Quantification 
was achieved with UV detection at 220 nm based on peak area. Twenty L of the solutions were 
injected with a 50 l Agilent analytical syringe in triplicates. 
1.3.2.4 Standard stock solutions preparation 
10 mg of each of MXP and IS as well as 20 mg of each of HCZ, ATN, VAL, ALS, AML 
and CND were accurately weighed and transferred in to 10 mL volumetric flasks separately. 
Then, they were dissolved in a solvent composed of acetonitrile and water (50:50, v/v) and the 
solutions were made up to volume with the same solvent to give final concentrations of 1000 g 
mL-1 of MXP and IS as well as 2000 g mL-1 for HCZ, ATN, VAL, ALS, AML and CND. 
Further dilutions were made to prepare 200 g mL-1 of HCZ, AML and CND in the same diluent. 
1.3.2.5 Procedure 
1.3.2.5.1 Construction of calibration graphs 
Accurate aliquots of HCZ, ATN, VAL, MXP, ALS, AML and CND from the suitable 
stock solutions were transferred into a series of 10 mL Fisherbrand disposable tubes so that the 
final concentrations were in the range of 2–40 µg mL-1 for HCZ and CND as well as 20–200, 10-
160, 5-40, 20-250 and 5-50 µg mL-1 for ATN, VAL, MXP, ALS and AML, respectively. A 
constant 80 µL IS stock solution was added and the volume was diluted to 4 mL with a solvent 
composed of acetonitrile and phosphate buffer (50:50, v/v). Each solution (n=5) was injected in 
triplicates and chromatographed under the described chromatographic conditions. The peak area 
ratio (peak area of the studied drug/ peak area of IS) was plotted versus the concentration of each 
drug in µg mL-1 to get the calibration graphs and the corresponding regression equations were 
derived.  
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1.3.2.5.2 Preparation of the laboratory prepared mixtures 
Accurate aliquots of ATN, VAL, MXP and ALS stock solutions as well as HCZ, AML 
and CND working solutions were transferred into a series of 10 mL Fisherbrand disposable tubes 
keeping the pharmaceutical ratios of 1:1.8:23.9 for AML/HCZ/ALS, 1:1.1:12.8 for 
HCZ/AML/VAL, 1:1.2 for HCZ/MXP, 1:4 for HCZ/ATN and 1:1.28 for HCZ/CND mixtures, 
diluted to 4 mL with a solvent composed of acetonitrile and phosphate buffer (50:50, v/v) after 
addition of 80µL IS and mixed well. The percentage recoveries were calculated using the 
corresponding regression equations. 
1.3.2.5.3 Samples preparation 
A composite of ten tablets of Amturnide®, Exforge HCT®, Uniretic®, and Atacand HCT® 
tablets were ground to fine and uniform size powder (after removing the coat from the first three 
dosage forms by rubbing with a tissue moistened with methanol). Then, they were triturated 
using mortar and pestle. After calculating the average tablet weight, amounts of powder 
equivalent to (5.00, 64.00, 6.00, 66.40 and 6.40 mg) for HCZ, VAL, MXP, ALS and CND, 
respectively, as well as 2.78 and 5.50 mg for AML in Amturnide® and Exforge HCT®, 
respectively, of each type of tablets were accurately weighed and transferred separately in to 25 
ml volumetric flasks and completed to volume with a solvent composed of acetonitrile and water 
(50:50, v/v). The solutions were sonicated for 30 min then filtered through a Whatman filter 
paper and then filtered again using 0.2µm Whatman inorganic membrane filter. For analysis, 
different aliquots from the prepared sample solution, spiked with 80 µL IS stock solution, were 
diluted to 4 mL using a solvent composed of acetonitrile and phosphate buffer (50:50, v/v). The 
percentage recoveries were calculated by referring to the corresponding regression equations. 
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1.3.3 Results and discussion 
The aim of this method was to develop and validate a simple and fast RP-LC method for 
the simultaneous determination of HCZ, along with commonly prescribed antihypertensive drugs 
from different pharmacological classes as mentioned before. The proposed method permitted the 
separation of the seven drugs in a reasonable run time less than 12 min. (Fig. 1.3.2), shows a 
typical chromatogram for a synthetic mixture of the seven drugs under the described 
chromatographic conditions. It also permitted the quantification of the drugs in their laboratory 
prepared mixtures and co-formulated tablets.  
1.3.3.1 Optimization of chromatographic conditions 
Several trials were carried out to obtain a simple, rapid, accurate, precise and reliable LC 
method for the simultaneous determination of the seven antihypertensive drugs with low cost and 
available accessories such as column and detector used. Different columns with different length 
and internal diameter were tried and a satisfactory separation was obtained on Agilent Eclipse 
XDB-C18 (4.6 x 150 mm, 5 µm) column. Isocratic mode of elution was tried and it was found 
that it is difficult to be used with such number of analytes as many compounds will overlap 
together so gradient elution mode was attempted. Methanol and acetonitrile were examined as 
organic modifiers and acetonitrile was found to be more suitable as it allowed appropriate 
separation of the seven analytes. The use of buffer was necessary in this method in order to keep 
the pH constant as ATN elution is affected by the mobile phase composition, pH and by the 
properties of the combined analytes, (Fig. 1.3.3 and 1.3.4).   Different gradient elution modes 
were tested in order to achieve proper separation of the cited analytes in a reasonable run time, 
(Fig. 1.3.5). The described gradient elution mode (0-3 min. sol-A: 95-65; 3-6 min. sol-A: 65-65; 
6-10 min. sol-A: 65-20; 10-15 min. sol-A: 20-95) was selected.  Then, the effect of pH on the 
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separation of the analytes was studied. It was found that pH lower than 5.5 and higher than 7.5 
were not suitable as shown in (Fig. 1.3.3) as it results in poor separation of the analyzed 
compounds. pH 5.5 was finally selected as it achieved the best separation between the seven 
analytes in a reasonable run time (<12min) and with good resolution between all peaks especially 
between HCZ and VAL, (Fig. 1.3.3).  Different flow rates were studied and flow rate of 1 mL 
min-1 was found to be the optimum. Proper choice of the detection wavelength is crucial for 
sensitivity of the method. Quantitation was achieved with UV-detection at 220 nm based on 
satisfactory peak area for each of the analyzed drugs especially for HCZ, (Fig. 1.3.6). Many trials 
were done to enhance symmetry and sharpness of peaks and hence improve the resolution of the 
cited drugs. Increasing the ionic strength of phosphate buffer up to 60mM as well as addition of 
0.25mM heptane 1-sulphonate, as ion pairing agent, did not produce significant improvement. 
The analytes were first dissolved in a solvent composed of acetonitrile and water (50:50, v/v). 
This solvent allowed proper dissolution for the analyzed compounds as ALS and ATN are 
sparingly soluble in acetonitrile while VAL and HCZ are sparingly soluble in water. Then 
aliquots withdrawn were completed to volumes with a solvent composed of acetonitrile and 
phosphate buffer (50:50, v/v) which successfully achieved significant enhancement in peaks 
symmetry as well as sharpness of peaks and hence improved the resolution between the studied 
analytes, (Fig. 1.3.2). The use of IS is recommended to compensate for injection errors, minor 
fluctuations effect of the retention time and to improve the quantitative analysis. Irbesartan was 
chosen as the IS in this study IS and itself is another antihypertensive drug belonging to ARBs so 
it can be determined selectively using this developed method. The retention times for ATN, 
HCZ, VAL, MXP, ALS, AML, CND and IS were 3.37, 4.62, 5.36, 6.49, 7.33, 8.59, 11.25 and 
7.79 min, respectively.  
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1.3.3.2  Validation of the method  
Validation of the proposed CZE method was performed according to ICH guidelines 
[http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4
/Q2_R1__Guideline.pdf] with respect to stability, linearity, range, specificity, limit of detection 
(LOD), limit of quantitation (LOQ), accuracy, precision and robustness.  
1.3.3.2.1 Linearity  
A linear relationship was established by plotting the peak area ratio (the studied drug 
peak area/IS peak area) against the corresponding drug concentration in the range of 2–40 µg 
mL-1 for HCZ and CND as well as 20–200, 10-160, 5-40, 20-250 and 5-50 µg mL-1 for ATN, 
VAL, MXP, ALS and AML, respectively. Statistical analysis of the data gave high value for the 
correlation coefficient (R2) of the regression equation, small values of the standard deviation of 
residuals (Sy/x), of intercept (Sa), and of slope (Sb), as well as small value of the percentage 
relative standard deviation and % Error, (Table 1.3.2). These data indicate the linearity of the 
calibration graphs. 
1.3.3.2.2 Limit of quantitation (LOQ) and limit of detection (LOD) 
LOD was considered as the minimum concentration with a signal to noise ratio of at least 
three (S/N˜3), while LOQ was taken as a minimum concentration with a signal to noise ratio of 
at least ten (S/N˜10). Results are given in (Table 1.3.2).  
1.3.3.2.3 Accuracy and precision 
The good recovery results obtained from the assay of HCZ, ATN, VAL, MXP, ALS, 
AML and CND indicate the accuracy of the proposed method, (Table 1.3.3 and 1.3.4). 
Repeatability (intra-day) and intermediate precision (inter-day) were assessed using 
three concentrations and three replicates of each concentration. The good relative standard 
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deviations indicate good precision of the proposed method, (Table 1.3.3).   
1.3.3.2.4 Stability 
Stability of the standard stock solutions of HCZ, ATN, VAL, MXP, ALS, AML and 
CND, stored at 2-8 ◦C, were evaluated at various time points over 2 months. The concentrations 
of freshly prepared solutions and those aged for 2 months were calculated by the method 
developed and the difference between them was found to be less than 1% for HCZ, AML, VAL 
and less than 2% for MXP, CND, ALS and ATN. Also, the solutions prepared for analysis were 
found to be stable for at least 3 days at 2-8 °C and for a day at room temperature. These solutions 
can therefore be used during this interval of time without the results being affected. 
1.3.3.2.5 Specificity 
 The specificity of the method was investigated by observing any interference 
encountered from common tablet excipients and it was confirmed that the signals measured was 
caused only by the analytes. The inactive ingredients in the four analyzed dosage forms were: 
colloidal anhydrous silicon dioxide, crospovidone, hypromellose, magnesium stearate, 
carboxymethylcellulose calcium, hydroxypropyl cellulose, corn starch, povidone, talc, titanium 
dioxide, hypromellose, macrogol 4000, polyethylene glycol 6000, lactose, magnesium oxide, 
gelatin, iron oxide red, iron oxide yellow and iron oxide black. Also, ATN and HCZ were 
analyzed in their in-house prepared formulation with some of the common excipients such as 
anhydrous silica, magnesium stearate, microcrystalline cellulose, lactose, polyethylene glycol 
and talc, (Fig. 1.3.8). It was found that the excipients did not interfere with the results of the 
proposed method, (Table 1.3.5). As shown in (Fig. 1.3.8) the chromatograms of the combined 
formulations did not show any additional peaks when compared to the chromatograms of their 
laboratory prepared mixtures which confirms the specificity of the developed method, (Fig. 
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1.3.7).  
1.3.3.2.6 Robustness 
Minor deliberate changes in different experimental parameters such as flow rate (±0.2 
mL min-1) and pH (±0.1) did not significantly affect resolution of the analyzed compounds 
indicating that the proposed method is robust, (Table 1.3.6). 
1.3.3.2.7 System suitability testing 
The results of the system suitability tests assure the adequacy of the proposed RP-LC 
method for routine analysis of the seven investigated analytes, (Table 1.3.7). The values of the 
capacity factor (k) indicate that all peaks are well resolved with respect to the void volume. The 
values of % RSD of six consecutive injections performed for each analyte show good injection 
repeatability. The tailing factors (T) reflect good peak symmetry. The values for resolution (Rs) 
indicate good separation of the investigated analytes. The theoretical plate numbers (N) 
demonstrate good column efficiency.  
1.3.3.3 Application of the proposed method for the analysis of HCZ in combination with one 
or more of either ATN, VAL, MXP, ALS, AML and CND in their laboratory prepared 
mixtures and combined formulations 
The proposed RP-LC method was applied to the simultaneous determination of HCZ with 
one or more of the other antihypertensive drugs in their laboratory prepared mixtures in the 
medicinally recommended ratios of 1:1.8:23.9 for AML/HCZ/ALS, 1:1.1:12.8 for 
HCZ/AML/VAL, 1:1.2 for HCZ/MXP, 1:4 for HCZ/ATN and 1:1.28 for HCZ/CND mixtures, 
(Fig. 1.3.7). Furthermore, the proposed method was successfully applied for their determination 
in co-formulated tablets, (Fig. 1.3.8).  
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1.3.3.4 Comparison methods and statistical analysis 
The results shown in Table 1.3.5 for the analysis of the cited medications in their 
combined formulations are in good agreement with those obtained using the reported methods 
for each combination. The reported method for simultaneous determination of HCZ, AML and 
ALS ternary mixture was based on an ion pairing RP-LC-UV technique using acetonitrile: 25 
mM octane sulphonic acid sodium salt monohydrate in water (60: 40, v/v) as the mobile phase 58, 
whereas the proposed method is more conventional for analysis of that mixture. Regarding the 
reported method for simultaneous determination of HCZ, AML and VAL, it was based also on a 
RP-LC technique using acetonitrile, methanol and 50 mM phosphate buffer adjusted to pH 3 
with orthophosphoric acid as the mobile phase in the ratio of (20: 50: 30, v/v) and the eluents 
were monitored at 239 nm   52. On the other hand, Erturk et al. reported a RP-LC method for 
simultaneous determination of  HCZ and MXP in tablets which was performed using a mobile 
phase consisting of acetonitrile and phosphate buffer (pH 4) (50: 50, v/v) 53. Also for HCZ and 
ATN simultaneous determination in tablets, Zaveri et al. reported a RP-LC method for analysis 
of that mixture using a mobile phase consisting of water: phosphate buffer: methanol (50:35:15, 
v/v) 42. Finally, Qutab et al. reported a RP-LC method for simultaneous determination of HCZ 
and CND in their combined formulation and they used phosphate buffer (pH 6), methanol and 
triethylamine (25:75:0.2, v/v) as the mobile phase 62.  The newly developed method is reliable, 
simple, rapid and selective in comparison to all of the reported methods for determination of the 
selected drug combinations in their pharmaceutical dosage forms. Statistical analysis of the 
results obtained using Student’s t-test and variance ratio F-test revealed no significant difference 
between the performance of the methods regarding the accuracy and precision, respectively. 
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Table 1.3.1 Examples for some prescribed antihypertensive dosage forms available in the market 
Dosage form Active ingredients 
Amturnide®  tablets ALS, AML and HCZ 
Exforge HCT® tablets VAL, AML and HCZ 
Ziblok-H® tablets ATN and HCZ 
Diovan HCT® tablets VAL and HCT 
Uniretic® tablets MXP and HCZ 
TeKturna® tablets ALS and HCZ 
Atacand HCT® tablets CND and HCZ 
Amlokind-AT® tablets ATN and AML 
Exforge® tablets VAL and AML 
Tekamlo® tablets ALS and AML 
Tenormin® tablets ATN 
Aquazide® tablets HCZ 
Diovan® tablets VAL 
Univasc® tablets MXP 
Tekturna® tablets ALS 
Norvasc® tablets AML 
Atacand® tablets CND 
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Table 1.3.2 Characteristics and results of the proposed RP-LC method 
Item HCZ ATN VAL MXP ALS AML CND 
Linearity range (µg mL-1) 2-40 20-120 10-160 5-40 20-250 5-50 2-40 
LOD (µg mL-1) 0.34 4.86 3.22 0.41 4.06 1.35 0.23 
LOQ (µg mL-1) 1.02 14.72 9.75 1.26 12.31 4.09 0.71 
Intercept (a) 0.0552 -0.0139 0.6631 0.0094 0.0628 -0.0038 0.0077 
Slope (b) 0.0614 0.0043 0.0395 0.0315 0.0101 0.0201 0.0509 
Correlation coefficient (R2) 0.9999 0.9996 0.9998 0.9999 0.9999 0.9997 1.000 
S.D. of residuals (Sy/x) 0.0093 0.0067 0.0545 0.0046 0.0161 0.0105 0.0053 
S.D. of intercept (Sa) 0.0063 0.0063 0.0385 0.0040 0.0124 0.0082 0.0036 
S.D. of slope (Sb) 0.0003 0.0001 0.0004 0.0002 0.0001 0.0003 0.0002 
% Error 1.33 1.57 1.01 0.73 0.69 1.19 2.18 
%RSD 2.99 3.54 2.24 1.63 1.55 2.64 0.97 
Accuracy  99.39 99.28 100.41 99.70 99.64 100.92 99.53  
 
  
 
 
 
 
 
 
 
 
 
  
47 
 
Table 1.3.3 Accuracy and precision results for the proposed RP-LC method 
Conc. of 
HCZ (g mL-1) 
Intra-day assay Inter-day assay 
Conc. of 
ALS (g mL-1) 
Intra-day assay Inter-day assay 
Recovery % ± 
%RSDa 
Recovery % ± 
%RSDa 
Recovery % ± 
%RSDa 
Recovery % ± 
%RSDa 
15.00 99.37 ± 1.79 101.63 ± 1.96 143.00 100.62 ± 0.66 100.41 ± 0.25 
20.00 98.51 ± 1.48 100.15 ± 1.68 191.00 101.58 ± 0.95 100.80 ± 0.77 
25.00 100.60 ± 0.92 100.77 ± 0.58 215.00 100.26 ± 1.23 99.56 ± 0.66 
Mean 99.49 ± 1.06 100.85 ± 0.74 Mean 100.82 ± 0.68 100.26 ± 0.63 
Conc. of 
ATN (g mL-1) 
Intra-day assay Inter-day assay 
Conc. of 
AML (g mL-1) 
Intra-day assay Inter-day assay 
Recovery % ± 
%RSDa 
Recovery % ± 
%RSDa 
Recovery % ± 
%RSDa 
Recovery % ± 
%RSDa 
60.00 99.32 ± 1.19 99.44 ± 0.81 8.25 101.13 ± 1.79 100.53 ± 2.16 
80.00 99.00 ± 1.62 98.71 ± 0.45 11.00 100.72 ± 0.45 100.72 ± 1.80 
100.00 98.50 ± 1.92 99.90 ± 1.40 13.75 99.88 ± 0.42 100.36 ± 2.05 
Mean 98.94 ± 0.42 99.35 ± 0.60 Mean 100.58 ± 0.63 100.54 ± 0.18 
Conc. of 
VAL (g mL-1) 
Intra-day assay Inter-day assay 
Conc. of 
CND (g mL-1) 
Intra-day assay Inter-day assay 
Recovery % ± 
%RSDa 
Recovery % ± 
%RSDa 
Recovery % ± 
%RSDa 
Recovery % ± 
%RSDa 
96.00 99.33 ± 1.29 99.33 ± 2.72 6.40 100.68 ± 1.23 99.45 ± 1.17 
128.00 100.72 ± 1.21 100.42 ± 1.58 19.20 100.89 ± 0.86 100.31 ± 0.67 
160.00 101.01 ± 1.12 101.39 ± 0.59 32.00 101.22 ± 0.14 100.75 ± 0.43 
Mean 100.35 ± 0.89 100.38 ± 1.03 Mean 100.93 ± 0.27 100.17 ± 0.66 
Conc. of 
MXP (g mL-1) 
Intra-day assay 
Recovery % ± 
%RSDa 
Inter-day assay 
Recovery % ± 
%RSDa 
   
18.00 98.82 ± 1.41 97.18 ± 1.53    
24.00 97.45 ± 1.56 99.40 ± 1.96    
30.00 97.56 ± 1.51 98.86 ± 1.10    
Mean 97.94 ± 0.78 98.48 ± 1.18    
a Mean and relative standard deviation of three determinations 
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Table 1.3.4 Assay and statistical results for the determination of the studied drugs in their 
laboratory prepared mixtures by the proposed method and comparison methods  
(HCZ:AML:ALS) 
(1.8:1:23.9) 
HCZ AML ALS 
The developed  
RP-LC method 
Comparison 
method [31] 
The developed  
RP-LC method 
Comparison 
method [31] 
The developed  
RP-LC method 
Comparison 
method [31] 
Mean recovery%  
± S.D. 
100.45±2.15 100.23±1.49 99.54±2.12 98.41± 0.88 101.05±1.45 100.09±1.99 
Student t test 
(2.78)* 
0.14 1.36 0.68 
F value (19)* 1.01 5.82 1.88 
    
 
(HCZ:AML:VAL) 
(1:1.1:12.8) 
HCZ AML VAL 
The developed  
RP-LC method 
Comparison 
method [25] 
The developed  
RP-LC method 
Comparison 
method [25] 
The developed  
RP-LC method 
Comparison 
method [25] 
Mean recovery%  
± S.D. 
99.94±1.67 99.52±1.91 99.66±0.53 100.66± 0.74 98.47±1.21 99.74± 1.53 
Student t test 
(2.78)* 
0.38 1.20 0.34 
F value (19)* 3.38 6.45 1.26 
    
 (HCZ:MXP) 
(1:1.2) 
HCZ MXP  
The developed  
RP-LC method 
Comparison 
method [26] 
The developed  
RP-LC method 
Comparison 
method [26] 
  
Mean recovery%  
± S.D. 
98.47±0.84 100.43±0.66 100.21±2.00 100.13 ± 1.72   
Student t test 
(2.78)* 
3.18 0.05  
F value (19)* 1.64 1.36  
    
 (HCZ:ATN) 
(1:4) 
HCZ ATN  
The developed  
RP-LC method 
Comparison 
method [15] 
The developed  
RP-LC method 
Comparison 
method [15] 
  
Mean recovery%  
± S.D. 
99.89±1.48 98.94±2.26 98.76±1.48 100.27± 1.14   
Student t test 
(2.78)* 
0.61 1.41  
F value (19)* 2.35 1.69  
    
 (HCZ:CND) 
(1:1.28) 
HCZ CND  
The developed  
RP-LC method 
Comparison 
method [35] 
The developed  
RP-LC method 
Comparison 
method [35] 
  
Mean recovery%  
± S.D. 
100.45±1.19 99.49±1.31 100.31±0.67 99.80± 0.40   
Student t test 
(2.78)* 
0.94 1.13  
F value (19)* 1.21 2.70  
Each result is the average of three separate determinations.  
The values between parentheses are the tabulated t and F values at P = 0.05. 
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Table 1.3.5 Assay results for the determination of the studied drugs in their co-formulations 
Amturnide® 300-10-25mg 
tablets 
(HCZ:AML:ALS) 
(1.8:1:23.9) 
HCZ AML ALS 
Proposed 
method 
Comparison 
method [31] 
Proposed 
method 
Comparison 
method [31] 
Proposed 
method 
Comparison 
method [31] 
Mean recovery% ± S.D. 97.70 ± 1.42 99.43 ± 1.58 
101.37 ± 
1.21 
99.50 ± 1.99 100.89±1.34 99.78 ± 1.83 
Student t test (2.78)* 1.42 1.39 0.85 
F value (19)* 1.24  2.71 1.86 
Exforge HCT® 
160/10/12.5mg tablets 
(HCZ:AML:VAL) 
(1:1.1:12.8) 
HCZ AML VAL 
Proposed 
method 
Comparison 
method [25] 
Proposed 
method 
Comparison 
method [25] 
Proposed 
method 
Comparison 
method [25] 
Mean recovery% ± S.D. 98.59 ± 0.7 99.75 ± 2.00 
101.80 ± 
1.64 
99.82 ± 1.38 98.80±1.08 99.78 ± 1.01 
Student t test (2.78)* 1.85 1.19 1.32 
F value (19)* 1.06 1.79 1.44 
Uniretic® 100/25mg 
tablets  
(HCZ:MXP) 
(1:1.2) 
HCZ MXP  
Proposed 
method 
Comparison 
method [26] 
Proposed 
method 
Comparison 
method [26] 
  
Mean recovery% ± S.D. 97.59 ± 1.15 101.60 ± 1.07 98.01 ± 2.25 99.20 ± 1.06   
Student t test (2.78)* 1.55 0.82  
F value (19)* 1.09 4.09  
In house formulation 
(HCZ:ATN) 
(1:4) 
HCZ ATN  
Proposed 
method 
Comparison 
method [15] 
Proposed 
method 
Comparison 
method [15] 
  
Mean recovery% ± S.D. 98.82 ± 1.11 100.51 ± 1.11 98.42 ± 0.67 98.88 ± 1.56   
Student t test (2.78)* 1.86 0.47  
F value (19)* 2.79 5.51  
Atacand HCT® 16/12.5mg 
tablets (HCZ:CND) 
(1:1.28) 
HCZ CND  
Proposed 
method 
Comparison 
method [35] 
Proposed 
method 
Comparison 
method [35] 
  
Mean recovery% ± S.D. 98.17±1.74 101.39 ± 0.76 100.54±1.99 100.63 ± 1.12   
Student t test (2.78)* 1.79 021  
F value (19)* 1.75 6.82  
Each result is the average of three determinations and values between parentheses are the 
tabulated t and F values at P = 0.05. 
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Table 1.3.6 Results of the robustness Study for the proposed RP-LC method 
Parameter Drug 
Standard 
Method 
Flow rate (mL min-1) pH 
0.8 1.2 5.4 5.6 
R
et
en
ti
o
n
 t
im
e 
(m
in
) 
ATN 3.4 4.1 2.9 3.3 3.4 
HCZ 4.6 5.5 4.0 4.6 4.6 
VAL 5.4 6 4.8 5.6 5.3 
MXP 6.5 7.3 5.7 6.5 6.5 
ALS 7.3 8.0 6.2 7.2 7.4 
IS 7.9 8.9 6.8 8.0 7.8 
AML 8.6 9.3 7.2 8.6 8.7 
CND 11.2 12.0 10.7 11.3 11.1 
R
es
o
lu
ti
o
n
 
ATN/HCZ 10.2 11.3 9.1 10.9 10.0 
HCZ/VAL 5.4 4.3 5.9 5.5 5.2 
VAL/MXP 7.0 7.5 6.6 6.5 6.7 
MXP/ALS 4.5 5.4 4.9 4.2 4.6 
ALS/IS 2.5 2.9 2.3 3.1 2.0 
IS/AML 4.9 5.2 3.9 4.6 5.4 
AML/CND 22.0 23.5 24 22.3 20.9 
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Table 1.3.7 System suitability data for the proposed RP-LC method 
Item ATN HCZ VAL MXP ALS IS AML CND 
N 18133 16751 27039 18151 24906 28634 58809 194583 
K` 0.94 1.56 1.98 2.60 3.06 3.33 3.77 4.45 
Tailing factor (T) 1.56 0.86 1.08 1.05 1.45 1.22 1.44 1.19 
%RSD of 6 injections 2.27 2.95 0.25 1.92 1.29 2.32 2.25 2.56 
R 
         
10.24 
5.38 6.99 4.45 2.47 4.89    21.80 
α         1.37 1.16 1.21 1.13 1.06 1.10     1.31 
(N: number of theoretical plates; K`: capacity factor; R: resolution factor; T: tailing factor; 
selectivity factor) 
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Figure 1.3.1 The structural formulae of the studied medications; (a) hydrochlorothiazide (HCZ), 
(b) atenolol (ATN), (c) valsartan (VAL), (d) candesartan cilexetil (CND), (e) Moexipril HCl 
(MXP), (f) aliskiren hemifumarate (ALS), (g) amlodipine besylate (AML), and (h) Irbesartan 
(IS) 
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Figure 1.3.2 Typical chromatogram of 80 µg mL-1   ATN (3.37 min), 40 µg mL-1  for each of 
HCZ (4.62 min), VAL (5.36 min), MXP (6.49 min), ALS (7.30 min), AML (8.59 min), CND 
(11.25 min) and IS 20 µg mL-1  (7.79 min) under the described chromatographic conditions 
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Figure 1.3.3 LC chromatograms of 10.0, 40.0, 128.0, 60.0, 239.0, 11.0, 12.8 and 20.0 µg mL-1 of 
HCZ, ATN, VAL, MXP, ALS, AML, CND and IS, respectively, dissolved in a solvent 
composed of acetonitrile and water (50:50, v/v) at different pH values of the phosphate buffer 
using the described chromatographic conditions 
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Figure 1.3.4 LC chromatograms of 200µg mL-1 ATN dissolved in a solvent composed of 
acetonitrile and water (50:50 v/v) at different pH values of the phosphate buffer using the 
described chromatographic conditions  
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Figure 1.3.5 LC chromatograms using mobile phase consisting of sol-A: phosphate buffer (pH 
5.5) and sol-B: acetonitrile at flow rate of 0.8 ml min-1 and at λ=220 nm in different gradient 
modes where (a)-  0-3 min. sol-A: 95-65; 3-6 min. sol-A: 65-65; 6-10 min. sol-A: 65-20; 10-15 
min. sol-A: 20-95. (b)-  0-2 min. sol-A: 95-65; 2-5.5 min. sol-A: 65-65; 5.5-8.5 min. sol-A: 65-
20; 8.5-15 min. sol-A: 20-95. (c)- 0-3 min. sol-A: 95-65; 3-10 min. sol-A: 65-20; 10-15 min. sol-
A: 20-95.  (d)-  0-12 min. sol-A: 90-60; 12-16 min. sol-A: 20-90.  (e)- 0-12 min. sol-A: 90-50; 
12-14 min sol-A: 50-20; 12-18 min. sol-A: 20-90. (f)- 0-3 min. sol-A: 90-65; 3-6 min. sol-A: 65-
65; 6-12 min. sol-A: 65-30; 12-16 min. sol-A: 30-90   
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Figure 1.3.6 LC chromatograms of 10.0, 40.0, 128.0, 60.0, 239.0, 11.0, 12.8 and 20.0 µg mL-1 of 
HCZ, ATN, VAL, MXP, ALS, AML, CND and IS, respectively, dissolved in a solvent 
composed of acetonitrile and water (50:50 v/v) using mobile phase consisting of sol-A: 
phosphate buffer (pH 5.5) and sol-B: acetonitrile, flow rate of 0.7 ml min-1 at variable detection 
wavelengths where the gradient elution mode was as follow:  0-2 min. sol-A: 95-65; 2-5.5 min. 
sol-A:65-65; 5.5-10.5 min. sol-A: 65-20; 10.5-15 min. sol-A: 20-95 
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Figure 1.3.7 LC chromatograms of different laboratory prepared mixtures using the described 
chromatographic conditions where; (a)- 16.2, 215, 9, 20 µg mL-1 of HCZ, ALS, AML and IS, 
respectively, (b)- 7.5, 96, 8.25, 20 µg mL-1 of HCZ, VAL, AML and IS, respectively, (c)- 20, 24, 
20 µg mL-1 of HCZ, MXP and IS, (d)- 15, 60, 20 µg mL-1 of HCZ, ATN and IS, respectively, 
and (e)- 15, 19.2, 20 µg mL-1 of HCZ, CND and IS, respectively 
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Figure 1.3.8 LC chromatograms of the analyzed combined formulations using the described 
chromatographic conditions where; (a)- Amturnide®  tablets: 16.2, 215, 9, 20 µg mL-1 of HCZ, 
ALS, AML and IS, respectively, (b)- Exforge HCT® tablets: 7.5, 96, 8.25, 20 µg mL-1 of HCZ, 
VAL, AML and IS, respectively, (c)- Uniretic® tablets: 20, 24, 20 µg mL-1 of HCZ, MXP and IS, 
(d)- In house formulation: 15, 60, 20 µg mL-1 of HCZ, ATN and IS, respectively, and (e)- 
Atacand HCT® tablets: 15, 19.2, 20 µg mL-1 of HCZ, CND and IS, respectively 
60 
 
1.4 Validated Ion-Pair LC Method for Simultaneous Determination of Aliskiren 
hemifumarate, Amlodipine besylate and Hydrochlorothiazide in Pharmaceuticals 
Copyright © Springer-Verlag Berlin Heidelberg 2013 
Chromatographia (2014) 77: 257 
DOI 10.1007/s10337-013-2592-6 
 
A rapid and precise LC method was developed for the simultaneous determination of 
aliskiren hemifumarate (ALS), amlodipine besylate (AML) and hydrochlorothiazide (HCZ) 
using acetonitrile: 25 mM octane sulphonic acid sodium salt monohydrate in water (60: 40 v/v) 
as the mobile phase. The flow rate was maintained at 1.2 mL min-1 on a stationary phase 
composed of Supelco, discovery HS (C18) column (25cm x 4.6mm, 5m). Isocratic elution was 
applied throughout the analysis. Detection was carried out at  max (232 nm) at ambient 
temperature. The method was validated according to ICH guidelines. Linearity, accuracy and 
precision were satisfactory over the concentration ranges of 32 – 320, 2 – 44 and 4 – 64 g mL-1 
for ALS, AML and HCZ, respectively. LOD and LOQ were estimated and found to be 0.855 and 
2.951 g mL-1, respectively, for ALS, 0.061 and 0.202 g mL-1, respectively, for AML as well as 
0.052 and 0.174 g mL-1, respectively, for HCZ. The method was successfully applied for the 
determination of the three drugs in their co-formulated tablets. The results were compared 
statistically with reference methods and no significant difference was found. The developed 
method is specific and accurate for the quality control and routine analysis of the cited drugs in 
pharmaceutical preparations.  
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1.4.1  Introduction 
Aliskiren hemifumarate, (2(S), 4(S), 5(S), 7(S)-N-(2-carbamoyl- 2- methylpropyl) -5-
amino-4-hydroxy2,7 diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy) phenyl] octanamide 
hemifumarate) (Fig 1.4.1a), is the first direct renin inhibitor suitable for oral administration. By 
achieving more complete renin–angiotensin system inhibition, direct renin inhibitors may afford 
greater protection from hypertensive complications 77. Present evidence indicates that ALS 
reduces baseline systolic and diastolic blood pressure and that it is as effective as other first-line 
antihypertensive agents. Extra advantages can be reached when it is used in combination therapy 
77. Amlodipine besylate (AML), (3-Ethyl 5-methyl (4RS)-2-[(2-aminoethoxy)methyl]-4-(2-
chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate) (Fig 1.4.1b) 
is a dihydropyridine long-acting calcium channel blocker that inhibits the transmembrane influx 
of calcium ions into vascular smooth muscle and cardiac muscle 78. AML is a peripheral arterial 
vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral 
vascular resistance and reduction in blood pressure 79. Hydrochlorothiazide is a potent orally 
diuretic and antihypertensive agent which inhibits active chloride reabsorption and thus increases 
the excretion of sodium chloride and water 80. It is chemically 6-chloro-1, 1-dichloro-3, 4, 
dihydro-2H-1, 2, 4-benzoliadiazine-7-sulphanomide1, 1-dioxide (Fig 1.4.1c). Triple combination 
therapy of ALS, AML and HCZ proved to be effective and well tolerated in treating hypertensive 
high-risk patients 81. Literature survey revealed LC 82-85, CE 86, UV-spectrophotometric 87, 88 and 
spectroflourimetric 89, 90 methods reported for the estimation of aliskiren hemifumarate alone or 
in combination with other anti-hypertensive agents. Methods such as LC 91-93, LC/MS/MS 78, CE 
94, UV-spectrophotometric 95-97 and spectroflourimetric 98, 99 are reported for estimation of 
amlodipine alone or in combination with other agents. Methods such as LC 100-105, LC-MS 106-109, 
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UPLC 110 and UV- spectrophotometric methods 111 are reported for the estimation of HCZ alone 
or in combination with other anti-hypertensive agents. The aim of the present study was to 
develop a reliable and validated chromatographic procedure for analysis of ALS, AML and HCZ 
in bulk drug samples and in combined dosage formulation. The developed RP-LC method has 
the advantages of being simpler, more sensitive and faster for quality control and routine analysis 
of ALS, HCZ and AML triple mixture in comparison with the reported methods 112, 113.  
1.4.2  Experimental  
1.4.2.1 Materials and reagents 
Working standards of ALS (certified to contain 99.51%) was supplied by Novartis 
Pharmaceuticals Corporation East, New Jersey, USA 07936, AML (certified to contain 99.75%) 
was kindly supplied by Global Nabi Co., (Giza -Egypt). HCZ (certified to contain 99.93%) was 
supplied by AstraZeneca - Cairo, - Egypt (Under license of AstraZeneca, Sweden). Amturnide® 
300-10-25 mg tablets; batch # NDC 0078-0614-15 (Novartis Pharmaceuticals Corporation East, 
New Jersey, USA 07936) were purchased from commercial sources in the USA market. Each 
labeled to contain 331 mg ALS (equivalent to 300 mg aliskiren as a free base), 13.9 mg AML 
(equivalent to 10 mg amlodipine as a free base) and 25 mg HCZ.  Acetonitrile (HPLC grade) and 
octane sulphonic acid sodium salt monohydrate were obtained from Sigma-Aldrich, MO, USA.  
1.4.2.2  Instrument and conditions 
The LC system consisted of a (Younglin instrument Acme 9000, Korea) equipped with 
vacuum degasser, mixer, gradient pump and UV/Vis detector. Separation and quantitation were 
made on Supelco, Discovery HS (C18) column (25cm x 4.6mm, 5m). A Soniclean120T 
ultrasonic processor was also used. 
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The mobile phase was filtered through 0.45 m membrane filter and degassed using 
ultrasonic bath. The flow rate was 1.2 mL min-1. The solutions were injected (30 l) with a 100 
l Agilent analytical syringe. All determinations were performed at ambient temperature. The 
system was equilibrated and saturated with the mobile phase for 30 min before the injection of 
the solutions. Quantification was achieved with UV detection at 232 nm based on peak area. 
Data acquisition was performed on Autochrome 3000 LC younglin software. 
1.4.2.3 Preparation of mobile phase 
A mixture of acetonitrile: 25 mM octane sulphonic acid sodium salt monohydrate in 
water (60: 40 v/v) was prepared.     
1.4.2.4 Standard stock solutions preparation 
40 mg of ALS, 10 mg of AML and HCZ were accurately weighed and transferred in to 
50 mL volumetric flasks separately. Then, they were dissolved in a solvent composed of 
acetonitrile and water (60:40 v/v) and the solutions were made up to volume with the same 
solvent to give final concentrations of 800 g mL-1 of ALS and 200 g mL-1 of both AML and 
HCZ. 
1.4.2.5 Procedure 
1.4.2.5.1 Construction of calibration graphs 
Different solutions containing 32 – 320, 2-44 and 4 – 64 µg mL-1 of ALS, AML and 
HCZ, respectively, were prepared in 10 mL volumetric flasks and completed to volume with the 
mobile phase. A volume of 30µL of each solution was injected in triplicates into the 
chromatogram. The chromatographic conditions were adjusted. The resulting chromatograms, 
retention times (tr) of the peaks and the areas under the peaks (AUPs) were recorded. The 
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recorded AUPs of ALS, AML and HCZ were plotted versus the concentrations of ALS, AML 
and HCZ (µg mL-1) to obtain the calibration curves.  
1.4.2.5.2 Application of the proposed methods to dosage form  
Twenty tablets of Amturnide 300-10-25 mg tablets were weighed and finely powdered. 
A portion of the powder equivalent to ALS (166.5 mg), AML (6.95 mg) and HCZ (12.5 mg) was 
introduced into a 100 mL beaker and sonicated with 50 mL acetonitrile for 15 min. The extract 
was filtered. Further dilutions of the filtrate were carried out with acetonitrile. The general 
procedure for LC method was followed and the concentrations of the examined drugs were 
calculated using the corresponding regression equation. 
1.4.2.6 Validation  
The suggested analytical method was validated according to ICH guidelines 114 with 
respect to certain parameters such as linearity, accuracy, LOD and LOQ, precision, specificity, 
stability and  robustness. 
1.4.2.6.1  Linearity 
The linearity of the method was established by spiking a series of standard mixtures in 
the range 32 – 320, 2-44 and 4 – 64 µg mL-1 of ALS, AML and HCZ, respectively. Above 
solutions were injected onto the LC system. Calibration curves were constructed for standard 
solutions by plotting their response ratios (ratios of the peak area of the analytes) against their 
respective concentrations. Linear regression was applied and standard deviation of slope (Sb), 
standard deviation of intercept (Sa), correlation coefficient (r) and standard error (Es) were 
determined. 
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1.4.2.6.2  Limit of detection and limit of quantification 
Detection and quantification limits were determined through dilution method using S/N 
approach by injecting a 30 μl sample. LOD was considered as the minimum concentration with a 
signal to noise ratio of at least three (S/N˜3), while LOQ was taken as a minimum concentration 
with a signal to noise ratio of at least ten (S/N˜10) 114. 
1.4.2.6.3  Accuracy 
Accuracy was determined in terms of percent recovery. A set of standard mixtures at six 
different concentration levels 48, 96, 144, 176, 224, 288 µg mL-1 of ALS, 4, 12, 20, 28, 36, 40 
µg mL-1 of AML and 12, 20, 32, 48, 56, 60 µg mL-1 of HCZ were prepared and injected onto the 
LC system in triplicate. The general procedure for LC method was followed and the percentage 
recoveries of ALS, AML and HCZ were calculated. 
1.4.2.6.4 Precision 
Method precision was determined both in terms of repeatability (intra-day 
reproducibility) and intermediate precision (inter-days reproducibility) using three different 
concentration levels 72, 176, 224 µg mL-1 of ALS, 12, 28, 36 µg mL-1 of AML and 12, 32, 48 µg 
mL-1 of HCZ.  
1.4.2.6.5  Specificity 
Specificity was examined by analyzing ALS, AML and HCZ in laboratory prepared 
mixtures and pharmaceutical dosage form to detect any interference caused by the combined 
drugs present in dosage formulations or the co-formulated excipients.  
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1.4.2.6.6 Robustness 
The robustness of the developed method was investigated by evaluating the influence of 
small deliberate variations in procedure variables like flow rate (±0.1 mL min-1) and mobile 
phase components` ratio (±2%). Retention time, peak area and resolution between fumaric 
acid/HCZ, HCZ/ALS and ALS/AML were recorded. 
1.4.2.6.7 Stability 
The stability studies of ALS, AML and HCZ samples were carried out over a period of 
72h at 2–8 0C (refrigerator) and standard stock solutions for one month at 2–8 0C. 
1.4.3 Results and discussion 
The goal of the present investigation was to develop a well validated, sensitive, simple 
and quick analytical method for the simultaneous determination and quantification of ALS, AML 
and HCZ in pharmaceutical preparations. Concerning ALS, AML and HCZ simultaneous 
analysis, only two LC methods to the best of our knowledge have been reported for the 
simultaneous determination of the triple mixture. Rao et al 112 described a LC method for 
determination of the drugs in their dosage form using C18 column and a mobile phase consisting 
of acetonitrile: methanol: 50mM phosphate buffer (pH 3) in the ratio of 20:50:30% v/v. The 
linearity range of ALS practically will not allow proper simultaneous determination of the three 
drugs in their co-formulated tablets.  Also, Selvakumar et al 113 reported a LC method using 20 
mM potassium dihydrogen phosphate buffer (pH 6.5): methanol: acetonitrile (55:10:35 v/v) as 
the mobile phase for determination of the triple mixture in their pure form only. The samples 
were separated with poor sensitivity on C8 column within a long run time of 18 min. The newly 
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developed method has distinct advantages regarding simplicity, reliability and suitability to be 
applied for the simultaneous analysis of the cited drugs either in pure form or in their co-
formulated tablets. 
1.4.3.1 Method development 
Various reversed phase chromatographic columns and a series of aqueous mobile phases 
containing different organic modifiers were tested to adjust the optimum conditions. Mobile 
phase systems such as phosphate and acetate buffers were tried at different pH values along with 
different organic modifiers such as methanol and acetonitrile in different ratios and flow rates. 
None of them achieved proper resolution and symmetric peaks. Since the analyzed compounds 
are ionic, the use of conventional RP-HPLC is somewhat restricted. Ionic suppression approach 
based on pH adjustment was examined to separate these charged analytes but it couldn`t achieve 
proper resolution with sharp and symmetric peaks. Ion Pair Chromatography is a more reliable 
approach that allows the separation of complex mixtures of ionic compounds. The separation 
pattern is determined by the mobile phase composition where an organic modifier is combined 
with a specific ion-pairing reagent in a certain ratio. The ion-pairing reagents are large ionic 
molecules having a charge opposite to the analytes of interest, as well as a hydrophobic region to 
interact with the stationary phase. The counter-ion combines with the ions of the eluent, 
becoming ion pairs in the stationary phase. This results in enhanced symmetry and sharpness of 
the peaks and hence increasing the reliability and reproducibility of the method. Using of ion 
pairing agents to achieve such goals and reduce tailing was examined. Triethylamine made the 
separation worse as it is basic ion pairing agent and the analyzed compounds need oppositely 
charged anionic alkyl sulphonate ion pairing agent. Also, the concentrations of both the ion pair 
agent and the organic modifier in the mobile phase are crucial for proper elution. It is worth 
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noting that the separation was improved with the relative increase of the percentage of the 
aqueous to organic phases. A satisfactory separation was obtained on a Supelco, Dicovery HS 
(C18) column (25cm x 4.6mm, 5m) with a mobile phase consisting of acetonitrile: 25 mM 
octane sulphonic acid sodium salt monohydrate in water (60: 40 v/v). Good separation of the 
cited compounds with good peaks’ shape and minimum retention times (< 5 min) were obtained 
with that mobile phase at a flow rate 1.2 mL min-1. Proper choice of the detection wavelength is 
crucial for sensitivity of the method. Quantitation was achieved with UV detection at 232 nm 
based on good peak area for each of the analyzed drugs. The retention times were 2.25, 3.13 and 
3.92 min for HCZ, ALS and AML, respectively, (Fig 1.4.2). In the course of optimizing the 
conditions of the proposed method, different parameters affecting the chromatographic 
separation were studied. The system suitability tests were used to verify that the conditions of the 
chromatographic system were adequate for the resolution and hence for the analysis 114 (Table 
1.4.1).  
1.4.3.2 LC method validation  
1.4.3.2.1 Linearity and range 
Linear relationships between the recorded AUPs of ALS, AML and HCZ versus their 
concentrations were obtained. The regression equation y = bC ± a for each drug was also 
computed. In this study, 6 concentrations for each compound were used. The linearity of the 
calibration curves was validated by the high value of correlation coefficients. The analytical data 
of the calibration curves including standard deviations for the slope and intercept (Sb, Sa) are 
summarized in (Table 1.4.2). The calibration ranges were established within protocol range 
necessary, according to the intact drugs’ concentrations in pharmaceutical product to give 
69 
 
accurate and precise results. The calibration ranges of the proposed procedure are given in (Table 
1.4.2). 
1.4.3.2.2 Limit of detection and limit of quantification  
Lower limit of detection (LOD) and lower limit of quantification (LOQ) for each drug 
were calculated. Results are given in (Table 1.4.2).  
1.4.3.2.3 Accuracy  
Accuracy of the results was calculated by % recovery of 6 different concentrations of the 
three drugs analyzed by the proposed LC method. The results obtained including the mean of the 
recovery and standard deviation were displayed in (Table 1.4.2).  
1.4.3.2.4 Precision 
Repeatability (intra-day, n=3) and intermediate precision (inter-day, n=3) were checked 
using three different concentrations at low, medium and high level of the standard curve. The 
relative standard deviation and SE were calculated to check the precision of the method, (Table 
1.4.3). 
1.4.3.2.5 Specificity 
Specificity was checked by analyzing ALS, AML and HCZ in laboratory prepared 
mixtures. Good resolution and absence of interference between drugs being analyzed and 
fumarate were shown in (Fig. 1.4.2, 1.4.3). Moreover, there was no interference observed from 
other materials in the pharmaceutical formulations (Fig. 1.4.2) confirming the specificity of the 
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method. Good recoveries were obtained in the sample indicating specificity of the proposed 
method, (Table 1.4.2). 
1.4.3.2.6 Robustness 
Minor deliberate changes in different experimental parameters such as flow rate (±0.1 
mL min-1) and mobile phase components` ratio (±2%) did not significantly affect resolution, 
peak area and retention time of the three drugs indicating that the proposed method is robust, 
(Table 1.4.4). 
1.4.3.2.7 Stability 
Results from the stability studies of working and stock solutions indicated that working 
solutions were stable for 72 h when stored at refrigerator (2–8 0C) while the stock solutions were 
stable for one month at 2–8 0C with satisfactory recovery % of about 98%. 
1.4.3.3 Statistics 
 Statistical analysis of the results obtained using Student`s t-test and variance ratio F-test 
revealed no significant difference between the performance of the proposed methods and 
reported methods 83, 115, 116 regarding accuracy and precision (Table 1.4.5). 
  
71 
 
Table 1.4.1 System Suitability Tests for the LC Method Applied for the Determination of ALS, 
AML and HCZ 
Item Fumaric acid HCZ ALS AML 
N 2870 4043 4000 3781 
R 5.769 5.212 3.466 
α 1.484 1.393 1.250 
T 1.17 1.00 1.08 1.19 
%RSD of 6 injections ----- 1.695 1.899 1.798 
(N: number of theoretical plates; R: resolution factor; T: tailing factor; : selectivity factor) 
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Table 1.4.2 Characteristics and Results of the Proposed LC Method for Simultaneous 
Determination of ALS, AML and HCZ 
Item ALS AML HCZ 
Linearity range (g/mL) 32 – 320  2 – 44  4 – 64  
LOD (g mL-1) 0.885 0.061 0.052 
LOQ (g mL-1) 2.951 0.202 0.174 
Regression equation (Y) a: Slope (b) 10.986 23.740 44.965 
Standard deviation of slope (Sb) 0.127 0.151 0.609 
Confidence limit of the slope b 10.986  0.353 23.740  0.148 44.965 ± 1.691 
Intercept (a) + 0.2838 + 9.3369 - 0.0094 
Standard deviation of intercept (Sa) 27.064 3.823 23.972 
Confidence limit of the intercept b 0.2838  75.147 9.3369  10.615 0.0094 ± 66.557 
Regression coefficient (r2) 0.9995 0.9993 0.9993 
Standard error of estimation 29.492 5.252 32.023 
Accuracy ± S.D.    
Drug in bulk 100.26 + 1.29 99.79 ± 1.13 99.10 + 1.58 
Amturnide® 300-10-25 mg tablets 100.06± 1.32 99.86± 0.99 99.98± 0.17 
a Y=a+bC, where C is the concentration in g mL-1 and Y is the peak area. 
b 95% confidence limit.  
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Table 1.4.3 Intra-and Inter-day Validation for the Determination of ALS, AML and HCZ 
Concentration of 
ALS (g mL-1) 
Intra-day assay Inter-day assay 
Found ± R.S.D a SE Found ± R.S.D a SE 
72.000 72.438 ± 0.51 0.21 72.822 ± 1.00 0.42 
176.000 173.255 ± 0.33 0.18 171.637 ± 0.43 0.43 
224.000 221.172 ± 0.96 1.22 217.782 ± 1.58 1.98 
Concentration of  
AML (g mL-1) 
Intra-day assay Inter-day assay 
Found  R.S.D a SE Found ± R.S.D a SE 
12.000 11.431 ± 1.60 0.11 11.798  ± 2.00 0.14 
28.000 27.960 ± 1.16 0.19 28.482 ± 1.60 0.26 
36.000 34.934 ± 1.24 0.25 36.035 ± 1.74 0.36 
Concentration of  
HCZ (g mL-1) 
Intra-day assay Inter-day assay 
Found ± R.S.D a SE Found ± R.S.D a SE 
12.000 12.210 ± 0.66 0.05 12.443 ± 1.57 0.11 
32.000 31.019 ± 0.48 0.09 31.258 ± 0.98 0.18 
48.000 46.414 ± 1.69 0.45 46.047 ± 1.81 0.48 
a Mean and standard deviation of three determinations 
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Table 1.4.4 Robustness Study for the Determination of ALS, AML and HCZ 
Parameters 
Retention time 
(min.) 
Area under the peak 
 
Resolution 
ALS AML HCZ ALS AML HCZ HCZ/ALS ALS/AML 
Fumaric 
acid/HCZ 
Standard 3.13 3.92 2.25 1921 175 712 5.21 3.47 5.77 
Flow rate 
(mL min-1) 
 
1.1 3.35 4.23 2.46 1915 174 705 4.80 3.54 5.61 
1.3 2.82 3.57 2.06 1867 167 686 4.80 3.50 5.80 
Mobile phase 
composition 
(acetonitrile: 
25mM 
sodium 
octane 
sulphonate) 
62:38 2.90 3.60 3.21 1993 182 728 4.40 3.20 5.45 
58:42 3.25 4.23 2.28 2046 182 754 5.70 3.80 5.96 
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Table 1.4.5 Statistical Comparison between Analysis Results of Pure Samples of the Studied 
Drugs using HPLC Method and those of the Reference Methods 
Statistical Term 
ALS AML HCZ 
Reference 
method (7)  
HPLC  
method 
Reference 
method (39)  
HPLC  
method 
Reference 
method (40)  
HPLC  
method 
Mean 101.10 100.26 99.90 99.79 100.64 99.10 
±S.D. 1.64 1.29 1.59 1.13 1.22 1.58 
±S.E. 0.73 0.53 0.71 0.46 0.55 0.65 
%RSD 1.62 1.29 1.59 1.13 1.21 1.59 
n 5.00 6.00 5.00 6.00 5.00 6.00 
V 2.69 1.66 2.53 1.27 1.49 2.44 
Student`s t test 
0.93 
(1.83*) 
0.11 
(1.83*) 
1.81 
(1.83*) 
F-test 
1.62 
(6.26*) 
1.99 
(6.26*) 
1.68 
(6.26*) 
* Figures in parentheses are the theoretical t and F values at (p= 0.05) and n is the number of 
experiments. 
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Figure 1.4.1 Chemical structures of aliskiren hemifumarate (a), amlodipine besylate (b) and 
hydrochlorothiazide (c) 
 
 
 
 
 
 
 
 
 
 
 
(a)
 
(c)
 
(b)
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Figure 1.4.2 A typical LC chromatogram of 30 µL injector for a tablet sample of the triple 
mixture: HCZ 15 μg mL-1 (tr= 2.25 min) (A), ALS 199.8 μg mL-1 (tr= 3.13 min) (B) and AML 
8.4 μg mL-1 (tr= 3.92 min) (C) 
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Figure 1.4.3 A typical LC chromatogram of 30 µL injector of fumaric acid 8 μg mL-1 (tr =1.81 
min) 
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1.5 Simultaneous determination of aliskiren hemifumarate, amlodipine besylate and 
hydrochlorothiazide in spiked human plasma using UPLC-MS/MS 
Copyright © The Author 2015. Published by Oxford University Press. All rights reserved. 
Journal of Chromatographic Science (2015) 53(7):1178-84 
DOI 10.1093/chromsci/bmu213 
 
A sensitive UPLC-MS/MS method was developed and validated for simultaneous 
estimation of aliskiren hemifumarate (ALS), amlodipine besylate (AML) and 
hydrochlorothiazide (HCZ) in spiked human plasma using valsartan as an internal standard (IS). 
Liquid-liquid extraction was used for purification and pre-concentration of analytes. The mobile 
phase consisted of 0.1% formic acid in ammonium acetate buffer (0.02 M, pH=3.5) and 
methanol (25: 75, v/v), flowing through XBridge BEH (50 mm x 2.1 mm ID, 5 µm) C18 column, 
at a flow rate of 0.6 mL min-1. Multiple reaction monitoring (MRM) transitions were measured 
using an electrospray source in the positive ion mode for ALS and AML, while HCZ and IS were 
measured in negative ion mode. Validation of the method was performed as per US-FDA 
guidelines with linearity in the range of 2.0 – 400.0, 0.3 – 25.0 and 5.0 – 400.0 ng mL-1 for ALS, 
AML and HCZ, respectively.  In human plasma, ALS, AML and HCZ were stable for at least 
one month at -70 ± 5 °C and for at least 6 hours at ambient temperature. After extraction from 
plasma, the reconstituted samples of ALS, AML and HCZ were stable in auto sampler at ambient 
temperature for 6 hours. The LC-MS/MS method is suitable for bioequivalence and 
pharmacokinetic studies of this combination.  
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1.5.1 Introduction 
Aliskiren hemifumarate, (2(S), 4(S), 5(S), 7(S)-N-(2-carbamoyl- 2- methylpropyl) -5-
amino-4-hydroxy2,7 diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy) phenyl] octanamide 
hemifumarate) (Fig. 1.5.1a). Aliskiren is the first orally taken direct renin inhibitor simulating 
endogenous peptides approved for clinical use. By achieving more complete renin–angiotensin 
system inhibition, direct renin inhibitors may afford greater protection from hypertensive 
complications 117. Present evidence indicates that aliskiren reduces baseline systolic and diastolic 
blood pressure and that it is as effective as other first-line antihypertensive agents. Extra 
advantages can be reached when it is used in combination therapy 117. Amlodipine besylate 
(AML), (3-Ethyl 5-methyl (4RS)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-
dihydropyridine-3,5-dicarboxylate benzenesulphonate) (Fig. 1.5.1b) is a dihydropyridine long-
acting calcium channel blocker that inhibits the transmembrane influx of calcium ions into 
vascular smooth muscle and cardiac muscle 118. Amlodipine is a peripheral arterial vasodilator 
that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular 
resistance and reduction in blood pressure 119. Hydrochlorothiazide (HCZ) is a potent diuretic 
and antihypertensive agent which inhibits active chloride reabsorption and thus increases the 
excretion of sodium chloride and water 80. It is chemically 6-chloro-1, 1-dichloro-3, 4, dihydro -
2H-1, 2, 4-benzoliadiazine-7-sulphanomide1, 1-dioxide (Fig. 1.5.1c). Triple combination therapy 
of ALS, AML and HCZ proved to be effective and well tolerated in treating hypertensive high-
risk patients 120. Literature survey revealed some LC 83, 121-126, CE 127, UV-spectrophotometric 128, 
129 and spectroflourimetric 130-132 methods for estimation of ALS alone or in combination with 
other anti-hypertensive agents. Methods such as LC 126, 133-135, LC-MS/MS 118, CE 136, UV-
spectrophotometry 137-139 and spectroflourimetry 140, 141 were reported for estimation of AML 
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only or in combination with other agents. Moreover, methods such as LC 142-147, LC-MS/MS 148-
151, UPLC 152 and UV- spectrophotometry 153 were reported for the estimation of HCZ alone or in 
combination with other anti-hypertensive agents. Regarding the simultaneous determination of 
ALS, HCZ and AML triple mixture, there are four reported LC methods 125, 154-156 with UV 
detection and one reported CE method 157 for their determination in pharmaceutical dosage 
forms. LC methods with UV detection are not sensitive enough to measure ALS, AML or HCZ 
in human plasma, while the use of GC-MS/MS requires derivatization steps prior to analysis. 
Amongst the reported LC-MS/MS methods, there was no developed one for simultaneous 
determination of ALS, AML and HCZ in biological fluids. Thus, the aim of the present work 
was to develop a highly selective and sensitive LC-MS/MS method with good precision and 
accuracy, besides a simple sample treatment procedure, for simultaneous estimation of ALS, 
AML and HCZ in human plasma, using valsartan as the internal standard (IS). A detailed 
validation of the proposed method was performed in accordance with US-FDA guidelines 158 to 
yield reliable results. Moreover, the developed method can be successfully applied for further 
research to assess for instance the pharmacokinetics of ALS, AML and HCZ in combination. 
1.5.2  Experimental  
1.5.2.1  Materials and reagents 
Working standards of ALS (certified to contain 99.51%) was supplied by (Novartis 
Pharmaceuticals Co., NJ, USA), AML (certified to contain 99.75%) was kindly supplied by 
(Global Nabi Co., Giza, Egypt). HCZ (certified to contain 99.93%) was supplied by 
(AstraZeneca, Cairo, Egypt). Pharmaceutical grade valsartan USP (certified to contain 99.40%) 
was supplied by (Zydus Pharmaceuticals, NJ, USA). Methanol HPLC grade, Methyl tert-butyl 
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ether and ammonium acetate were obtained from Sigma-Aldrich, USA. Formic acid was 
obtained from El-Nasr Pharmaceutical Chemicals Co., Egypt. Human plasma was obtained from 
VACSERA Blood Bank, Egypt. Deionized and purified water produced in-house from 
Millipore's Milli-Q System (USA) was used throughout the analysis. 
1.5.2.2  Instrument and conditions 
Quantitation was performed via MS/MS detection using Waters ACQUITY triple 
quadrupole LC-MS/MS mass spectrometer (Waters Corp., Milford, MA, USA). A Waters series 
UPLC system (Waters Corp., Milford, MA, USA) equipped with degasser, electrospray interface 
(ESI) and a solvent delivery unit along with an auto-sampler were used to inject 10 μL aliquots 
of the processed samples. The chromatographic separation was carried out on XBridge BEH (50 
mm x 2.1 mm ID, 5 µm) C18 column obtained from Waters. Soniclean120T ultrasonic processor 
(Australia), Eppendorf Vacufuge 5301 Vacuum Centrifuge Concentrator (Germany) and Vortex-
2 G-560 Lab Shaker Mixer (USA) were used as well. 
Chromatographic elution was performed with a mobile phase consisted of 0.1% formic 
acid in 20 mM ammonium acetate and methanol, pH 3.5 (25: 75, v/v) pumped through the 
column at a flow rate of 0.6 mL min-1. The column temperature was maintained at 30 °C. Under 
these conditions, the retention times for the HCZ, AML, ALS and IS were at 1.20, 2.91, 3.21 and 
2.04 min, respectively (Fig. 1.5.2). The injection volume was 10 µL. The LC-MS/MS system 
allowed using the positive ion mode for monitoring ALS and AML as well as the negative ion 
mode for monitoring HCZ and IS simultaneously in each run.  Multiple reaction monitoring 
(MRM) is a highly sensitive method of targeted mass spectrometry that can be used to 
selectively detect and quantify specific molecules in a complex mixtures based on the screening 
of specified precursor molecule-to-fragment ion transitions 159. MRM transitions were measured 
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at positive mode at m/z 552.7 → 117.1, CV=35V, CE=40eV for ALS and at m/z 409.4 → 238.2, 
CV=15V, CE=10eV for AML, while HCZ was measured at negative mode at m/z 296.2 → 
269.1, CV=35V, CE=20eV and at m/z 434.3 → 179.2, CV=40V, CE=30eV for the IS, where; 
CV is the cone voltage and CE is the value of collision energy for MRM acquisition, with a 20 
ms dwell time of all analytes. The capillary voltage was set at +4000 V for both of ALS and 
AML, while it was set at -4000V for HCZ and IS. The cone gas flow was set at 40 L h-1 at 4 psi, 
and temperature at 350 °C with nozzle voltage of 2900 V. Nitrogen (99.99% purity) was used in 
the ion source and the collision cell. Quantitation of the analytes in spiked human plasma was 
based on the peak area ratio of cited drugs to IS. Data acquisition and processing were performed 
using Empower2 software (Waters Corp., MA, USA). 
1.5.2.3 Standard stock solutions preparation 
Standard stock solutions of 200 g mL-1 of ALS and HCZ as well as 100 g mL-1 of 
AML and IS were prepared separately in methanol. Appropriate further dilutions were prepared 
in the same solvent. All solutions were stored under refrigeration (2-8 ◦C) when not in use. 
1.5.2.4 Procedure 
1.5.2.4.1 Calibration and quality control samples preparation 
Seven non-zero calibration standard solutions ranging from 20-4000 ng mL-1 for ALS, 3-
250 ng mL-1 for AML and 50-4000 ng mL-1 of HCZ were prepared in 10 ml volumetric flasks 
where 100 µL of IS stock solution was added to each flask and completed to the mark with 
methanol. 50 µL of each working solution was added to 450 µL of drug free human plasma 
containing EDTA as anticoagulant. The quality control samples (QC) were prepared in the same 
manner similar to the calibration standards at three concentration levels; low, medium and high 
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(60, 1600 and 3200 ng mL-1), (9, 100 and 200 ng mL-1), (150, 1600 and 3200 ng mL-1) for ALS, 
AML and HCZ, respectively. All samples were vortexed to ensure complete mixing. During each 
run, five replicates of the QC samples were used along with the calibration standards to verify 
the repeatability and integrity of the method. 
1.5.2.4.2 Sample preparation 
To 500 μL of each spiked calibration plasma standard or QC sample, 4 mL of methyl tert- 
butyl ether was added. It was then vortexed for 30 sec. and centrifuged at 4000 rpm, at 4 °C for 5 
min. 1350 μL of the supernatant was collected and evaporated using an Eppendorff concentrator. 
The residue was reconstituted in 150 μL of the mobile phase and transferred to a glass vial for 
LC-MS/MS analysis. 
1.5.3  Discussion and Method development 
To the best of our knowledge there is no reported method for simultaneous determination 
of ALS, AML and HCZ in human plasma using LC-MS/MS, so the aim of the present work was 
to simultaneously determine ALS, AML and HCZ using UPLC system interfaced with tandem 
mass spectrometry to attain higher sensitivity and selectivity for detection and quantitation of the 
cited drugs in human plasma with a rapid and affordable extraction procedure. Moreover, the 
proposed method should be suitable for human clinical pharmacology, bioavailability and 
bioequivalence studies requiring simultaneous pharmacokinetic evaluation of ALS, AML and 
HCZ either separately or in combination in human plasma. Peak plasma concentrations for ALS 
reach 186±91 ng mL-1 following oral administration of a single oral dose (300 mg) of ALS 160. 
Also, peak plasma concentrations for AML and HCZ reach 6.7±1.2 ng mL-1 and 131±4 ng mL-1 
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following oral administration of single oral doses (10 mg and 25 mg) of AML 161 and HCZ 162, 
respectively. Based on the Cmax value of each drug, suitable linearity ranges of 2.0 – 400.0 ng 
mL-1, 0.3 – 25.0 ng mL-1 and 5.0 – 400.0 ng mL-1 for ALS, AML and HCZ, respectively, were 
selected. For sample preparation, extraction methods including direct precipitation and liquid-
liquid extraction were studied. Liquid-liquid extraction using 4 mL methyl tert-butyl ether as the 
extraction solvent has the advantage of better deproteinization of the plasma samples, lower cost 
and good recovery results for the cited drugs, (Table 1.5.1). The use of C18 column was suitable 
for optimum separation of ALS, AML and HCZ. During the optimization cycle, various mobile 
phase compositions of ammonium acetate buffer, 0.1% formic acid in water, 0.1% formic acid in 
20 mM ammonium acetate buffer, methanol and acetonitrile, in different proportions were tried 
in an isocratic mode. It was found that methanol allowed good elution of the analytes with better 
responses. The use of 0.1% formic acid in 20 mM ammonium acetate buffer was to obtain higher 
detection response through assisting the ionization of the cited drug molecules especially AML. 
Thus, the optimized conditions allowed the proposed method to be selective, sensitive, rapid and 
suitable for human clinical pharmacology, bioavailability and bioequivalence studies requiring 
pharmacokinetic simultaneous evaluation of ALS, AML and HCZ combination in human 
plasma. 
1.5.4  Results and Bio-analytical method validation 
1.5.4.1 Calibration, linearity and limit of quantitation 
Blank samples (matrix samples processed without internal standard) and zero samples 
(matrix samples processed with internal standard) were analyzed. To establish the linearity, 
seven non-zero samples covering the expected range of each drug were prepared and added to 
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drug free human plasma then analyzed. Calibration curves were constructed by plotting peak 
area ratio of cited drug to the IS versus the corresponding concentration of each cited drug. 
Satisfactory linearity was obtained in the concentration range of 2.0 – 400.0, 0.3 – 25.0 and 5.0 – 
400.0 ng mL-1 for ALS, AML and HCZ, respectively. The lowest standard on the calibration 
curve was to be accepted as the lower limit of quantitation (LLOQ) if the analytes response in 
the standard was at least five times more than that of drug free (blank) plasma 158. In addition, the 
analyte peak in LLOQ sample was identifiable, discrete, and reproducible with satisfactory 
precision and accuracy (Table 1.5.2). A correlation coefficient of more than 0.998 for each of the 
analytes was obtained (Table 1.5.3). The regression equation for each of the cited drugs was also 
computed (Table 1.5.3).  
1.5.4.2 Specificity 
Six randomly selected drug free human plasma samples were processed by the similar 
liquid-liquid extraction procedure and analyzed. No endogenous plasma components showed 
interference at retention time of any analyte or of the IS. 
1.5.4.3 Recovery (extraction efficiency) from human plasma matrix 
Recovery of ALS, AML and HCZ were evaluated by comparing the mean peak responses 
of five extracted quality control (QC) samples of low, medium and high concentrations to mean 
peak responses of five plain standards of equivalent concentration. Similarly, the recovery of IS 
was also evaluated at the concentration of 100 ng mL-1. The recovery of the analytes was 
consistent, precise and reproducible. The mean recovery results for the cited drugs in human 
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plasma are listed in table 1.5.1. The recovery for the IS from plasma was found to be 88.54 ± 
1.91 (mean recovery % ± S.D.). 
1.5.4.4  Accuracy and precision (inter- and intra-day) 
The satisfactory recovery percentage results obtained from the assay of ALS, AML and 
HCZ indicate the accuracy of the proposed method, (Table 1.5.4). Repeatability (intra-day) and 
intermediate precision (inter-day) were assessed using three concentrations and three replicates 
of each concentration. The intermediate precision it was performed over three different days. 
The acceptable values for the coefficient of variation indicate good precision of the proposed 
method, (Table 1.5.4).   
1.5.4.5 Stability 
Three aliquots each of the low and high unprocessed QC samples of ALS, AML and 
HCZ were stable at -70 ± 5 °C for 36 days (long term stability) in human plasma, (Table 1.5.5). 
Also, three aliquots each of the low and high unprocessed QC samples of ALS, AML and HCZ 
were found to be stable over 6.0 hours in human plasma at room temperature (23-30 °C) (short 
term stability). After 6.0 hours the samples were processed, analyzed and compared with 
nominal concentrations, (Table 1.5.5). Auto-sampler stability was determined by analyzing three 
aliquots each of low and high QC samples of ALS, AML and HCZ that were stable for 6.0 hours 
after sample processing, (Table 1.5.5). Three aliquots each of low and high unprocessed quality 
control samples were stored at -70 ± 5 °C and subjected to three freeze and thaw cycles. After 
the completion of third cycle the samples were processed, analysed and results were compared 
with nominal values, (Table 1.5.5). Working solutions of 320 ng mL1 of ALS and HCZ as well 
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as 20 ng mL1 and 100 ng mL-1 of AML and IS, respectively, were found to be stable for 6 days at 
2-8 °C and at room temperature (23-30 °C) for 6 hours, (Table 1.5.6).  
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Table 1.5.1 Recovery results for ALS, AML and HCZ from spiked human plasma 
QC 
sample 
Concentration of drug 
in plasma (ng mL-1) 
Mean Recovery % CV n 
 ALS AML HCZ ALS AML HCZ ALS AML HCZ  
Low 6.00 0.90 15.0 88.32 86.63 83.84 2.56 4.08 2.66 5 
Medium 160.00 10.00 160.0 90.36 88.32 85.37 4.50 5.28 3.02 5 
High 320.00 20.00 320.0 92.85 90.05 88.62 2.02 2.74 2.30 5 
CV, coefficient of variation; n, number of determinations. 
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Table 1.5.2 Summary for ALS, AML and HCZ calibration standards results in spiked human 
plasma 
Conc. of drug in 
plasma (ng mL-1) 
Mean conc. found  
(ng mL-1) 
± S.D. CV Recovery % n 
ALS AML HCZ ALS AML HCZ ALS AML HCZ ALS AML HCT ALS AML HCT 
2.00 0.30 5.00 2.16 0.30 4.73 0.14 0.02 0.06 9.63 13.03 16.98 108.15 99.33 94.50 5 
6.00 0.90 15.00 6.05 0.92 14.52 0.12 0.01 0.02 4.04 4.26 4.60 100.75 102.67 96.82 5 
40.00 5.00 40.00 39.14 4.78 40.83 0.90 0.09 0.03 6.02 8.20 3.03 97.84 95.5 102.08 5 
80.00 10.00 80.00 79.38 10.00 79.83 2.05 0.09 0.09 7.18 3.91 5.99 99.23 99.96 99.78 5 
160.00 15.00 160.00 160.49 15.07 157.81 1.67 0.14 0.23 2.70 4.05 8.93 100.31 100.49 98.63 5 
320.00 20.00 320.00 328.49 20.25 323.45 2.80 0.30 0.47 2.33 6.77 9.28 102.65 101.25 101.08 5 
400.00 25.00 400.00 400.19 25.72 396.13 2.85 0.37 0.36 1.92 6.64 5.84 100.05 102.87 99.03 5 
S.D., standard deviation; CV, coefficient of variation; n, number of determinations 
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Table 1.5.3 Characteristics and results of the proposed LC-MS/MS method for simultaneous 
determination of ALS, AML and HCZ in spiked human plasma 
a Y=a+bC, where C is the concentration in ng/ml and Y is the peak area ratio. 
 
 
  
Item ALS AML HCZ 
Linearity range (ng mL-1) 2.0 – 400.0  0.30– 25.0  5.0 – 400.0 
Regression equation (Y) a: Slope (b) 0.374 0.221 0.373 
Intercept (a) 0.301 0.064 0.850 
Regression coefficient (r2) 0.9997 0.9989 0.9998 
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Table 1.5.4 Intra-day and inter-day results of ALS, AML and HCZ in human plasma 
QC 
sample 
Conc. Of 
ALS  
(ng mL-1) 
Intra-day assay Inter-day assay 
Found ± S.D.  CV  
Recovery 
% 
Found ± S.D.  CV 
Recovery 
% 
Low 6.00 6.48 ± 0.03 0.42 107.97 6.60 ± 0.19 2.83 110.01 
Medium 160.00 149.52 ± 1.53 1.02 93.45 146.61 ± 6.46 4.40 91.63 
High 320.00 290.52 ± 4.56 1.57 90.79 298.71 ± 7.33 2.45 93.35 
 
Conc. of 
AML  
(ng mL-1) 
Intra-day assay Inter-day assay 
Found ± S.D.  CV 
Recovery 
% 
Found ± S.D.  CV 
Recovery 
% 
Low 0.90 0.85 ± 0.03 3.41 94.43 0.82 ± 0.02 2.49 91.18 
Medium 10.00 9.24 ± 0.49 3.63 92.39 9.27 ± 0.30 2.98 92.66 
High 20.00 18.03 ± 2.69 0.73 90.15 18.27 ± 0.33 1.83 91.34 
 
Conc. of HCZ  
(ng mL-1) 
Intra-day assay Inter-day assay 
Found ± S.D.  CV 
Recovery 
% 
Found ± S.D.  CV  
Recovery 
% 
Low 15.00 13.61 ± 0.25 1.87 90.71 13.50 ± 0.40 2.99 89.97 
Medium 160.00 148.87 ± 0.51 0.34 92.28 143.38 ± 4.60 3.21 89.01 
High 320.00 283.99 ± 3.78 1.33 88.74 293.47 ± 4.44 1.51 91.71 
S.D., standard deviation; CV, coefficient of variation. 
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Table 1.5.5 Summary of stability data of ALS in spiked human plasma 
Drug Stability term 
Conc.  
(ng mL-1) 
Mean conc.  
found (ng 
mL-1) 
S.D.± CV  Mean recovery % n 
A
L
S
 
Long term (36 days) 
6.00 5.85 0.17 2.61 97.50 3 
320.00 289.27 3.95 1.36 90.40 3 
      
Short term (6 hours) 
6.00 6.16 0.11 1.62 102.67 3 
320.00 295.22 2.83 0.96 92.26 3 
      
Auto-sampler (6 
hours) 
6.00 6.09 0.05 0.72 101.56 3 
320.00 294.76 1.93 0.65 92.11 3 
      
Freeze and thaw 
6.00 5.67 0.31 4.60 94.50 3 
320.00 288.42 7.18 2.49 90.13 3 
      
A
M
L
 
Long term (36 days) 
0.90 0.82 0.02 2.66 90.76 3 
20.00 17.98 0.72 4.00 89.88 3 
      
Short term (6 hours) 
0.90 0.81 0.03 4.19 90.26 3 
20.00 18.09 0.28 1.54 90.44 3 
      
Auto-sampler 
(6hours) 
0.90 0.81 0.02 1.95 89.92 3 
20.00 18.14 0.47 2.61 90.68 3 
      
Freeze and thaw 
0.90 0.80 0.03 3.50 88.79 3 
20.00 17.81 0.22 1.21 89.05 3 
      
H
C
Z
 
Long term (36 days) 
15.00 13.49 0.26 1.94 89.91 3 
320.00 295.14 5.31 1.80 92.23 3 
      
Short term (6 hours) 
15.00 13.41 0.10 0.77 89.38 3 
320.00 285.59 3.49 1.22 89.25 3 
      
Auto-sampler 
(6hours) 
15.00 13.51 0.12 0.91 90.09 3 
320.00 284.88 3.51 1.23 89.03 3 
      
Freeze and thaw 
15.00 13.15 0.29 2.22 87.67 3 
320.00 286.82 6.32 2.20 89.63 3 
      
S.D., standard deviation; CV, coefficient of variation; n, number of determinations 
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Table 1.5.6 Summary of the stability data of ALS, AML, HCZ and internal standard in solution 
Stability 
of stock 
solution 
Conc. 
(ng mL-1) 
Mean peak 
area at 25 ◦C 
after 6 hours 
Mean peak 
area at (2-8 
◦C) after 6 
days 
Mean peak 
area of freshly 
prepared 
solution 
Bias (%) at 25 
◦C after 6 
hours 
Bias (%) at 
(2-8 ◦C) 
after 6 days 
n 
ALS 320.00 241.1 x 104 239.9 x 104 242.1 x 104 0.40 0.89 3 
AML 20.00 10.4 x 104 10.3 x 104 10.4 x 104 0.41 1.62 3 
HCZ 320.00 10.2 x 104 10.0 x 104 10.3 x 104 0.81 2.18 3 
IS 100.00 2.1 x 104 2.1 x 104 2.2 x 104 1.27 0.59 3 
n, number of determinations. 
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Figure 1.5.1 Chemical structures of aliskiren hemifumarate (a), amlodipine besylate (b) and 
hydrochlorothiazide (c) 
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Figure 1.5.2 LC-MS/MS chromatogram of a 10 μL injection of quality control high sample 
showing elution of 20 ng mL-1 AML at 2.91 min, 160 ng mL-1 HCZ at 1.20 min, 160 ng mL-1 
ALS at 3.20 min and 100 ng mL-1 IS at 2.04 min. 
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1.6 Conclusions 
The study presented in section 1.2 represents the first report of a stability-indicating LC 
method for determination of AZL and CLT in their commercially available tablets. The proposed 
method has the advantages of being simple, specific, accurate and selective, so that, it was 
applied to the analysis of the studied drugs in their pharmaceutical dosage forms. Moreover, the 
suggested method permits separation of the studied drugs from their alkaline, acidic, oxidative, 
thermal (wet heat) or photolytic degradation products within a reasonable time. Furthermore, the 
proposed method was successfully applied to study the kinetics of the acidic degradation 
processes in the case of AZL as well as the kinetics of the alkaline degradation processes in the 
case of CLT, and to derive the first order degradation rate constant, half-life time (t1/2), shelf-life 
(t90) and the activation energy Ea of the investigated drugs. 
The study presented in section 1.3 represents rapid, selective, specific and validated RP-
LC method which was developed and validated for the simultaneous determination of the most 
important diuretics, HCZ, along with most commonly prescribed antihypertensive drugs 
representing different pharmacological classes, namely; ATN, VAL, MXP, ALS, AML and 
CND. This method is characterized by simplicity, accuracy, preciseness besides its wide range of 
applications, and it can be used for routine analysis and quality control of the cited drugs 
separately or in combinations in many dosage forms.  
The proposed ion pair LC method in section 1.4 found to be reliable, simple, quick, 
sensitive and accurate for simultaneous determination of ALS, AML and HCZ in pharmaceutical 
preparation. Therefore, the proposed method can be used routinely for quality control of the cited 
drugs.  
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The proposed bio-analytical method in section 1.5 was specific, sensitive accurate and 
precise enough to be successfully applied to human clinical pharmacology, bioavailability, and 
bioequivalence studies requiring pharmacokinetic evaluation. The method employed sample 
preparation by liquid-liquid extraction with adequate recovery results, followed by isocratic 
HPLC coupled with tandem mass spectrometric detection. The LC-MS/MS method was rapid 
enough and capable of simultaneous estimation of ALS, AML and HCZ in human plasma with 
satisfactory sensitivity and precision. 
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2 SEPARATION AND DETERMINATION OF SELECTED PHARMACEUTICAL 
COMPOUNDS USING CAPILLARY ELECTROPHORESIS 
2.1 Introduction 
Capillary electrophoresis (CE) is a separation technique depends on different migration 
of solutes in an electric field. Electrophoresis is performed in narrow-bore capillaries filled with 
background electrolyte (BGE). Driving forces in CE are electrophoretic migration and the 
electro-osmotic flow (EOF) 1, 2.  
Compared with other techniques, the instrumentation of CE is simple consisting of 
electrodes, sample introduction systems, a capillary column, a power supply, a detector, and 
liquid-handling systems. Detection can be achieved with on-line (UV/diode-array 
spectrophotometric, spectrofluorimetric or electrochemical detectors) or external detectors (mass 
spectrometer) 3. 
There are five major modes of operation of CE: capillary zone electrophoresis (CZE, 
based on analytes’ charge-to-size ratios) also referred to as free solution or free flow capillary 
electrophoresis, micellar electrokinetic chromatography (MEKC, based on chromatographic 
partition of analytes between micelles and the BGE), capillary isoelectric focusing (CIEF, based 
on analytes’ isoelectric points), capillary gel electrophoresis (CGE, based on analytes’ 
size/molecular weight ratio) and capillary isotachophoresis (CITP, based on moving boundaries) 
3, 4.  
Separation in CZE mode is based upon differences in charge-to-size ratios for each 
analyte in the sample. The larger this ratio, the higher the mobility and the faster an ion migrates 
in the applied electrical field 2. The migration velocity v of an ion (cm/sec) in an electric field is 
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equal to the product of the field strength E and the electrophoretic mobility ep. The 
electrophoretic mobility is in turn proportional to the ionic charge on the analyte and inversely 
proportional to frictional retarding factors. The electric field acts only on ions 4. If two ionized 
species differ either in charge or in the frictional forces they experience in moving through the 
buffer because of the structural variations, they will migrate in a different velocity and separate 
from each other. Neutral species are not separated using CZE. When a high potential is applied 
across a capillary column containing a BGE, EOF is usually produced, in which the BGE 
migrates toward the cathode or the anode. EOF is caused by the electric double layer that occurs 
at the silica/solution interface. Above pH 3, the inside wall of a silica capillary is negatively 
charged due to ionization of the surface silanol groups (Si-OH). Buffer cations accumulate in an 
electrical double layer adjacent to the negative surface of the silica capillary. The cations in the 
diffuse outer layer are attracted toward the cathode dragging the bulk solvent along with them. 
The rate of EOF is generally higher than the electrophoretic migration nobilities of the analyzed 
ions 2, 4. Figure (1) represents a simplified diagram of CZE system 5.  
Capillary electrophoresis has grown from a simple to a sophisticated method because of 
several innovations during recent decades. This growth has expanded applications of CE to 
various analytes including pharmaceuticals.  
A major advantage of CE is the availability of various modes, which enable the 
separation and analysis of different compounds ranging from inorganic species to biopolymers. It 
is well accepted that CZE and MEKC are still mainly employed for drug analysis. Nevertheless, 
various techniques have been established to improve CE selectivity, sensitivity, efficiency, 
applicability, or flexibility. 
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Figure 2.1.1 Simplified diagram for typical CE Instrument Configuration 
 
Numerous applications of CE in drug analysis are reported daily and reviews on CE for 
drug analysis are regularly published. In 2011, Hendrickx et al. 6 surveyed the applicability of 
capillary electrophoresis to analyze drug impurity mixtures, formulations, biological samples, 
and chiral compounds.  Suntornsuk  3 reviewed the recent advances of CE in pharmaceutical 
analysis and their applications in assay of active pharmaceutical ingredients, drug impurity 
testing, chiral drug separation, and determination in biological fluids between 2008 to 2009. In 
2009, Gilpin and Gilpin  7 reported separation-based (including CE), and other methods for 
analysis of active ingredients and related drugs in bulk and formulations during 2007 - 2008. 
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 Separation Science and Technology published a series of reviews on CE including the role 
of CE in drug substance and drug product development 8, the need for CE methods in 
pharmacopeial monographs 9, CE in impurity profiling of drugs 10, and the role of CE in 
biopharmaceutical development and quality control 11. In 2007, Suntornsuk 12 surveyed recent 
applications of CE in pharmaceutical analysis published during 2005–2007. Altria et al. 13 
reviewed use of CE for analysis of small-molecule pharmaceuticals in 2006. CE reviews on some 
classes of drugs have also been published, for example metal-based drugs 14, and sulfonamides 15. 
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2.2    Simultaneous determination of valsartan, amlodipine besylate and 
hydrochlorothiazide using capillary zone electrophoresis (CZE) 
Copyright © 2015 Avoxa - Mediengruppe Deutscher Apotheker GmbH 
Pharmazie (2015) 70: 368–373 
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A capillary zone electrophoresis method was developed for simultaneous determination 
of valsartan (VAL), amlodipine besylate (AML) and hydrochlorothiazide (HCZ) in their 
combined tablets. Separation was achieved on fused silica capillary by applying a potential of 15 
kV (positive polarity) and a running buffer containing 40 mM phosphate buffer at pH 7.5 with 
UV detection at 230 nm. The samples were injected hydrodynamically for 3 s at 0.5 psi and the 
temperature of the capillary cartridge was kept at 25 °C. Pyrazinoic acid was used as an internal 
standard. The method was validated according to ICH guidelines regarding specificity, linearity, 
limits of detection and quantitation, accuracy and precision. The method showed satisfactory 
linearity in the ranges of 10-200, 2-20 and 2-20 µg mL-1 with LODs of 1.82, 0.39, 0.65 µg mL-1 
and LOQs of 5.51, 1.17, 1.96 µg mL-1 for VAL, AML and HCZ, respectively. The proposed 
method was successfully applied for the analysis of the studied drugs in their laboratory prepared 
mixtures and co-formulated tablets. The results were compared with reported methods and no 
significant difference was found statistically. The proposed method can be used for quality 
control of the cited medications in ordinary laboratories. 
2.2.1 Introduction 
Valsartan (VAL) chemically, (S)-N-valeryl-N-([2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-
methyl)-vali ne (Fig. 2.2.1a), is a potent, highly selective, and orally active non peptide 
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antagonist on AT1-receptor subtype 16. Angiotensin receptor blockers are a major class of 
antihypertensive therapies due to their powerful lowering effects on blood pressure and excellent 
tolerability 17. Amlodipine besylate (AML), (3-Ethyl 5-methyl (4RS)-2-[(2-
aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate 
benzenesulphonate) (Fig.2.2.1b) is a long acting dihydropyridine calcium channel blocker that 
prevents the transmembrane influx of calcium ions into vascular smooth muscles and cardiac 
muscles 18. Also, it is a direct peripheral arterial vasodilator that   reduces peripheral vascular 
resistance and hence lowers blood pressure 19. Hydrochlorothiazide (HCZ) is an orally potent 
diuretic and antihypertensive agent which inhibits active chloride reabsorption and thus increases 
the excretion of sodium chloride and water 20. It is chemically 6-chloro-1, 1-dichloro-3, 4, 
dihydro -2H-1, 2, 4-benzothiadiazine-7-sulphanomide1, 1-dioxide (Fig.2.2.1c). Triple 
combination therapy of VAL, AML and HCZ proved to be effective and well tolerated in 
treating hypertensive high-risk patients 21. Literature survey revealed methods using HPLC 22-24, 
LC-MS 25-27, CE 28, 29, UV spectrophotometric 30, 31 and spectroflourimetric 32 techniques 
reported for estimation of VAL either alone or in combination with other agents. Methods such 
as HPLC 33-35, LC/MS/MS 36, 37, CE 38, UV-spectrophotometry 39-41 and spectroflourimetry 32, 42 
are reported for estimation of AML either alone or in combination with other agents. Also, 
methods such as HPLC 43-48, LC-MS 49-51, UPLC 52 and UV- spectrophotometry 53 are reported 
for the estimation of HCZ alone or in combination with other anti-hypertensive agents. There are 
many methods reported for the simultaneous determination of the three medications in different 
matrices such as HPLC 44, 54, 55, and UV-spectrophotometry 56. To the best of our knowledge, no 
capillary electrophoresis method was reported yet for the simultaneous determination of the 
studied medications either in pharmaceutical preparations or in biological fluids.   CE has a lot of 
133 
 
proved successful applications in the field of pharmaceutical analysis such as assay of drugs, 
determination of impurities, chiral separation, and in the analysis of pharmaceutical excipients. 
The advantages of using CE for pharmaceutical analysis include its reliability and low cost of 
analysis, reductions in solvent consumption and disposal, and the possibility of rapid method 
development and feasibility of a high degree of automation. Moreover, CE allows a single set of 
separation conditions to be applied for a wide range of analyses, introducing efficiency savings 
57, 58. Recently, CE techniques have been applied for the simultaneous determination of co-
formulated medication in their dosage forms 29, 38.  
2.2.2 Investigation, results and discussion 
The goal of this study was to develop and validate a reliable, accurate, inexpensive, 
selective and efficient method using capillary electrophoresis that could be used for routine 
quality control analysis of VAL, AML and HCZ simultaneously in their co-formulated tablets. 
VAL, AML and HCZ are co-formulated in a medicinally recommended ratio of 12.8:1.1:1. 
Analysis of such mixture with strong spectral overlapping is challenging. The proposed CZE 
method allowed the separation and simultaneous quantification of the three medications in a 
reasonable time less than 15 min with satisfactory accuracy and precision in their co-formulated 
dosage form.  
Figure 2.2.2, shows a typical electropherogram for a laboratory prepared mixture of the 
three drugs under the described electrophoretic conditions. The migration times for VAL, AML 
and HCZ were 12.74, 5.21 and 6.45 min., respectively.  
The proposed CZE method was applied to the simultaneous determination of VAL, AML 
and HCZ in laboratory prepared mixtures in the medicinally recommended ratio of 12.8:1.1:1. 
Furthermore, the proposed method was successfully applied for their determination in their co-
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formulated tablets (Fig. 2.2.3). The results shown in (Tables 2.2.1, 2.2.2) are in good agreement 
with those obtained using the comparison method 55. The comparison method was performed on 
RP-C18 column using a mobile phase consisting of acetonitrile: methanol: 50 mM phosphate 
buffer adjusted to pH 3 with orthophosphoric acid (20: 50: 30, v/v/v) at a flow rate of 1.0 mL 
min−1 in and the eluents were monitored at 239 nm. Statistical analysis of the results obtained 
using Student’s t-test and variance ratio F-test revealed no significant difference between the 
performance of the methods regarding the accuracy and precision, respectively.   
2.2.2.1 Optimization of the CE conditions 
In CZE, the background electrolyte (BGE) type as well as its pH and its concentration are 
crucial for optimizing the separation of the ionizable analytes as they determine the degree of the 
analyte ionization, its electrophoretic mobility and the magnitude of the electroosmotic flow 
(EOF). As AML has pKa value of 9.5 and HCZ has pKa values of 8.8 and 9.9, they are positively 
charged at pH 7.5. On the other hand, VAL has pKa values of 3.6 and 4.7 and it is negatively 
charged at the same pH. Several capillaries of different length and internal diameter as well as 
different pHs and molarities of phosphate buffer were tested for CZE analysis and the results 
were evaluated taking into consideration different parameters such as migration time, resolution, 
peak shape, height, baseline noise and the electric current produced. 
2.2.2.1.1 Effect of phosphate buffer pH 
The effect of buffer pH was investigated within the range of 5.0–8.0 at a 40mM 
phosphate buffer concentration.  Electropherograms showed in (Fig. 2.2.4) demonstrated that the 
four compounds needed longer time to be separated at pH lower than 6.5. Also, both resolution 
and migration times decreased with increasing the pH. Taking into consideration the ionization 
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percentage of the analytes, resolution, peak symmetry and migration time, pH 7.5 was selected as 
the optimum pH for separation (Fig. 2.2.4). 
2.2.2.1.2 Effect of phosphate buffer concentration 
Buffer concentration has also a significant effect on the separation performance through 
its influence on the EOF and the current produced in the capillary. The effect of phosphate 
running buffer concentrations was examined by varying the concentration from 5 to 50 mM with 
the increase in phosphate buffer concentration, both resolution and migration times increased. A 
40mM concentration of phosphate buffer was chosen in order to achieve reliable electrolyte 
background for analysis while maintaining reasonable run time, good resolution and acceptable 
current (≈ 78µA), (Fig. 2.2.5).  
2.2.2.1.3 Effect of applied voltage 
The applied voltage effect was investigated under the optimized conditions selected 
above from 5 to 20 kV. As expected, increasing the applied voltage increases the EOF, leading to 
shorter separation time and higher efficiencies. However, lowering the applied voltage than 15 
kV decreases the EOF so the separation time will be high and increasing the applied voltage 
exhibits higher currents and produces Joule’s heating. To limit this heating inside the capillary, 
the maximum applied voltage was chosen from an Ohm’s plot (current versus voltage) and it was 
found to be 15 kV (current (≈ 78µA)).  
2.2.2.1.4 Effect of injection time 
Injection time affects the peak width and peak height. Sample solutions were 
hydrodynamically injected at 0.5 psi while the injection time was varied from 1.0 to 4.0 s. After 
3.0 s, the peak widths of VAL, HCZ and IS were increased and the peak shapes were deformed, 
so 3.0 s was selected as the optimum injection time, (Fig. 2.2.6). 
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2.2.2.1.5 Selection of the internal standard (IS)  
The use of IS is recommended to compensate for injection errors, minor fluctuations 
effect of the migration time and improve the quantitative analysis. Then pyrazinoic acid was 
chosen as it possesses pKa value 2.9 
59 and its molecular weight is less than VAL so it will be 
negatively charged under the optimized condition and as expected it eluted after VAL. 
2.2.2.1.6 Selection of the detection wavelength  
In order to optimize sensitivity and detection limit of the method, a multiwavelength 
detection system (190 – 300 nm) was used in the CE system. For simultaneous determination of 
VAL, AML and HCZ, reasonable detection sensitivities were obtained at 230 nm (bandwidth 20 
nm), (Fig. 2.2.7, Table 2.2.3). 
2.2.2.2 Validation of the method  
Validation of the proposed CZE method was performed with respect to stability, linearity, 
range, specificity, limit of detection (LOD), limit of quantitation (LOQ), accuracy and precision 
according to the ICH Guidelines 
[http://www.fda.gov/downloads/Regulator%20yInformation/Guidances/UCM128049.pdf]. 
2.2.2.2.1 Linearity  
A linear relationship was established by plotting the peak area ratio (the studied drug 
peak area/IS peak area) against the corresponding drug concentration in the range of 10–200, 2-
20 and 2-20 µg mL-1 for VAL, AML and HCZ, respectively. Statistical analysis of the data gave 
high value for the correlation coefficient (r) of the regression equation, small values of the 
standard deviation of residuals (Sy/x), of intercept (Sa), and of slope (Sb), and small value of the 
percentage relative standard deviation, (Table 2.2.4). These data proved the linearity of the 
calibration graphs. 
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2.2.2.2.2 Limit of quantitation (LOQ) and limit of detection (LOD) 
LOQ and LOD were calculated according to ICH Q2 (R1) recommendations. Results are 
given in (Table 2.2.4).  
2.2.2.2.3 Accuracy and precision 
To prove the accuracy of the proposed method, the recovery percentage results of the 
assay of VAL, AML and HCZ were compared with those of the reference methods  60, 61. 
Statistical analysis of the results using Student's t-test and variance ratio F-test revealed no 
significant difference between the performance of the two methods regarding accuracy and 
precision, (Supplementary materials Table 2.2.5). The reference methods depend on the analysis 
of VAL, AML and HCZ using HPLC. Repeatability (intra-day) and intermediate precision (inter-
day) were assessed using three concentrations and three replicates of each concentration. 
The relative standard deviations were found to be very small indicating reasonable repeatability 
and intermediate precision of the proposed method, (Table 2.2.1).   
2.2.2.2.4 Stability 
Stability of the standard solutions of VAL, AML and HCZ, stored at 2 ◦C, were evaluated 
at various time points over 3 months. The concentrations of freshly prepared solutions and those 
aged for 2 months were calculated by the method developed and the difference between them 
was found to be less than 0.3 %. These solutions can therefore be used during this interval of 
time without the results being affected. 
2.2.2.2.5 Specificity 
 The specificity of the method was investigated by observing any interference 
encountered from common tablet excipients and it was confirmed that the signals measured was 
caused only by the analytes. Each film-coated tablet of Exforge HCT® contains the following 
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inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, iron oxide red, iron 
oxide yellow, iron oxide black, magnesium stearate, microcrystalline cellulose, polyethylene 
glycol, povidone, talc, and titanium dioxide. It was found that the excipients did not interfere 
with the results of the proposed method. As shown in (Fig. 2.2.3) the tablets electropherogram 
did not show any additional peaks when compared to VAL, AML and HCZ laboratory prepared 
mixture electropherogram which confirm the specificity of the method. 
2.2.3 Experimental 
2.2.3.1 Instruments 
The assay was developed and validated using a Beckman P/ACE 5510 system (Fullerton, 
CA, U.S.A) equipped with an autosampler, a photodiode array (PDA) detector, a temperature 
controlling system(4 - 40 oC) and power supply able to deliver up to 30 kV. Beckman P/ACETM 
station software (version 1.2) was used for the instrument control, data acquisition and analysis. 
Electrophoretic analyses were performed in a fused silica capillary (Polymicro Technologies, 
Phoenix, AZ, U.S.A) of 57.0-cm-long (50.0-cm effective length) and 75.6 µm i.d. in normal 
mode, applying a voltage of 15 kV. The wavelength for analysis was 230 nm, hydrodynamic 
injection of samples for 3 s under a pressure of 0.5 psi and the temperature of the capillary 
cartridge was 25 oC. 
The BGE was filtered using 0.2 µm Anatop 25 Whatman inorganic membrane filter 
(Maidstone, England) and degassed using Branson Ultrasonic 5510 degasser (Danbury, CT, 
U.S.A). A SympHonly (SB20) pH-meter (Thermo Orion Beverly, MA, U.S.A) was used for pH 
measurements. Deionized water was prepared using a Barnstead NANO pure DIamond 
Analytical (USA) ultrapure water system. 
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2.2.3.2 Materials and reagents 
All the chemicals used were of Analytical Reagent grade, and the solvents were of HPLC 
grade. Pharmaceutical grade valsartan USP was supplied Zydus, batch Number: VSK1MK A02B 
(certified to contain 99.40%). Amlodipine besylate (certified to contain 99.75%) was kindly 
supplied by Global Nabi Co., (Giza -Egypt). Hydrochlorothiazide (certified to contain 99.93%) 
was supplied by AstraZeneca - Cairo, - Egypt (Under license of AstraZeneca, Sweden). 
Methanol and Pyrazinoic acid (certified to contain 99%) were obtained from (Sigma-Aldrich, 
MO, U.S.A).  Exforge HCT® 160/10/12.5 mg tablets each labeled to contain 160 mg Valsartan, 
13.9 mg amlodipine besylate and 12.5 mg hydrochlorothiazide were purchased from commercial 
sources in the local market.  Sodium hydroxide, sodium dihydrogen phosphate (J.T. Baker,NJ, 
U.S.A) and Orthophosphoric acid 85% (Fisher Scientific, NJ, U.S.A) ) and methanol (Sigma-
Aldrich, MO, U.S.A) were used.  
2.2.3.3 Standard and working solutions 
2.2.3.3.1 Standard solutions 
Stock solutions 2000 µg mL-1 of VAL and 1000 µg mL-1 of AML, HCZ and IS were 
prepared in a solvent composed of methanol and water (10: 90, v/v), 10% methanol. Working 
solutions were prepared by further dilution of AML and HCZ stock solutions with 10% methanol 
to give a final concentration of 200 µg mL-1.  
2.2.3.3.2 Background running electrolyte (BGE) 
The optimized BGE solution consisted of 40 mM sodium dihydrogen phosphate buffer 
adjusted to pH 7.5 with 1M NaOH and filtered through a 0.2 µm membrane filter. 
140 
 
2.2.3.4 Electrophoretic procedure 
Before the first use, the capillary was conditioned by flushing with 1M NaOH for 90 min, 
then with water for 30 min and BGE for 30 min at 0.5 psi pressure. At the beginning of each 
working day, the capillary was rinsed with 0.1M NaOH for 10 min, water for 5 min and then 
with BGE for 5 min at 20 psi pressure. Before each injection, the capillary was preconditioned 
with 0.1M NaOH (5 min), water (5 min) and BGE (5 min) at 20 psi pressure to maintain proper 
reproducibility of run-to-run injections. Injection was carried out under hydrodynamic pressure 
at 0.5 psi for 3 s. A diode-array UV detector was set at 230 nm with a bandwidth of 20 nm. The 
capillary temperature was kept constant at 25 ◦C and a voltage of 15 kV was applied. 
2.2.3.5 Procedures 
2.2.3.5.1 Construction of the calibration graphs 
Accurate aliquots of VAL stock solution as well as AML and HCZ working solutions 
were transferred into a series of 4-mL vials so that the final concentrations were in the range of 
10-200 µg mL-1 for VAL, 2-20 µg mL-1 for AML and 2-20 µg mL-1 for HCZ. A constant 100µL 
IS stock solution was added and the volume was diluted to 4 mL with 10% methanol. The peak 
area ratio (peak area of the studied drug/ peak area of IS) was plotted versus the final 
concentration of each drug in µg mL-1 to get the calibration graphs. Alternatively, the 
corresponding regression equations were derived.  
2.2.3.5.2 Analysis of VAL/AML/HCZ laboratory prepared mixture 
Accurate aliquots of VAL stock solution as well as AML and HCZ working solutions 
keeping the pharmaceutical ratio of 12.8:1.1:1 were transferred into a series of 4-mL vials, 
diluted with 10% methanol after addition of 100µL IS and mixed well. The above procedure 
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described under "section 2.5.1" was then applied. The percentage recoveries were calculated 
using the corresponding regression equations. 
2.2.3.5.3 Analysis of the studied drugs in their co-formulated tablets 
Ten tablets of Exforge HCT® 160-10-12.5 were weighed and then crushed to a fine 
powder. An accurately weighed amount of the finely powdered tablets, equivalent to 50.00 mg 
VAL, 4.30 mg AML and 3.91 mg HCZ, was transferred to 25 mL volumetric flask. Twenty 
milliliters of methanol were added and the solution was sonicated for 30 min. The solution 
was completed to volume with the same solvent and then filtered through Whatman filter 
paper and filtered again using 0.2 µm Whatman inorganic membrane filter. For analysis, 
different aliquots from the prepared sample solution, spiked with 100 µL IS stock solution, were 
diluted to 4 mL using 10% methanol. The above procedure described under "section 2.5.1" was 
then applied. The percentage recoveries were calculated by referring to the corresponding 
regression equations. 
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Table 2.2.1 Accuracy and precision data for the determination of VAL, AML and HCZ by the 
proposed CZE method 
Concentration of 
VAL (g mL-1) 
Intra-day assay Inter-day assay Comparison method  
Recovery % ± S.D a Recovery % ± S.D a Recovery % 
32.00 101.42 ± 1.40 100.90 ± 0.57 98.04 
96.00 99.44 ± 0.32 100.26 ± 1.16 100.64 
128.00 99.38 ± 1.35 99.71 ± 1.60 98.66 
Mean ± S.D. 100.08 ± 1.16 100.29 ± 0.60 99.11 ± 1.36 
Student t test 0.94 (2.78) 1.38 (2.78)  
F 1.37 (19.00) 5.21 (19.00)  
Concentration of  
AML (g mL-1) 
Intra-day assay Inter-day assay Comparison method  
Recovery % ± S.D a Recovery % ± S.D a Recovery % 
2.75 101.60 ± 1.71 99.63 ± 2.96 102.20 
8.25 99.56 ± 2.05 99.56 ± 2.48 99.70 
13.75 101.52 ± 0.59 100.54 ± 1.49 100.09 
Mean ± S.D. 100.89 ± 1.16 99.91 ± 0.55 100.66 ± 1.35 
Student t test 0.23 (2.78) 0.89 (2.78)  
F 1.37 (19.00) 6.10 (19.00)  
Concentration of  
HCZ (g mL-1) 
Intra-day assay Inter-day assay Comparison method  
Recovery % ± S.D a Recovery % ± S.D a Recovery % 
2.50 100.31 ± 0.88 98.84 ± 1.35 100.28 
7.50 100.84 ± 0.59 99.96 ± 0.78 99.77 
12.50 99.65 ± 0.89 100.94 ± 1.16 100.07 
Mean ± S.D. 100.27 ± 0.60 99.91 ± 1.05 100.04 ± 0.26 
Student t test 0.60 (2.78) 0.20 (2.78)  
F 5.26 (19.00) 16.33 (19.00)  
a Mean and standard deviation of three determinations 
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Table 2.2.2 Assay results for the determination of the studied drugs in Exforge HCT® 
160/10/12.5 mg tablets 
Compound 
 
Proposed method Comparison method  
Amount taken 
(g mL-1) 
Amount found 
(g mL-1) 
Recovery % Recovery % 
VAL 32.00 32.26 100.80 99.41 
 64.00 64.97 101.52 99.28 
 96.00 97.42 101.48 101.58 
 128.00 127.64 99.72 99.32 
 160.00 163.18 101.99 99.32 
Mean ± S.D.   101.10 ± 0.88 99.78 ± 1.01 
Student t test   2.21 (2.31)  
F   1.30 (6.39)  
AML 2.75 2.82 102.59 97.93 
 5.50 5.58 101.55 99.95 
 8.25 8.35 101.21 101.78 
 11.00 11.03 100.30 99.97 
 13.75 13.96 101.52 99.45 
Mean ± S.D.   101.43 ± 0.82 99.82 ± 1.38 
Student t test   2.26 (2.31)  
F   2.82 (6.39)  
 HCZ 2.50 2.57 102.96 97.20 
 5.00 5.07 101.37 99.52 
 7.50 7.63 101.72 102.67 
 10.00 10.06 100.57 100.34 
 12.50 12.84 102.71 99.00 
Mean ± S.D.   101.87 ± 0.98 99.75 ± 2.00 
Student t test   2.13 (2.31)  
F   4.15 (6.39)  
Each result is the average of three separate determinations.  
The values between parentheses are the tabulated t and F values at P = 0.05. 
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Table 2.2.3 Effect of detection wavelength on VAL, AML, HCZ and IS: (16 g mL-1 of AML, 
16 g mL-1 of HCZ, 160 g mL-1 of VAL and 100 g mL-1 of IS) 
Wavelength (nm) 
Peak Area Peak Area Ratio to IS 
AML HCZ VAL IS AML HCZ VAL 
203 66265 146077 1841391 365774 0.181 0.399 5.034 
210 52578 109062 1825075 363935 0.144 0.300 5.015 
220 32218 134227 1489437 258277 0.125 0.520 5.767 
230 27050 148232 1048758 124057 0.218 1.195 8.454 
240 27816 82551 769974 65863 0.422 1.253 11.691 
250 25836 26766 621544 76513 0.388 0.350 8.123 
260 17552 35390 562031 170272 0.103 0.208 3.301 
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Table 2.2.4 Performance data for the determination of the studied drugs by the proposed CZE 
method 
Parameter VAL AML HCZ 
Linearity range (µg mL-1) 10-200 2-20 2-20 
Intercept (a) -0.0837 -0.0047 0.0154 
Slope (b) 0.0637 0.0123 0.0453 
Correlation coefficient (r) 0.9999 0.9998 0.9995 
S.D. of residuals (Sy/x) 0.052 0.002 0.0114 
S.D. of intercept (Sa) 0.035 0.001 0.0089 
S.D. of slope (Sb) 0.0004 0.0001 0.0007 
% RSD 3.362 3.357 3.164 
% Error 1.368 1.380 1.304 
LOD (µg mL-1) 1.819 0.385 0.647 
LOQ (µg mL-1) 5.513 1.166 1.960 
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Table 2.2.5 Assay results for the determination of the studied drugs in pure form by the CZE and 
reference methods 
Compound 
 
Proposed method 
Reference                     
method  
Amount taken 
(g mL-1) 
Amount found 
(g mL-1) 
Recovery % Recovery % 
VAL 32.00 31.942 99.82 99.78 
 64.00 64.124 100.19 100.47 
 96.00 95.129 99.09 99.98 
 128.00 128.190 100.15 99.68 
 160.00 158.834 99.27 100.16 
Mean ± S.D.   99.70± 0.50 100.01± 0.32 
Student t test   1.17 (2.31)  
F   2.56 (6.39)  
AML 2.75 2.740 99.63 100.07 
 5.50 5.585 101.55 97.69 
 8.25 8.309 100.71 102.13 
 11.00 11.033 100.30 100.11 
 13.75 13.902 101.11 99.52 
Mean ± S.D.   100.66± 0.74 99.90± 1.59 
Student t test   0.97 (2.31)  
F   4.61 (6.39)  
 HCZ 2.50 2.552 102.08 99.48 
 5.00 4.936 98.72 102.02 
 7.50 7.519 100.25 101.44 
 10.00 9.815 98.15 100.99 
 12.50 12.442 99.53 99.25 
Mean ± S.D.   99.74± 1.53 100.64± 1.22 
Student t test   1.02 (2.31)  
F   1.57 (6.39)  
Each result is the average of three separate determinations.  
The values between parentheses are the tabulated t and F values at P = 0.05. 
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Figure 2.2.1 The structural formulae for the studied drugs; (a) valsartan (VAL), (b) amlodipine 
besylate (AML), (c) hydrochlorothiazide (HCZ) and (d) Pyrazinoic acid (IS) 
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Figure 2.2.2 Typical electropherogram for a laboratory prepared mixture; (a) 11 µg mL-1 AML, 
(b) 10 µg mL-1 HCZ, (c) 128 µg mL-1 VAL and (d) 100 µg mL-1 IS under the described 
electrophoretic conditions 
 
 
 
 
 
 
 
 
 
 
 
149 
 
 
Figure 2.2.3 Application of the proposed method for the simultaneous determination of VAL, 
AML and HCZ in their co-formulated tablets; (a) 11 µg mL-1 AML, (b) 10 µg mL-1 HCZ, (c) 128 
µg mL-1 VAL and (d) 100 µg mL-1 IS under the described electrophoretic conditions   
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Figure 2.2.4 Effect of phosphate buffer pH; operating conditions: 40mM phosphate buffer, 
injection (3 s), 15 kV, 25 ◦C, 210 nm (bandwidth 20 nm). (12 g mL-1 AML, 30 g mL-1 HCZ, 
192 g mL-1 VAL and 100 g mL-1 IS) 
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Figure 2.2.5 Effect of phosphate buffer concentration.  
Operating conditions: pH 7.5 phosphate buffer, injection (3 s), 15 kV, 25 ◦C, 210 nm (bandwidth 
20 nm). (12 g mL-1 AML, 30 g mL-1 HCZ, 192 g mL-1 VAL and 100 g mL-1 IS) 
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Figure 2.2.6 Effect of injection time.  
Operating conditions: pH 7.5 phosphate buffer, injection (3 s), 15 kV, 25 ◦C, 210 nm (bandwidth 
20 nm). (12 g mL-1 AML, 30 g mL-1 HCZ, 192 g mL-1 VAL and 100 g mL-1 IS) 
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Figure 2.2.7 Selection of the detection wavelength.  
Operating conditions: 40mM phosphate buffer, pH 7.5, injection (3 s), 15 kV, 25 ◦C. (16 g mL-1 
AML, 16 g mL-1 HCZ, 160 g mL-1 VAL and 100 g mL-1 IS) 
 
 
 
 
 
 
 
 
 
  
154 
 
2.3    Simultaneous determination of aliskiren hemifumarate, amlodipine besylate, and 
hydrochlorothiazide in their triple mixture dosage form by capillary zone 
electrophoresis 
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
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A novel, specific, reliable and accurate capillary zone electrophoresis (CZE) method was 
developed and validated for the simultaneous determination of aliskiren hemifumarate (ALS), 
amlodipine besylate (AML) and hydrochlorothiazide (HCZ) in their triple mixture dosage form 
AMTURNIDE®. Separation was carried out in fused silica capillary (57.0 cm total length and 
50.0 cm effective length, 75.6 µm i.d.) by applying a potential of 17 KV (positive polarity) and a 
running buffer consisting of 40 mM phosphate buffer at pH 6.0 with UV detection at 245 nm. 
The samples were injected hydrodynamically for 2 s at 0.5 psi and the temperature of the 
capillary cartridge was kept at 25 °C. Meoxipril (MXP) was used as internal standard (IS). The 
method was suitably validated with respect to specificity, linearity, limit of detection and 
quantitation, accuracy, precision, and robustness. The method showed good linearity in the 
ranges of 1-10, 2.5-25 and 30-300 µg/mL with limits of detection of 0.11, 0.33 and 5.83 µg/mL 
and limits of quantification of 0.33, 1.01 and 17.65µg/mL for AML, HCZ and ALS, respectively. 
The proposed method was successfully applied for the analysis of the studied drugs in their 
laboratory prepared mixtures and co-formulated tablets without any interfering peaks. The 
estimated amounts of AML, HCZ and ALS were almost identical with the certified values, and 
their percentage relative standard deviation values (%R.S.D.) were found to be ≤ 1.80% (n = 3). 
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The results were compared to reference methods and no significant difference was found 
statistically. 
2.3.1. Introduction 
Aliskiren hemifumarate (ALS), (2(S), 4(S), 5(S), 7(S)-N- (2-carbamoyl- 2- methylpropyl) 
-5-amino-4-hydroxy2,7diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy) phenyl] octanamide 
hemifumarate) (Fig 2.3.1a) is the first direct renin inhibitor (DRI) suitable for oral administration 
62. ALS reduces baseline systolic and diastolic blood pressure (BP) by directly inhibiting the 
catalytic activity of renin system at its rate-limiting step 62. Therefore, ALS is used as a new 
effective treatment for hypertension alone and extra antihypertensive activity  can be achieved 
when it is used in combination therapy 63. Amlodipine besylate (AML), 2-[(2-
Aminoethoxy)methyl]-4-(2–chlorophenyl)-1,4–dihydro–6–methyl–3,5–pyridinedicarboxylic 
acid 3–ethyl 5–methyl ester 64  (Fig 2.3.1b) is an oral dihydropyridine calcium channel blocker, 
which acts only on the L-type channel to produce its pharmacological effect 65. Like most of the 
second generation dihydropyridine derivatives, AML has greater selectivity for the vascular 
smooth muscle than myocardial tissue and therefore their main effect is vasodilatation 66. AML 
is used alone or in combination with other medicines for the treatment of chronic stable angina 
and in the management of mild-to-moderate essential hypertension 65. Hydrochlorothiazide 
(HCZ), 6-chloro-1, 1-dichloro-3, 4, dihydro -2H-1, 2, 4-benzoliadiazine-7-sulphanomide1, 1-
dioxide 64 (Fig 2.3.1c) is a potent oral thiazide diuretic and antihypertensive agent. HCZ affects 
the renal tubular mechanisms of electrolytes reabsorption, directly increasing excretion of 
sodium salt and chloride in approximately equivalent amount 67. The ALS/AML/HCZ triple 
combination therapy in patients with moderate to severe hypertension was well tolerated and 
provided clinically significant BP reductions and effective BP control 68.  
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Literature survey revealed several reported methods for the determination of ALS in 
pharmaceutical preparation or biological fluids alone or in combination with other anti-
hypertensive agents. These methods include HPLC 69-73, CE 74, UV-spectrophotometry 75, 76 and 
spectroflourimetry  77, 78. Several methods have also been reported for the estimation of AML 
alone or in combination with other anti-hypertensive agents such as HPLC 79-81, LC-MS 82, CE 
83, UV-spectrophotometric41, 84, 85 and spectroflourimetric 86, 87. For HCZ determination alone or 
in combination with other anti-hypertensive agents, several methods like HPLC 88-93, LC-MS 94-
97, UPLC 98 and UV- spectrophotometric 99 have been described. 
Regarding ALS, AML and HCZ simultaneous analysis, only two RP-HPLC methods 100, 
101 have been reported for the simultaneous determination of the triple mixture either in pure 
form or in their co-formulated dosage form. Rao et al 100 described a RP-HPLC method for 
determination of the drugs in their dosage form using C18 column and  a complex mobile phase  
consisting of  acetonitrile: methanol: 50mM phosphate buffer( pH 3) in the ratio of 20:50:30% 
v/v. Moreover, the linearity range of ALS practically will not allow proper simultaneous 
determination of the three drugs in their co-formulated tablets.  However,  Selvakumar et al 101 
reported a RP-HPLC method using  20 mM potassium dihydrogen phosphate buffer ( pH 6.5 ): 
methanol: acetonitrile (55:10:35 v/v) as mobile phase for determination of the triple mixture in 
pure form only. The samples were separated with poor sensitivity on C8 column within a long 
run time of 16 min.  
To the best of our knowledge, no CZE method has been yet described for the 
simultaneous determination of ALS, AML and HCZ in their triple co-formulated dosage form.  
The use of capillary electrophoresis (CE) methods for pharmaceutical analysis has 
become increasingly popular in recent years. The wide range of pharmaceutical applications for 
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which its use has proved successful, include assay of drugs, determination of drug-related 
impurities, physicochemical measurements of drug molecules, chiral separation, and the analysis 
of vitamins and pharmaceutical excipients. The advantages of using CE for pharmaceutical 
analysis include its speed and low cost of analysis, reductions in solvent consumption and 
disposal, and the possibility of rapid method development. CE also offers the possibility that a 
single set of separation conditions can be applied for a wide range of analyses, giving efficiency 
savings 6, 102. Recently, CE techniques have been applied to the simultaneous determination of 
co-formulated drugs in dosage form 3, 103.  
The goal of this study is to develop and validate a reliable, accurate, inexpensive, 
selective and sensitive method using capillary electrophoresis that could be applied to the routine 
quality control analysis of ALS, AML and HCZ simultaneously in bulk drug samples and in 
combined dosage formulation.  The studied drugs; ALS, AML and HCZ, are co-formulated in a 
medicinally recommended ratio of 23.9:1.0:1.8, respectively. Analysis of such mixture with 
strong spectral overlapping is challenging. The proposed CZE method allowed the separation 
and quantitation of the three drugs with satisfied accuracy and precision. The developed CZE 
method has the advantages of being more simple, sensitive, accurate and faster for quality 
control and routine analysis of ALS, HCZ and AML triple mixture in comparison with the 
reported methods 100, 101. Moreover, this method consumes no organic solvent so it can be 
considered a green method. 
2.3.2. Experimental 
2.3.2.1. Instruments 
The assay was developed and validated using a Beckman P/ACE 5510 system (Fullerton, 
CA, U.S.A) equipped with an autosampler, a photodiode array (PDA) detector, a temperature 
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controlling system (4 oC - 40 oC) and power supply able to deliver up to 30 KV. Beckman 
P/ACETM station software (version 1.2) was used for the instrument control, data acquisition and 
analysis. Electrophoretic analyses were performed in a fused silica capillary (Polymicro 
Technologies, Phoenix, AZ, U.S.A) of 57.0-cm-long (50.0-cm effective length) and 75.6 µm i.d. 
in normal mode, applying a voltage of 17 KV. The wavelength for analysis was 245 nm, 
hydrodynamic injection of samples for 2 s under a pressure of 0.5 psi and the temperature of the 
capillary cartridge was kept at 25 oC. The background running buffer (BRB) was filtered using 
0.2 µm Anatop 25 Whatman inorganic membrane filter (Maidstone, England) and degassed 
using Branson Ultrasonic 5510 degasser (Danbury, CT, U.S.A). A SympHonly (SB20) pH-meter 
(Thermo Orion Beverly, MA, U.S.A) was used for pH measurements. Deionized water was 
prepared using a Barnstead NANO pure DIamond Analytical (USA) ultrapure water system. 
2.3.2.2. Materials and reagents 
All the chemicals used were of Analytical Reagent grade, and the solvents were of HPLC 
grade. Aliskiren hemifumarate (certified to contain 99.51%) was supplied by Novartis 
Pharmaceuticals Corporation East, New Jersey, USA. Amlodipine besylate (certified to contain 
99.75%) was kindly supplied by Global Nabi Co., Giza, Egypt. Hydrochlorotiazide (certified to 
contain 99.93%) was supplied by AstraZeneca - Cairo, Egypt. Moexipril hydrochloride was 
purchased from Sigma-Aldrich (Saint Louis, MO, USA) with labeled purity > 98%. Amturnide® 
300-10-25 mg tablets; batch # NDC 0078-0614-15 (Novartis Pharmaceuticals Corporation East, 
New Jersey, USA 07936) were purchased from commercial sources in the USA market. Each 
labeled to contain 331.5 mg aliskiren hemifumarate (equivalent to 300 mg aliskiren as a free 
base), 13.87 mg amlodipine besylate (equivalent to 10 mg amlodipine as a free base) and 25 mg 
hydrochlorothiazide, sodium hydroxide, acetic acid and sodium dihydrogen phosphate (J.T. 
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Baker,NJ, U.S.A), orthophosphoric acid 85%, sodium acetate and boric acid (Fisher Scientific, 
NJ, U.S.A), acetonitrile, methanol and ethanol (Sigma-Aldrich, MO, U.S.A) were used.  
2.3.2.3. Standard and sample solutions 
2.3.2.3.1. Standard solutions 
Stock solutions 1.0 mg/mL of AML, HCZ, MXP and 4.0 mg/mL of ALS were prepared 
by dissolving 25 mg of AML, HCZ, MXP and 100 mg of ALS separately in 25 mL of solvent 
composed of methanol and water (10:90 v/v). Working solutions were prepared by further 
dilution of the stock solutions with the same solvent to give a final desired concentration. The 
solutions were stable for one week when kept in the refrigerator at 2 oC. 
2.3.2.3.2. Background electrolyte (BGE) 
Optimized BGE solution was 40 mM sodium dihydrogen phosphate buffer adjusted to pH 
6 with 1 M NaOH 104 and filtered through a 0.2 µm membrane filter. 
2.3.2.4. Electrophoretic procedure 
Before the first use, the capillary was conditioned by flushing with 1.0 M NaOH for 60 
min, then with water for 30 min and BGE for 30 min at 0.5 psi pressure. At the beginning of 
each working day, the capillary was rinsed with 0.1 M NaOH for 10 min, water for 5 min and 
then with BGE for 5 min at 20 psi pressure. Before each injection, the capillary was 
preconditioned with 0.1 M NaOH (5 min), water (5 min) and BGE (5 min) at 20 psi pressure to 
maintain proper repeatability of run-to-run injections. Injection was carried out under 
hydrodynamic pressure at 0.5 psi for 2 s. PDA detector was set at 245 nm with a bandwidth of 20 
nm. The capillary temperature was kept constant at 25 ◦C and a voltage of 17 kV was applied 
(positive polarity). 
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2.3.2.5. Procedures 
2.3.2.5.1. Construction of calibration graphs 
Aliquots of the suitable drug stock or working standard solutions were transferred into a 
series of 4-mL vials so that the final concentrations were in the range of 1-10 µg/mL for AML, 
2.5-25 µg/mL for HCZ and 30-300 µg/mL for ALS. A constant 100 µL MXP stock solution was 
added (final concentration of 25 µg/mL) and the volumes were diluted to 4 mL with a solvent 
composed of methanol and water (10:90 v/v). The peak area ratio (peak area of the studied drug/ 
peak area of MXP) was plotted versus the final concentration of each drug in µg/mL to get the 
calibration graph. Alternatively, the corresponding regression equations were derived. 
2.3.2.5.2. Analysis of the cited drugs separately 
Aliquots of ALS, AML and HCZ standard solutions covering the working concentration 
ranges were transferred into a series of 4-mL vials, diluted with a solvent composed of methanol 
and water (10:90 v/v) after addition of 100 µL MXP and mixed well. The above procedure 
described under "Construction of calibration graphs" was then applied. The percentages found 
were calculated by referring to the calibration graphs, or using the corresponding regression 
equations. 
2.3.2.5.3. Analysis of ALS/AML/HCZ laboratory prepared mixtures 
Aliquots of ALS, AML and HCZ standard solutions keeping the pharmaceutical ratio of 
23.9:1.0: 1.8 m/m/m were transferred into a series of 4-mL vials, diluted with a solvent 
composed of methanol and water (10:90 v/v) after addition of 100 µL MXP and mixed well. The 
above procedure described under "Construction of calibration graphs" was then applied. The 
percentages found were calculated by referring to the calibration graphs, or using the 
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corresponding regression equations. 
2.3.2.5.4. Analysis of the studied drugs in Amturnide® co-formulated tablets 
Ten tablets were weighed and finely pulverized after decoating by careful rubbing with a 
clean tissue wetted with methanol. An accurately weighed amount of the fine powder (0.2748 
gm) equivalent to 4.000 mg ALS, 0.167 mg AML and 0.301 mg HCZ was transferred to 10-
mL volumetric flask and 6 mL of a solvent composed of methanol and water (10:90 v/v) was 
added. The flask was sonicated for 30 min and vortex mixing for 15 min by Fisher vortex 
(Fisher Scientific), and then diluted to the mark with the same solvent. The solution was 
filtered through Whatmann filter paper and then filtered again using 0.2 µm Whatmann 
inorganic membrane filter. For analysis, appropriate aliquots from the prepared sample solution, 
spiked with 100 µL MXP stock solution, was diluted to 4 mL using the same solvent. The above 
procedure described under "Construction of calibration graphs" was then applied. The 
percentages found were calculated by referring to the calibration graphs, or using the 
corresponding regression equations. All solutions were filtered through a 0.2 µm membrane filter 
and degassed for 5 min before injection to the CE system. 
2.3.3. Results and discussion 
The proposed method offered the separation and quantification of the studied drugs in 
their co-formulated tablets in a single run (less than 7 min) with good resolution.  Figure 2.3.2 
shows a typical electropherogram for a synthetic mixture of the studied drugs under the 
described electrophoretic conditions. The retention times for AML, ALS, HCZ and MXP were 
4.2, 4.4, 5.4 and 6.8 min., respectively. A large peak width of HCZ and MXP compared to AML 
and ALS was observed. The contributors to the peak width may be analyte wall interactions 
(wall adsorption) and/or electromigration dispersion 105-107. The proposed method offers good 
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sensitivity as about 0.11 µg/mL of AML, 0.33 of HCZ and 5.83 µg/mL of ALS could be 
detected. 
2.3.3.1. Optimization of CE conditions 
In CZE, the buffer type, pH and concentration is the key strategy for optimizing the 
separation of ionizable analytes as it determines the degree of the analyte ionization, its 
electrophoretic mobility and the magnitude of EOF. Several running buffers such as phosphate, 
acetate and borate at different pHs and molarities were tested for CZE analysis and the best 
results were obtained in phosphate buffer taking into consideration different parameters 
(migration time, resolution, peak shape, height, baseline noise and the electric current produced). 
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Figure 2.3.1 Typical electropherogram of synthetic mixture of 8 µg/mL of AML (4.2 min), 240 
µg/mL ALS (4.4 min), 20 µg/mL HCZ (5.4 min) and 25 µg/mL MXP (6.8 min). 
Operating conditions: 40 mM phosphate buffer (pH 6), injection (2 s at 0.5 psi), 17 kV, 25 
◦C, 245 nm (bandwidth 20 nm) 
  
  
164 
 
2.3.3.1.1. Effect of phosphate buffer pH 
The effect of the buffer pH was investigated within the range of 5.0–7.0 at a 40 mM 
phosphate buffer concentration.  The results demonstrated that the studied compounds were easily 
separated in this pH range and both resolution and migration times decreased with increasing pH. At 
pH less than 5, the separation of the sample matrix will take long time. At pH more than 7 
overlapping of ALS peak with AML peak was noticed. pH 6.0 was selected as optimum pH as it 
gave a good compromise regarding resolution, peak symmetry and migration time (Fig. 2.3.3). As 
ALS has pKa value of 9.49 
108, AML has pKa value of 8.6 
109  and HCZ has pKa values 7.0 and 9.09 
110, 
111, ALS and AML are positively charged at pH 6.0  and can be analyzed and separated from the 
unionized  HCZ by CZE. In fact, at this pH value HCZ neither underwent protonation nor deprotonation 
and as such remained a neutral compound thus migrated with the EOF. 
2.3.3.1.2. Effect of phosphate buffer concentration 
Buffer concentration has also a significant effect on the separation performance through 
its influence on the EOF and the current produced in the capillary. The effect of phosphate 
concentration of running buffer was examined by varying the concentration from 10 to 50 mM. 
As shown in Figure 2.3.4, with an increasing in phosphate concentration, both resolution and 
migration times increased. A 40 mM concentration of phosphate buffer was chosen in order to 
reduce the analysis time while maintaining good resolution (≈ 2.9, 8.8, 3.4, respectively) and 
acceptable current (≈ 41µA).  
2.3.3.1.3. Effect of organic modifiers 
The addition of organic modifiers to the running buffer was considered because they 
affect several parameters such as viscosity, dielectric constant and Zeta potential. In order to 
investigate the effect of organic modifiers, methanol, ethanol and acetonitrile were added at 
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various concentrations (5, 10 and 15% v/v) to the running background electrolyte of 40 mM 
phosphate buffer pH 6.0. No appreciable improvements were observed, but migration times 
increased significantly with the addition of organic modifiers. Therefore, no organic modifiers 
were incorporated in the proposed analysis method (Fig. 2.3.5). 
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Figure 2.3.2  Effect of phosphate buffer pH on separation of the studied drugs.  
Operating conditions: 40 mM phosphate buffer, injection (2 s, 0.5 psi), 17 kV, 25 ◦C, 245 nm 
(bandwidth 20 nm). Peak names and drugs conc.: are as given in Figure 2.3.1. 
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Figure 2.3.3 Effect of phosphate buffer conc. on separation of the studied drugs. 
Operating conditions: phosphate buffer (pH 6), injection (2 s, 0.5 psi), 17 kV, 25 ◦C, 245 nm 
(bandwidth 20 nm). Peak names and drugs conc.: are as given in figure 2 and the produced 
current (µA) is written. 
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Figure 2.3.4 Effect of organic modifiers on separation of the studied drugs (A) methanol, (B) 
ethanol, and (C) acetonitrile. 
Operating conditions: 40 mM phosphate buffer (pH 6), injection (2 s, 0.5 psi), 17 kV, 25 ◦C, 245 
nm (bandwidth 20 nm). Peak names and drugs conc.: are as given in figure 2.3.2. 
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2.3.3.1.4. Effect of applied voltage 
The applied voltage effect was investigated under the optimized conditions selected 
above from 5 to 20 kV. As expected, increasing the applied voltage increases the EOF, leading to 
shorter analysis time and higher efficiencies as shown in Figure 2.3.6. However, lowering the 
applied voltage to less than 10 kV decreases the EOF so the time for separation was more than 
20 min and increasing applied voltage to more than 20 kV exhibited higher currents and 
produced Joule’s heating. To limit this heating inside the capillary, the maximum applied voltage 
was chosen from an Ohm’s plot (current vs voltage). The selected voltage was 17 kV (current (≈ 
41 µA).  
2.3.3.1.5. Effect of injection time 
Injection time affects the peak width and peak height. Sample solutions were 
hydrodynamically injected at 0.5 psi while the injection time was varied from 1.0 to 5.0 s. After 
3.0 s, the peak widths of the studied compounds were increased and the peak shapes were 
deformed, so 2.0 s was selected as the optimum injection time (Fig. 2.3.7). 
2.3.3.1.6. Effect of capillary cartridge temperature 
Controlling the temperature of the capillary cartridge is important in capillary 
electrophoresis. The viscosity of the running buffer is dependent on capillary temperature, so 
changes in temperature cause changes in EOF, electrophoretic mobilities and injection volume. 
The influence of the temperature on analysis was investigated at 20, 25 and 30 ◦C. As shown in 
Figure 2.3.8, the selected temperature was 25 ◦C because it provided the best resolution and the 
generated current was not more than 42 µA. 
170 
 
-50000
0
50000
100000
150000
200000
250000
300000
0 2 4 6 8 10 12 14 16 18 20
mAU
Time,min
20 kV
17 kV
15 kV
13 kV
10 kV
5 kV
 
Figure 2.3.5 Effect of applied voltage (kV) on separation of the studied drugs. 
 Operating conditions: 40 mM phosphate buffer (pH 6), injection (2 s, 0.5 psi), 25 ◦C, 245 nm 
(bandwidth 20 nm). Peak names and drugs conc.: are as given in figure 2.3.2. 
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Figure 2.3.6 Effect of injection time (sec.) on separation of the studied drugs. 
Operating conditions: 40 mM phosphate buffer (pH 6), 17 kV, 25 ◦C, 0.5 psi, 245 nm (bandwidth 
20 nm). Peak names and drugs conc.: are as given in figure 2.32. 
 
172 
 
-50000
0
50000
100000
150000
200000
0 2 4 6 8 10 12 14 16 18 20
mAU
Time, min
20 ◦C
25◦C
30 ◦C
 
 
Figure 2.3.7 Effect of capillary cartridge temperature (◦C) on separation of the studied drugs. 
Operating conditions: 40 mM phosphate buffer (pH 6), 17 kV, 2 sec, 0.5 psi, 245 nm (bandwidth 
20 nm). Peak names and drugs conc.: are as given in figure 2.3.2. 
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2.3.3.1.7. Selection of internal standard (IS) 
The use of IS is recommended to compensate for injection errors, minor fluctuations 
effect of the migration time and improve the quantitative analysis. Then MXP was chosen as it 
possesses pka value of 5.4 
112 and its molar mass is high (535.03 g/mol) so it will be negatively 
charged under the optimized condition and as expected it eluted after HCZ 11. 
2.3.3.1.8. Selection of the detection wavelength 
In order to optimize sensitivity and detection limit of the method, a multi wavelength 
detection system (190–300 nm) was used in the CE system. For the simultaneous determination 
of the triple mixture, the maximum detection sensitivities were obtained at 245 nm (bandwidth 
20 nm). Figure 2.3.9 shows the effect of detection wavelength on the proposed CZE method.  
Optimum electrophoretic conditions for the CZE determination of the studied drugs are 
summarized in Table 2.3.1. At 5.4 minutes on the electropherogram (Fig. 2.3.2), this distinct 
wide CE peak corresponds to the migration time of HCZ (neutral analyte at pH 6.0) which also 
corresponds to the EOF. The electroosmotic mobility (μeof), apparent mobility (μa) and effective 
mobility (μe) was calculated and the data were abridged in Table 2.3.2. The subsequent apparent 
mobility (μap) of HCZ is determined to be 5.2 × 10-4 cm2/Vs (the electroosmotic mobility (μeof)) 
and its effective mobility (μe) is equal to zero as it is neutral compound under the optimized 
conditions.  On the other hand, AML retained overall positive charge under the operating 
conditions and thus is first to be eluted in the CZE process (the small positive ion migrated the 
fastest). ALS also retained overall positive charge and migrate with different mobility rate than 
AML according to charge-to-size ratio. MXP (IS) at pH 6.0 becomes negatively charged and 
migrated eventually towards the cathode due to the higher force of EOF.  Negatively charged 
species exhibit higher migration time and consequently negative effective mobilities.  
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Figure 2.3.8 Selection of the detection wavelength.  
Operating conditions: Operating conditions: 40mM phosphate buffer (pH 6), injection (2 s, 0.5 
psi), 17 kV, 25 ◦C. Peak names and drugs conc.:  are as given in figure 2.3.2. 
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Table 2.3.1 Typical electrophoretic conditions for the CZE determination of the studied drugs 
Capillary 
Fused silica capillary  
(57.0 cm total length and 50.0 cm effective length, 75.6 µm id)  
 
BGE 40 mM phosphate buffer at pH 6.0 
Applied Voltage Normal (positive) polarity, + 17 kV 
Detector DAD at 245 nm 
Bandwidth 20 nm 
Sample Injection  Hydrodynamic injection for 2 s under a pressure of 0.5 psi 
capillary Cartridge Temperature 25 oC 
Sample Solvent Methanol and water (10:90 v/v). 
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Table 2.3.2 Mobilities and migration times of the studied compounds using CZE 
Analyte Average 
Migration time 
(s) 
Electroosmotic 
mobility (μeof)  
 (× 10-4 cm2/ Vs) 
Apparent 
mobility (μa) 
(× 10-4 m2/Vs) 
Effective 
mobility (μe) 
(× 10-4 cm2/ Vs) 
EOF 
 
324 5.2   
AML 
 
252  6.7 1.5 
ALS 
 
264  6.4 1.2 
HCZ 
 
324  5.2 0 
MXP 
 
408  4.1 -1.1 
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2.3.3.2. Validation 
Validation of the proposed CZE method was performed with respect to linearity and 
range, specificity, limit of detection, limit of quantitation, accuracy, precision and robustness 
according to the ICH Guidelines 113   
2.3.3.2.1. Linearity and Range 
A linear relationship was established by plotting the peak area ratio (the studied drug 
peak area / IS peak area) against the drug concentration in µg/mL as shown in Figures 2.3.10-
2.3.12. The concentration ranges were found to be linear in the range of 1-10 µg/mL, 2.5-25 
µg/mL and 30-300 µg/mL for AML, HCZ and ALS, respectively. Linear regression analysis of 
the data gave the following equations: 
P = 0.0110 C - 0.0009                                (r=0.9999)      for AML 
P = 0.0203 C + 0.1298                               (r=0.9999)      for HCZ 
P = 0.0122 C + 0.0846                               (r=0.9998)      for ALS 
Where: P is the peak area, C is the concentration of the drug in µg/mL and r is the 
correlation coefficient.  
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Figure 2.3.9 Calibration curve for the CZE determination of ALS 
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Figure 2.3.10 Calibration curve for the CZE determination of AML. 
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Figure 2.3.11 Calibration curve for the CZE determination of HCZ. 
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The statistical analysis of the data 114 gave high values of the correlation coefficient (r) of 
the regression equations, small values of the standard deviation of residuals (Sy/x), 
of intercept (Sa), and of slope (Sb), and small values of the percentage relative standard deviation 
and the percentage relative error (Table 2.3.3). These data proved the linearity of the calibration 
graphs and indicated the high accuracy and precision of the proposed method. 
2.3.3.2.2. Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
LOQ and LOD were calculated according to ICH Q2R1 recommendations using the 
following equations 113:  
LOQ = 10 Sa /b and LOD = 3.3 Sa /b 
Where Sa = standard deviation of the intercept and b = slope of the calibration curve. 
  
The limit of quantitation (LOQ) was determined by establishing the lowest concentration 
that can be measured and below which the calibration graph is nonlinear. The limit of detection 
(LOD) 115 115 115 [238] [225] was determined by establishing the minimum level at which the 
analyte can be reliably detected. LOQ values were found to be 0.33, 1.01 and 17.65 µg/mL 
while, LOD values were found to be 0.11, 0.33 and 5.83 µg/mL for AML, HCZ and ALS, 
respectively. The results are shown in Table 2.3.3. 
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Table 2.3.3 Performance data for the determination of the studied drugs by the proposed CZE 
method 
Parameter AML HCZ ALS 
Linearity and range (µg/mL) 1-10 2.5-25 30-300 
Intercept (a) -0.0009 0.1298 0.0846 
Slope (b) 0.0110 0.0203 0.0122 
Correlation coefficient (r) 0.9999 0.9999 0.9998 
S.D. of residuals (Sy/x) 0.0005 0.0026 0.0277 
S.D. of intercept (Sa) 0.0004 0.0021 0.0215 
S.D. of slope (Sb) 0.0001 0.0002 0.0001 
Percentage relative standard deviation, % RSD 0.79 0.67 0.80 
Limit of detection, LOD (µg/mL) 0.11 0.33 5.83 
Limit of quantitation, LOQ (µg/mL) 0.33 1.01 17.65 
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2.3.3.2.3. Accuracy 
To prove the accuracy of the proposed method, the results of the assay of ALS, AML and 
HCZ, both in pure form and in pharmaceutical preparations were compared with those of the 
comparison method 116. Statistical analysis  114 of the results using Student's t-test and variance 
ratio F-test revealed no significant difference between the performance of the two methods 
regarding the accuracy (Tables 2.3.4 - 2.3.6). The comparison method 116 depends on the analysis 
of ALS, AML and HCZ triple mixture by ion-pair LC using C18 column, acetonitrile: 25 mM 
octane sulphonic acid sodium salt monohydrate (60: 40 v/v) as the mobile phase and UV 
detection at 232 nm. 
2.3.3.2.4. Precision 
2.3.3.2.4.1. Repeatability 
Intra-day precision (repeatability) was performed through replicate analysis of three 
concentrations of the studied drugs in pure forms on three successive times (Table 2.3.7). 
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 Table 2.3.4 Assay results for the determination of the studied drugs in pure forms by the CZE 
and comparison methods 
Compound 
Proposed method 
Comparison  method 
(HPLC) 116 
Amount taken 
(g/mL) 
Amount found 
(g/mL) 
% Found % Found 
AML 1.00 0.990 99.00 100.7 
 2.00 1.990 99.55 99.78 
 4.00 3.990 99.78 99.34 
 6.00 6.080 101.4 100.4 
 
8.00 7.990 99.89  
10.0 9.990 99.91  
Mean ± S.D.   99.92± 0.79 100.1± 0.60 
t   0.28 (2.31)  
F   1.73 (9.01)  
HCZ 2.50 2.490 99.68 100.0 
 5.00 4.950 99.00 99.22 
 10.0 10.10 100.7 101.1 
 15.0 15.10 100.6 99.57 
 
20.0 20.10 100.4  
25.0 24.90 99.64  
Mean ± S.D.   100.0± 0.67 99.98± 0.82 
t   0.04(2.31)  
F   1.50 (5.41)  
 ALS 30.0 30.00 100.1 101.2 
 60.0 60.20 100.3 99.14 
 120 120.5 100.5 99.66 
 180 181.8 101.1 100.5 
 
240 237.1 98.79  
300 302.7 100.9  
Mean ± S.D.   100.3± 0.81 100.1± 0.91 
t   0.26(2.31)  
F   1.27 (5.41)  
N.B.   Each result is the average of three separate determinations.  
The values between parentheses are the tabulated t and F values at P = 0.05 114. 
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Table 2.3.5 Assay results for the determination of the studied drugs in their laboratory prepared 
mixture and comparison methods 
Ratio 
 
Compound 
 
Proposed method 
Comparison                     
method 116 
 
Amount taken 
(g/mL) 
Amount found 
(g/mL) 
% Found % Found 
A
M
L
: 
H
C
Z
: 
A
L
S
 
1
.0
 :
 1
.8
: 
2
3
.9
  
m
/m
/m
 
AML 3.14 3.150 100.29 100.52 
 7.50 7.500 99.97 99.35 
 10.0 10.01 100.06 100.24 
Mean ± 
S.D. 
  100.11± 0.17 100.04± 0.61 
% RSD   0.17  
     
t   0.22 (2.36)  
F   1.68 (19.29)  
HCZ 5.65 5.610 99.26 99.18 
 13.5 13.71 101.58 100.84 
 18.0 18.05 100.27 99.71 
Mean ± 
S.D. 
  100.37± 1.17 99.91± 0.85 
% RSD   1.16  
     
t   0.18(2.36)  
F   1.62 (5.79)  
ALS 75.0 73.94 98.59 98.63 
 179 177.9 99.27 101.05 
 239 238.0 99.61 99.82 
Mean ± 
S.D. 
  99.16± 0.52 99.83± 2.21 
% RSD   0.52  
     
t   0.65(2.36)  
F   2.27 (5.79)  
N.B.   Each result is the average of three separate determinations.  
The values between parentheses are the tabulated t and F values at P = 0.05 114. 
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Table 2.3.6 Assay results for the determination of the studied drugs in their co-formulated tablets 
and comparison methods.  
Dosage 
Form 
 
Compound 
 
Proposed method 
Comparison                     
method (HPLC) 
116 
Amount 
taken 
(g/mL) 
Amount 
found 
(g/mL) 
% Founda % Founda 
A
M
T
U
R
N
ID
E
®
 3
0
0
-1
0
-2
5
 m
g
 t
a
b
le
ts
b
 
AML 3.14 3.180 101.2 98.88 
 7.50 7.500 99.98 100.86 
 10.0 10.10 101.1 99.85 
Mean ± 
S.D. 
  
100.75± 
0.67 
99.86± 0.99 
% RSD   0.67  
     
t   0.09 (2.36)  
F   1.56 (5.79)  
HCZ 5.65 5.720 101.3 99.82 
 13.5 13.60 100. 9 100.2 
 18.0 17.70 98.4 99.97 
Mean ± 
S.D. 
  
100.2± 
1.59 
99.98± 0.17 
% RSD   1.58  
     
t   0.05(2.36)  
F   
15.29 
(19.29) 
 
ALS 75.0 75.10 100.1 99.28 
 179 182.0 101.8 101.6 
 239 242.0 101.2 99.32 
Mean ± 
S.D. 
  
101.1± 
0.85 
100.1± 1.32 
% RSD   0.84  
     
t   0.29(2.36)  
F   2.68 (5.79)  
a Each result is the average of three separate determinations. 
b Labeled to contain 331.5 mg aliskiren hemifumarate (equivalent to 300 mg aliskiren as a free 
base), 13.87 mg amlodipine besylate (equivalent to 10 mg amlodipine as a free base) and 25 mg 
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hydrochlorothiazide; manufactured by Novartis Pharmaceuticals Corporation East, NJ, USA; 
batch # NDC 0078-0614-15. Nominal contents of AML = 10.07 mg as free base, of HCZ = 
25.05 mg as free base and of ALS = 303.30 mg as free base per tablet.The values between 
parentheses are the tabulated t and F values at P = 0.05 114. 
2.3.3.2.4.2. Intermediate Precision 
Inter-day precision (Intermediate precision) was assessed using three concentrations of 
the studied drugs in pure forms and three replicates of each concentration on three successive 
days. The results are summarized in Table 2.3.7. The relative standard deviations and percentage 
relative errors were found to be very small indicating excellent repeatability and intermediate 
precision of the proposed method. 
2.3.3.2.5. Robustness 
The robustness of the proposed method was evaluated by the constancy of the peak area 
ratio with the deliberated changes in the experimental parameters; these parameters include 
(phosphate buffer pH 6.0 ± 0.2, Phosphate buffer concentration 40 ± 5 mM, applied voltage 17 ± 
2 kV and capillary cartridge temperature 25 ± 2 ◦C). Analyses were carried out in triplicate and 
only one parameter was changed in the experiments at a time. These changes didn’t greatly affect 
the peak area ratio and migration times of the studied drugs (Table 2.3.8).  
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Table 2.3.7 Precision data for the determination the studied drugs by the proposed CZE method 
Parameters 
AML concentration 
(g/mL) 
HCZ concentration 
(g/mL) 
ALS concentration 
(g/mL) 
3.14 7.50 10.00 5.65 13.50 18.00 75.00 179.25 239.00 
In
tr
a
-d
a
y
 
Amount 
founda 
(g/mL) 
3.17 7.41 9.96 5.72 13.51 17.87 75.02 178.68 239.60 
3.11 7.57 10.21 5.65 13.63 17.97 75.72 179.36 242.08 
3.16 7.63 10.14 5.62 13.72 17.67 74.92 180.95 243.71 
(x ) 100.18 100.47 101.03 100.26 100.90 99.10 100.29 100.23 101.17 
±S.D. 1.05 1.50 1.29 0.87 0.79 0.85 0.59 0.65 0.87 
%RSD 1.05 1.49 1.28 0.87 0.78 0.86 0.58 0.65 0.86 
          
In
te
r-
d
a
y
  
 
Amount 
founda 
 (g/mL) 
3.21 7.42 10.09 5.66 13.85 18.12 75.97 181.56 239.60 
3.11 7.49 9.81 5.74 13.65 18.25 76.56 180.49 244.64 
3.18 7.68 9.97 5.62 13.63 17.98 75.22 177.58 243.73 
(x ) 100.83 100.40 99.57 100.43 101.54 100.64 101.22 100.35 101.53 
±S.D. 1.48 1.80 1.41 1.14 0.88 0.76 0.89 1.15 1.13 
%RSD 1.47 1.80 1.41 1.13 0.87 0.75 0.88 1.14 1.11 
          
a Each result is the average of three separate determinations 
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Table 2.3.8 Robustness data for the determination the studied drugs by the proposed CZE 
method 
Parameters 
Migration times 
(min.) 
Peak area ratios 
 
AML ALS HCZ AML ALS HCZ 
Optimized condition 4.20 4.40 5.40 0.066 2.976 0.538 
Buffer pH 
 
5.82 4.33 4.51 5.59 0.065 2.961 0.534 
6.21 4.05 4.25 5.15 0.067 2.979 0.538 
Buffer 
concocent-
ration (mM) 
35 4.10 4.25 5.20 0.064 2.969 0.537 
45 4.25 4.80 5.55 0.069 2.994 0.528 
Applied 
voltage (kV) 
15 4.76 4.98 6.13 0.076 2.606 0.524 
20 3.46 3.62 4.43 0.076 2.645 0.561 
Capillary 
temp. (oC) 
23 4.40 4.65 5.83 0.068 2.805 0.537 
27 4.08 4.25 4.95 0.066 2.928 0.585 
N.B.  Each result is the average of three separate determinations. 
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2.3.3.2.6. Specificity 
The specificity of the method was investigated by observing any interference encountered 
from common tablet excipients and it was confirmed that the signals measured was caused only 
by the analytes. Each film-coated tablet of Amturnide® contains the following inactive 
ingredients: colloidal silicon dioxide, crospovidone, hypromellose, iron oxide red, iron oxide 
yellow, iron oxide black, magnesium stearate, microcrystalline cellulose, polyethylene glycol, 
povidone, talc, and titanium dioxide. It was found that these compounds did not interfere with 
the results of the proposed method. As shown in Figures 2.3.13, 2.3.14 the tablets did not show 
any additional peak when compared to the synthetic mixture electropherogram which confirm 
the specificity of the method (Table 2.3.6). 
2.3.3.3. Analysis of AML, HCZ and ALS in laboratory prepared mixtures and co-formulated 
tablets 
The proposed CZE method was applied to the simultaneous determination of AML, 
HCZ and ALS in laboratory prepared mixtures in the medicinally recommended ratio of 1.0: 
1.8: 23.9 m/m/m, respectively (Fig. 2.3.13). Furthermore, the proposed method was successfully 
applied to their determination in co-formulated tablets (Fig. 2.3.14). The average percent found 
of different concentrations were based on the average of three replicate determinations. The 
results shown in Tables 2.3.5,2.3.6 are in good agreement with those obtained using a 
comparison method 116. Statistical analysis of the results obtained using Student’s t-test and 
variance ratio F-test 114 revealed no significant difference between the performance of the two 
methods regarding the accuracy and precision, respectively.  
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Figure 2.3.12 Application of the proposed method for the simultaneous determination of a 
laboratory prepared mixture of 8 g/mL of AML, 240 g/mL ALS, 20 g/mL HCZ and 25 
g/mL MXP (IS).  
Operating conditions: 40mM phosphate buffer (pH 6), injection (2 s, 0.5 psi), 17 kV, 25 ◦C and 
DAD at 245 nm (bandwidth 20) 
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Figure 2.3.13 Application of the proposed method for the simultaneous determination of the 
studied drugs in Amturnide® tablets (7.5 g/mL of AML, 179.25 g/mL ALS, 13.5 g/mL HCZ 
and 25 g/mL MXP; IS).  
Operating conditions: 40 mM phosphate buffer (pH 6), injection (2 s, 0.5 psi), 17 kV, 25 ◦C and 
DAD at 245 nm (bandwidth 20) 
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2.4 Conclusions 
In section 2.2, a new, simple, accurate, selective and validated CZE method was 
developed for the simultaneous determination of VAL, AML and HCZ in ternary mixture. The 
proposed method has distinct advantages regarding reliability, selectivity and operation cost.  
LOD of 1.82, 0.39, 0.65 µg mL-1 and LOQ of 5.51, 1.17, 1.96 µg mL-1 for VAL, AML and HCZ, 
respectively were obtained. Moreover, this method was successfully applied for the analysis of 
the three medications in their laboratory prepared mixtures and co-formulated tablets.  
In section 2.3, a novel, simple, accurate and precise CZE method was explored for the 
simultaneous determination of AML, HCZ and ALS in triple mixture. The developed method has 
distinct advantages regarding analysis time, sensitivity and cost compared with those of the 
previously reported methods.  Limits of detection of 0.11, 0.33 and 5.83 g/mL and limits of 
quantitation of 0.33, 1.01 and 17.65 g/mL for AML, HCZ and ALS, respectively were obtained. 
The good validation criteria of the proposed method allow its utilization for quality control 
laboratories. In addition, it is a good analytical tool for the simultaneous analysis of the studied 
drugs in their co-formulated tablets. Moreover, the analysis of the same therapeutic class drugs in 
a single run has the advantage of a unique sample extraction procedure and a shorter analytical 
run, thus reducing the overall turnaround time. In addition, this method consumes no organic 
solvents and thus it can be classified as green chemistry. 
Finally, the proposed methods can be used for the quality control of the cited drugs in 
ordinary laboratories.  
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3 SPECTROMETRIC DETERMINATION OF SOME SELECTED 
PHARMACEUTICAL COMPOUNDS 
3.1 Introduction 
Fluorescence spectrometry, by virtue of its great inherent sensitivity, finds wide applications 
in quantitative studies of rates of degradation, metabolism and excretion of drugs where other 
analytical techniques are not sufficiently sensitive 1. The two main advantages of fluorimetric 
analysis are that, it is capable of measuring much lower concentrations than spectrophotometric 
analysis, and that it is potentially more selective because both the excitation and emission 
wavelengths can be varied and because not every compound fluoresce. Moreover, measuring the 
synchronous fluorescence spectra of analytes with overlapping emission spectra can help also to 
increase the selectivity of the spectrfluorimetric technique 2. Fluorimetric analysis is typically 
sensitive down to 10-8 to 10-9 M concentration, depending on the intensity of the excitation 
source, the quantum efficiency and molar absorptivity of the analyte 3. 
Different compounds can be assayed fluorimetrically by procedures utilizing, either their 
inherent fluorescence or the fluorescence of suitable derivatives of them. The most important 
application of fluorimetry is in the analysis of pharmaceuticals, clinical samples, food products, 
and natural products. The sensitivity and selectivity of the method make it a particularly valuable 
tool in these fields. Moreover, several inorganic species can be determined fluorometrically 
based on either direct formation of fluorescent chelates or the measurement of the decrease in 
fluorescence intensity due to the quenching action of the substance being determined 4.  
Fluorescence techniques are based on the measurement of emitted photons of an excited 
analyte. Fluorescence can be enhanced by increasing the radiative rate of a molecule. In 
particular, shielding the fluorescent molecule from quenching impurities and/or solvent 
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molecules can be used to achieve this enhancement. Surfactant organized assemblies such as 
micelles, reversed micelles, and microemulsions have been used extensively to enhance the 
fluorescence. It is well known that the addition of a surfactant at a concentration above its critical 
micellar concentration to a given fluorophore solution increases the molar absorptivity and/or the 
fluorescence quantum yield of the fluorophore 5, 6.  
The enhanced fluorescence in micellar media may be attributed to stabilization and/or 
protection of the excited singlet state, which hinders decay by quenching, and other non‐radiative 
deactivation processes. The radiative relaxation process of the analyte is modified when it is 
solubilized in the micellar system because the micelle not only protects the analyte from 
quenching molecules but also modifies the physical properties of the environment around it, i.e., 
viscosity, polarity, etc. The enhancement was found to be dependent on the structure of the 
surfactant and the analyte 7, 8. 
This enhancement facilitates the use of this technique as a complementary means for the 
detection and identification of fluorescent compounds. This general observation has been used to 
improve the performance of spectrofluorimetric methods of various analytes and active drugs 9-20. 
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3.2  Steady-state and synchronous spectrofluorimetric methods for simultaneous 
determination of aliskiren hemifumarate and amlodipine besylate in dosage forms 
Copyright © 2014 John Wiley & Sons, Ltd 
Luminescence (2014) 29(7): 878-83 
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Aliskiren hemifumarate (ALS) and amlodipine besylate (AML) were simultaneously 
determined by two different spectrofluorimetric techniques.  The first technique depends on 
direct measuring of the steady state fluorescence intensities of ALS and AML at 313 nm and 452 
nm upon excitation at 290 and 375 nm, respectively, in a solvent composed of methanol and 
water (10:90 v/v). The second technique utilizes synchronous fluorimetric quantitative screening 
of the emission spectra of ALS and AML at 272 and 366 nm, respectively using Δλ of 97 nm. 
Effects of different solvents and surfactants on relative fluorescence intensity were studied. The 
method was validated according to ICH guidelines. Linearity, accuracy and precision were found 
to be satisfactory in both techniques over the concentration ranges of 1 – 15 and 0.4 – 4 µg ml-1 
for ALS and AML, respectively. In the first technique, LOD and LOQ were estimated and found 
to be 0.256 and 0.776 g ml-1 for ALS as well as 0.067 and 0.204 g ml-1 for AML, respectively. 
Also, LOD and LOQ were calculated in the synchronous method and found to be 0.293 and 
0.887 g ml-1 for ALS as well as 0.034 and 0.103 g ml-1 for AML, respectively. The methods 
were successfully applied for the determination of the two drugs in their co-formulated tablets. 
The results were compared statistically with reference methods and no significant difference was 
found. The developed methods are rapid, sensitive, cheap and accurate for the quality control and 
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routine analysis of the cited drugs in bulk and in pharmaceutical preparations without pre-
separation. 
3.2.1. Introduction 
Aliskiren hemifumarate, (2(S), 4(S), 5(S), 7(S)-N- (2-carbamoyl- 2- methylpropyl) -5-
amino-4-hydroxy2,7 diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl] octanamide 
hemifumarate) (Fig. 1.3.1f), is the first orally active direct renin inhibitor. It may provide higher 
protection from hypertension 21. Also, its efficacy to decrease systolic and diastolic blood 
pressure could be compared to other first-line antihypertensive agents. Additional advantages can 
be achieved when it is used in combination with other antihypertensive drugs 21. Amlodipine 
besylate (AML), (3-Ethyl 5-methyl (4RS)-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-6-
methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate) (Fig. 1.3.1g), is a long-acting 
dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular 
and cardiac muscles 22. Amlodipine acts directly on vascular smooth and reduces peripheral 
vascular resistance and blood pressure 23. Combination therapy of ALS and AML proved to be 
effective and well tolerated in treating hypertensive patients 24.  
Literature survey revealed LC 25-28, CE 29, UV-spectrophotometric 30, 31 and 
spectrofluorimetric 32, 33 methods reported for the estimation of aliskiren hemifumarate alone or 
in combination with other anti-hypertensive agents. Also, LC 34-36, LC/MS/MS 22, CE 37, UV-
spectrophotometric 38-40 and spectrofluorimetric 41, 42 methods are reported for estimation of 
amlodipine alone or in combination with other agents. To the best of our knowledge, there are no 
reported direct or synchronous spectrofluorimetric methods for determination of ALS either 
alone or in combination with AML without the need for derivatization methodologies. Thus, the 
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aim of the present study was to develop validated, sensitive, simple, rapid, cheap and precise 
spectrofluorimetric procedures for analysis of ALS and AML in bulk drug samples and in their 
combined dosage formulations. The developed methods are suitable for quality control and 
routine analysis of ALS in its commercial dosage forms either alone or co-formulated with 
AML.  
3.2.2. Experimental 
3.2.2.1. Materials and Reagents 
All the chemicals used in the present studies were of analytical reagent grade and the solvents 
were of HPLC grade.  
Working standard of ALS (certified to contain 99.51%) was kindly supplied by Novartis 
Pharmaceuticals Corporation (East, New Jersey- USA 07936). AML (certified to contain 99.75%) 
was kindly supplied by Global Nabi Co., (Giza- Egypt). Hydrochlorothiazide (HCZ) (certified to 
contain 99.93%) was supplied by AstraZeneca (Cairo- Egypt) (Under license of AstraZeneca, 
Sweden). Tekamlo® 150/10 mg tablets labeled to contain 165.8 mg ALS and 13.9 mg AML per each 
tablet were purchased from commercial sources in the local market. Methanol, Sodium dodecyl 
sulphate (SDS), cetyl trimethyl ammonium bromide (CTAB), hydroxymethyl cellulose (HMC) and 
Triton® X-100 were obtained from Sigma-Aldrich, MO, USA. β-Cyclodextrin (β-CD) (TCI, Tokyo 
Kasei, Japan). Orthophosphoric acid 85% and hydrochloric acid (Fisher Scientific, NJ, USA) were 
used. Sodium hydroxide and sodium dihydrogen phosphate were purchased from J.T. Barker, NJ, 
USA. Phosphate buffer (0.2 M, pH 4) solution was freshly prepared. SDS, CTAB, β-CD, HMC and 
Triton® X-100 were prepared as 1% w/v aqueous solutions. Also, 0.1N NaOH and 0.1N HCl were 
prepared. 
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3.2.2.2. Instruments 
A LS 55 Fluorescence Spectrometer, 120 V (PerkinElmer, Waltham, MA, USA), 
equipped with a high energy pulsed xenon source for excitation, variable slit and holographic 
gratings was used. Fluorescence spectra and measurements were recorded using PekinElmer FL 
WinLab™ software. A 1 cm quartz cell was used. A VWR SympHoly (SB20) pH meter (Thermo 
Orion, Beverly, MA, USA) was used for pH measurements. Deionized water was prepared using 
a Barnstead NANO pure Dlamond Analytical ultrapure water system (Thermo Fischer Scientific, 
Waltham, MA, USA). 
3.2.2.3. Standard solutions 
Ten mg of ALS, AML and HCZ were accurately weighed and transferred separately into 
10 mL volumetric flasks. Then, they were dissolved and made up to volume with methanol to 
give concentrations of 1000 g mL-1 for each. Further dilutions were made separately using the 
same solvent to prepare 100 g mL-1 of AML and HCZ. 
3.2.2.4. Procedures 
3.2.2.4.1. Linearity and construction of calibration graphs 
Aliquots of ALS and AML standard stock solutions were separately transferred into two 
series of 10 ml Fisherbrand disposable tubes to give final concentrations of 1–15 and 0.4–4 µg 
mL-1 for ALS and AML, respectively, then completed to 500 µL with methanol. Finally, 4.5 mL 
deionized water were added to each tube to reach final volume of 5 mL, the contents were mixed 
well. Relative fluorescence intensity (RFI) was measured in two ways. In the first technique, it 
was measured directly against a solvent blank at 313 and 452 nm upon excitation at 290 and 375 
nm for ALS and AML, respectively. Excitation and emission slit width of 4.5 were used in the 
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case of ALS as well as 8 in the case of AML, (Fig. 3.2.1). In the second technique, RFI of the 
synchronous spectrofluorimetric spectra were measured against a solvent blank using Δλ of 97 at 
272 and 366 nm for ALS and AML, respectively, (Fig. 3.2.2). The excitation and emission slit 
width were 8. RFI was plotted versus the corresponding final drug concentration of ALS and 
AML (µg mL-1) to obtain the calibration graphs and regression equations. Figures (3.2.3 – 3.2.6) 
show linear relationships which were established by plotting the RFI against ALS and AML 
concentrations in µg mL-1. Linear regression analysis of the data gave the following equations:         
RFIALS = 063.679C + 7.138             (r=0.9999); (Conventional method)                  eq. (1) 
RFIAML= 241.398C + 0.417             (r=0.9998); (Conventional method)                  eq. (2) 
RFIALS = 060.459C + 28.911           (r=0.9999); (Synchronous method)                   eq. (3) 
RFIAML= 233.118C – 0.214             (r=0.9999); (Synchronous method)                   eq. (4) 
Where: RFI is the relative fluorescence intensity, C is the concentration of ALS or AML 
in µg mL-1 and r is the correlation coefficient. 
3.2.2.4.2. Analysis of ALS and AML laboratory prepared mixtures 
Aliquots of ALS and AML standard stock solutions were accurately transferred into a 
series of 10 mL Fisherbrand disposable tubes to give final concentrations of 4.8 – 14.4 and 0.4 – 
1.2 µg mL-1 for ALS and AML, respectively. The procedure described under "Linearity and 
construction of calibration graphs" was then applied. The recovery percentage was calculated 
using the corresponding regression equation. Tables 3.2.1 and 3.2.2 show the mean percentage 
recoveries ± S.D. of ALS and AML using the proposed methods. 
3.2.2.4.3. Sample preparation and application to Dosage Form 
Twenty tablets of Tekamlo were weighed and finely powdered. A portion of the powder 
equivalent to ALS (50 mg) and AML (4.192 mg) was introduced into a 50 mL volumetric and 
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sonicated with 30 mL methanol for 15 minutes, and then diluted to the mark with methanol. The 
solution was filtered through Whatman filter paper. The procedure described under "Linearity 
and construction of calibration graphs" was then applied. The recovery percentage was 
calculated using the corresponding regression equations. Standard addition technique was 
applied and the concentrations of the examined drugs were calculated using the corresponding 
regression equation. Tables (3.2.3 – 3.2.6) show the mean percentage recoveries ± S.D. of ALS 
and AML using the proposed methods. 
3.2.2.5. Validation 
The suggested analytical method was validated according to ICH guidelines with respect 
to certain parameters such as linearity, LOD and LOQ, accuracy, precision, specificity and 
stability. 
3.2.2.5.1. Linearity 
The linearity of the method was established by spiking a series of standard mixtures in 
the range 1–15 and 0.4–4 µg mL-1 of ALS and AML, respectively. The procedure described 
under "Linearity and construction of calibration graphs" was applied. Linear regression was 
applied and standard deviation of slope (Sb), standard deviation of intercept (Sa), correlation 
coefficient (r) and standard error (Es) were determined. 
3.2.2.5.2. Limit of detection & Limit of quantification 
Detection and quantification limits were determined through dilution method using S/N 
approach. LOD was considered as the minimum concentration with a signal to noise ratio of at 
219 
 
least three (S/N˜3), while LOQ was taken as a minimum concentration with a signal to noise 
ratio of at least ten (S/N˜10). 
3.2.2.5.3. Accuracy 
Accuracy was determined in terms of percent recovery. A set of standard mixtures at six 
different concentration levels 4.8, 7.2, 9.6, 12, 13.2, 14.4 µg mL-1 of ALS and 0.4, 0.6, 0.8, 1, 
1.1, 1.2 µg mL-1 of AML were prepared. The procedure described under "Linearity and 
construction of calibration graphs" was then applied. The percentage recoveries of ALS and 
AML were calculated. 
3.2.2.5.4. Precision 
Method precision was determined both in terms of repeatability (intra-day 
reproducibility) and intermediate precision (inter-day reproducibility) using three different 
concentration levels 2, 6, 12 µg mL-1  of ALS and 0.6, 1.8, 3.4 µg mL-1 of AML.  
3.2.2.5.5. Specificity 
Specificity was examined by analyzing ALS and AML in their laboratory prepared 
mixtures and pharmaceutical dosage forms to detect any interference caused by the combined 
drugs present in dosage formulations or the co-formulated excipients.  Also, specificity was 
checked by analyzing 12 µg mL-1 ALS and 0.5 µg mL-1 AML in their triple mixture with 0.5, 1 
and 2 µg mL-1 of HCZ. The percentage recovery and standard deviation were calculated.  
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3.2.2.5.6. Stability 
The stability studies of ALS and AML samples were carried out over a period of 72h at 
2–80 °C (refrigerator) and standard stock solutions for one month at 2–80 °C. 
 
 
 
 
Figure 3.2.1 Excitation (A, C) and direct fluorescence spectra of (B, D) of ALS and AML 
respectively (ALS: 12 µg mL-1 and AML: 3 µg mL-1) in a solvent composed of methanol and 
water (10:90, v/v) and (A`, B`, C`, D`) for blank solvent composed of methanol and water 
(10:90, v/v). Where (A, C, A`, C`) are the excitation spectra and (B, D, B`, D`) are the emission 
spectra 
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Figure 3.2.2 Synchronous fluorescence spectra of (A) ALS (12 µg mL-1), (B) AML (3 µg mL-1) 
in a solvent composed of methanol and water (10:90, v/v) and (A, B`) solvent composed of 
methanol and water (10:90, v/v) 
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Figure 3.2.3 Standard calibration curve for determination of ALS by the proposed conventional 
spectrofluorimetric method 
 
 
Figure 3.2.4 Standard calibration curve for determination of AML by the proposed conventional 
spectrofluorimetric method 
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Figure 3.2.5 Standard calibration curve for determination of ALS by the proposed synchronous 
spectrofluorimetric method 
 
 
 
Figure 3.2.6 Standard calibration curve for determination of AML by the proposed synchronous 
spectrofluorimetric method 
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Table 3.2.1 Determination of ALS and AML using the conventional spectrofluorimetric method 
RFIALS = 063.679C + 7.138 
RFIAML= 241.398C + 0.417 
 
Mixture 
No 
Amount taken 
[μg/ml] 
ALS AML 
ALS AML 
RFI of 
ALS 
Found 
[μg/ml] 
Recovery 
% 
RFI of 
AML 
Found 
[μg/ml] 
Recovery 
% 
1 4.8 0.4 303 96 4.870 0.396 101.47 98.99 
2 7.2 0.6 456 148 7.273 0.611 101.01 101.89 
3 9.6 0.8 593 196 9.424 0.810 98.17 101.28 
4 12.0 1.0 747 241 11.843 0.997 98.69 99.66 
5 13.2 1.1 822 264 13.021 1.092 98.64 99.26 
6 14.4 1.2 936 295 14.811 1.220 102.85 101.69 
Mean 
 
100.14 
 
100.46 
± S.D. 1.90 1.30 
± S.E. 0.78 0.53 
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Table 3.2.2 Determination of ALS and AML using the synchronous spectrofluorimetric method 
RFIALS = 060.459C + 28.911            
RFIAML= 233.118C – 0.214 
 
Mixture 
No 
Amount taken 
[μg/ml] 
ALS AML 
ALS AML 
RFI of 
ALS 
Found 
[μg/ml] 
Recovery 
% 
RFI of 
AML 
Found 
[μg/ml] 
Recovery 
% 
1 4.8 0.4 317 92 4.765 0.396 99.27 98.89 
2 7.2 0.6 459 139 7.114 0.597 98.80 99.53 
3 9.6 0.8 599 187 9.429 0.803 98.22 100.39 
4 12.0 1.0 757 231 12.043 0.992 100.36 99.18 
5 13.2 1.1 832 254 13.283 1.090 100.63 99.14 
6 14.4 1.2 906 279 14.507 1.198 100.74 99.81 
Mean 
 
99.67 
 
99.49 
± S.D. 1.05 0.54 
± S.E. 0.43 0.22 
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Table 3.2.3 Determination of ALS using the conventional spectrofluorimetric method 
RFIALS = 063.679C + 7.138 
 
Mixture 
No 
Amount of ALS 
(μg/ml) 
RFI of ALS 
Amount of ALS found 
(μg/ml) 
Recovery % 
Tablet Added Tablet 
Tablet & 
added 
Tablet 
Tablet & 
added 
Added Tablet Added 
1 6 4 363 616 5.813 9.786 3.973 96.88 99.33 
2 6 6 363 748 5.813 11.859 6.046 96.88 100.77 
3 6 9 363 939 5.813 14.858 9.045 96.88 100.50 
4 9 4 551 806 8.767 12.769 4.002 97.41 100.06 
5 9 5 551 876 8.767 13.869 5.102 97.41 102.03 
6 9 6 551 940 8.767 14.874 6.107 97.41 101.78 
Mean 
 
97.14 100.74 
± S.D. 0.29 1.03 
± S.E. 0.12 0.42 
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Table 3.2.4 Determination of AML using the conventional spectrofluorimetric method 
RFIAML= 241.398C + 0.417 
 
Mixture 
No 
Amount of AML 
(μg/ml) 
RFI of AML 
Amount of AML found 
Recovery % 
(μg/ml) 
Tablet Added Tablet 
Tablet & 
added 
Tablet 
Tablet & 
added 
Added Tablet Added 
1 0.503 0.4 115 213 0.475 0.881 0.406 94.38 101.49 
2 0.503 1.0 115 355 0.475 1.469 0.994 94.38 99.42 
3 0.503 2.0 115 602 0.475 2.492 2.017 94.38 100.87 
4 0.754 0.6 179 323 0.740 1.336 0.597 98.06 99.42 
5 0.754 1.0 179 422 0.740 1.746 1.007 98.06 100.66 
6 0.754 2.0 179 671 0.740 2.778 2.038 98.06 101.91 
Mean 
 
96.22 100.63 
± S.D. 2.02 1.03 
± S.E. 0.82 0.42 
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Table 3.2.5 Determination of ALS using the synchronous spectrofluorimetric method. 
RFIALS = 060.459C + 28.911            
 
Mixture 
No 
Amount of ALS 
(μg/ml) 
RFI of ALS 
Amount of ALS found 
Recovery % 
(μg/ml) 
Tablet Added Tablet 
Tablet & 
added 
Tablet 
Tablet & 
added 
Added Tablet Added 
1 6 4 376 621 5.749 9.793 4.045 95.81 101.11 
2 6 6 376 738 5.749 11.728 5.980 95.81 99.66 
3 6 9 376 925 5.749 14.821 9.073 95.81 100.81 
4 9 4 563 801 8.834 12.770 3.937 98.15 98.41 
5 9 5 563 869 8.834 13.895 5.061 98.15 101.23 
6 9 6 563 928 8.834 14.871 6.037 98.15 100.62 
Mean 
 
96.98 100.31 
± S.D. 1.28 1.08 
± S.E. 0.52 0.44 
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Table 3.2.6 Determination of AML using the synchronous spectrofluorimetric method 
RFIAML= 233.118C – 0.214 
 
Mixture 
No 
Amount of AML 
(μg/ml) 
RFI of AML 
Amount of AML found 
Recovery % 
(μg/ml) 
Tablet Added Tablet 
Tablet & 
added 
Tablet 
Tablet & 
added 
Added Tablet Added 
1 0.503 0.4 113 205 0.486 0.880 0.395 96.56 98.66 
2 0.503 1.0 113 351 0.486 1.507 1.021 96.56 102.09 
3 0.503 2.0 113 588 0.486 2.523 2.038 96.56 101.88 
4 0.754 0.6 174 313 0.747 1.344 0.596 99.06 99.38 
5 0.754 1.0 174 409 0.747 1.755 1.008 99.06 100.81 
6 0.754 2.0 174 649 0.747 2.785 2.038 99.06 101.88 
Mean 
 
97.81 100.78 
± S.D. 1.37 1.46 
± S.E. 0.56 0.59 
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3.2.3. Results and Discussion: 
The goal of the present investigation was to develop validated, sensitive, simple and rapid 
specrofluorimetric analytical methods for simultaneous determination and quantification of ALS 
and AML in pharmaceutical preparations. Also, many trials were attempted to enhance the 
intensity of the emission bands and increase molar absorptivity and quantum yield through 
selection of proper solvent and addition of surfactants at concentrations above their critical 
micellar concentration in order to perform micelles or reversed micelles able to stabilize the 
exited singlet states and delay the decay process. The fluorescence performance of ALS was 
studied in various solvents and micellar media and a solvent composed of methanol and water 
(10:90 v/v) was chosen as no one of the studied media caused significant enhancement in RFI of 
ALS (Fig. 3.2.1 and 3.2.2).  
3.2.3.1. Optimization of the experimental conditions 
3.2.3.1.1. Effect of different organized media 
The fluorescence properties of ALS in various micellar media were studied using anionic 
surfactant (SDS), cationic surfactant (CTAB) and non-ionic surfactant (Triton® X-100) and 
different macromolecules, like β-Cyclodextrin (β-CD) and hydroxyl methyl cellulose (HMC). 
ALS has pKa above 9 so it will be positively charged under acidic conditions obtained by adding 
phosphate buffer (pH 4). No one of the examined surfactants showed significant enhancement in 
RFI of ALS, (Fig. 3.2.7). 
3.2.3.1.2. Effect of the diluting solvent 
For the steady state spectrofluorimetric procedure, the influence of different diluting 
solvents on RFI of ALS was investigated using water, methanol, phosphate buffer solution at pH 
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4, 0.1N HCl and 0.1N NaOH to give final solutions containing 10% v/v methanol for each. 
Water was chosen as diluting solvent as it showed a good RFI compared with methanol but it is 
friendlier to the environment and with much less blank readings, (Fig. 3.2.8). 
3.2.3.1.3. Selection of Δλ in the synchronous spectrofluorimetric method 
To separate entirely synchronous fluorescence peaks of ALS and AML, the synchronous 
fluorescence spectra of the mixtures were recorded using different Δλ. It was found that Δλ of 97 
nm is suitable for simultaneous determination of ALS and AML in their medicinally 
recommended ratio of (12: 1), respectively. The result was showed in (Fig. 3.2.2), where the 
maximum synchronous fluorescence peaks of ALS and AML were at 272 and 366 nm, 
respectively. Obviously, no significant interference would occur in their combined formulation`s 
ratio. 
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Figure 3.2.7 Effect of type of surfactant (1mL of 1% solution for each) on the RFI of ALS (8 µg 
mL-1) 
 
 
Figure 3.2.8 Effect of different diluting solvents on the RFI of ALS (8 µg mL-1) 
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3.2.3.2. Validation 
3.2.3.2.1. Linearity and Range 
The linearity of the calibration curves was validated by the high value of correlation 
coefficients (r) of the regression equation, small values of the standard deviation of residuals 
(Sy/x) and small value of the percentage relative error (Table 3.2.7). The analytical data of the 
calibration curves including standard deviations for the slope and intercept (Sb, Sa) are 
summarized in (Table 3.2.7). These data proved the linearity of the calibration graphs. 
3.2.3.2.2. Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
LOQ and LOD were calculated according to ICH Q2R1 recommendations using the 
following equations:    
LOQ = 10 Sa /b and LOD = 3.3 Sa /b 
Where: Sa = standard deviation of the intercept and b = slope of the calibration curve. 
 
 LOQ was determined by establishing the lowest concentration that can be measured and below 
which the calibration graph is nonlinear. LOD was determined by establishing the minimum level at 
which the analyte can be reliably detected. LOD and LOQ were estimated and found to be 0.256 and 
0.776 g mL-1 for ALS as well as 0.067 and 0.204 g mL-1 for AML, respectively. Also, LOD and 
LOQ were calculated in the synchronous method and found to be 0.293 and 0.887 g mL-1 for ALS as 
well as 0.034 and 0.103 g mL-1 for AML, respectively. The results are shown in Table 3.2.7. 
3.2.3.2.3. Accuracy  
Accuracy of the results was calculated by % recovery of 6 different concentrations of the 
two drugs analyzed by the proposed spectrofluorimetric methods. The results obtained including 
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the mean of the recovery and standard deviations are displayed in (Table 3.2.7). To prove the 
accuracy and utility of the proposed method, the results of the assay of ALS and AML with the 
proposed spectrofluorimetric methods were compared with those of the reference methods 26, 43. 
Statistical analysis of the results using Student's t-test and variance ratio F-test revealed no 
significant difference between the performance of the developed methods and reference methods 
regarding the accuracy and precision, respectively (Table 3.2.8). The reference method 26 and 
pharmacopeal method 43 depend on the analysis of ALS and AML, respectively, using RP-HPLC.  
3.2.3.2.4. Precision 
Repeatability (intra-day, n=3) and intermediate precision (inter-day, n=3) were checked 
using three different concentrations at low, medium and high level of the standard curve. Relative 
standard deviations were calculated to check the precision of the method, (Table 3.2.9). 
The relative standard deviations and percentage relative errors were found to be very small 
indicating reasonable repeatability and intermediate precision of the proposed method. 
3.2.3.2.5. Specificity 
The specificity of the methods was investigated by observing any interference 
encountered from the excipients of the tablets. It was shown that these compounds do not 
interfere with the proposed method (Table 3.2.7). It was also found that ALS and AML do not 
interfere with each other either in their laboratory prepared mixtures or in their co-formulated 
tablets (Table 3.2.7). Moreover, the steady state method showed better results and higher 
tolerance in presence of 1 µg mL-1 HCZ for the determination of ALS and AML than the 
synchronous method (Table 3.2.7). So, the steady state method is more reliable to be used for 
simultaneous determination of ALS and AML in presence of HCZ specifically in the medicinally 
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recommended ratio of (12:0.5:1), respectively, in their co-formulated tablets, Amturnide® (Table 
3.2.7).  
3.2.3.2.6. Stability 
Results from the stability studies of standard stock solutions indicated that they were 
stable for one month at 2–8 °C with satisfactory recovery percentage of about 98%. These 
solutions can therefore be used during this interval of time without the results being affected. 
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Table 3.2.7 Performance data and results of the proposed spectrofluorimetric methods for the 
simultaneous determination of ALS and AML 
Item 
Conventional fluorescence Synchronous fluorescence 
ALS AML ALS AML 
Linearity range (g mL-1) 1 – 15 0.4 – 4 1 – 15 0.4 – 4 
LOD (g mL-1) 0.256 0.067 0.293 0.034 
LOQ (g mL-1) 0.776 0.204 0.887 0.103 
Regression equation (Y) a: Slope (b) 63.679 241.398 60.459 233.118 
Standard deviation of slope (Sb) 0.548 2.114 0.595 1.031 
Intercept (a) 7.1382 0.4170 28.9113 - 0.2143 
Standard deviation of intercept (Sa) 4.942 4.928 5.362 2.403 
Regression coefficient (r) 0.9999 0.9998 0.9999 0.9999 
Standard deviation of residuals (Sy/x) 5.937 6.480 6.442 3.159 
%Error 1.292 0.448 1.378 0.467 
Results (Recovery ± S.D.) 
Drug in bulk 101.33 + 0.91 99.81 ± 0.84 100.74 ± 0.88 100.68 + 0.72 
Drugs in lab. mixture 100.14 + 1.90 100.46 ± 1.30 99.67 ± 1.05 99.49 + 0.54 
Drugs in lab. Mixture with HCZ 100.72 + 1.58 100.02 ± 0.35 95.68 ± 1.39 99.86 + 0.77 
Tekamlo® 150/10 mg tablets 97.14 + 0.29 96.22 + 2.02 96.98 ± 1.28 97.81 + 1.37 
Drug spiked to dosage form 100.74 + 1.03 100.63 + 1.03 100.31 ± 1.08 100.78 + 1.46 
a Y=a+bC, where C is the concentration in g mL-1 and Y is the peak area. 
b 95% confidence limit. 
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Table 3.2.8 Statistical comparison between analysis results of pure samples of the studied drugs 
using spectrofluorimetric methods and those of the reference methods 
Statistical 
Term 
ALS AML 
Reported 
method [6] 
Conventional 
fluorescence 
Synchronous 
fluorescence 
Reported 
method 
[24] 
Conventional 
fluorescence 
Synchronous 
fluorescence 
Mean 101.10 101.33 100.74 99.90 99.81 100.68 
±S.D. 1.64 0.91 0.88 1.59 0.84 0.72 
±S.E. 0.73 0.37 0.36 0.71 0.34 0.29 
%RSD 1.62 0.90 0.87 1.59 0.84 0.72 
n 5 6 6 5 6 6 
V 2.69 0.83 0.77 2.53 0.71 0.52 
Student`s t 
test 
 
0.783 
(1.833*) 
1.003 
(1.833*) 
 
0.180 
(1.833*) 
1.312 
(1.833*) 
F-test  
3.241 
(6.260*) 
3.494 
(6.260*) 
 
3.563 
(6.260*) 
4.865 
(6.260*) 
* Figures in parentheses are the theoretical t and F values at (p= 0.05) and n is the number of 
experiments. 
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Table 3.2.9 Intra-and inter-day validation for the spectrofluorimetric determination of ALS and 
AML 
Concentration of 
ALS (g mL-1) 
Intra-day assay Inter-day assay 
Direct 
fluorescence 
Found ± RSDa 
Synchronous 
fluoresence 
Found ± RSDa 
Direct 
fluorescence 
Found ± RSDa 
Synchronous 
fluoresence 
Found ± RSDa 
2 1.997 ± 0.79 1.959 ± 2.97 2.004 ± 1.18 1.967 ± 1.90 
6 5.975 ± 1.35 6.006 ± 1.26 5.996 ± 1.32 5.942 ± 1.74 
12 12.021 ± 0.72 12.092 ± 1.54 11.955 ± 1.13 12.056 ± 1.20 
Concentration of 
AML (g mL-1) 
Intra-day assay Inter-day assay 
Direct 
fluorescence 
Found ± RSDa 
Synchronous 
fluoresence 
Found ± RSDa 
Direct 
fluorescence 
Found ± RSDa 
Synchronous 
fluoresence 
Found ± RSDa 
0.6 0.609 ± 1.42 0.591 ± 1.51 0.604 ± 1.55 0.601 ± 2.09 
1.8 1.797 ± 0.96 1.813 ± 0.90 1.814 ± 1.13 1.835 ± 1.26 
3.4 3.397 ± 0.46 3.394 ± 0.58 3.419 ± 0.97 3.396 ± 0.41 
a Mean and standard deviation of three determinations 
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3.3  Spectrophotometric and Spectrofluorimetric Studies on Azilsartan Medoxomil and 
Chlorthalidone to be Utilized in their Determination in Pharmaceuticals 
Copyright © 2014 the author(s), publisher and licensee Libertas Academica Ltd. 
Analytical Chemistry Insights (2014) 7; 9:33-40 
DOI:  10.4137/ACI.S13768 
 
The angiotensin II receptor blocker, Azilsartan medoxomil (AZL) was determined 
spectrophotometrically and spectrfluorimetrically in its combination with chlorthalidone (CLT).  
The UV-spectrophotometric technique depends on simultaneous measurement of the first 
derivative spectra for AZL and CLT at 286 nm and 257 nm, respectively, in methanol. The 
spectrofluorimetric technique depends on measurement of the fourth derivative of the 
synchronous spectra intensities of AZL in presence of CLT at 298 nm in methanol. Effects of 
different solvents on spectrophotometric and spectrfluorimetric responses were studied. For, the 
spectrofluorimetric study, the effect of pH and micelle assisted fluorescence enhancement were 
also studied. The method was validated according to ICH guidelines. Linearity, accuracy and 
precision were found to be satisfactory over the concentration ranges of 8 – 50 and 2 – 20 µg 
mL-1 for AZL and CLT, respectively, in the spectrophotometric method as well as 0.01 - 0.08 µg 
mL-1 for AZL in the spectrofluorimetric method. The methods were successfully applied for the 
determination of the studied drugs in their co-formulated tablets. The developed methods are 
inexpensive and simple for the quality control and routine analysis of the cited drugs in bulk and 
in pharmaceuticals.  
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3.3.1 Introduction 
Azilsartan medoxomil (AZL), (5-Methyl-2-oxo-1,3-dioxol-4yl) methyl 2-ethoxy-1-{[2`-
(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-
carboxylate, (Fig. 1.2.1a). AZL is practically insoluble in water, freely soluble in methanol, 
dimethylsulfoxide, soluble in acetic acid, slightly soluble in acetone, and acetonitrile and 
sparingly soluble in tetrahydrofuran and 1-octanol 44. Azilsartan, the active metabolite of AZL, is 
a novel non-peptide angiotensin II type 1 (AT1) receptor blocker (ARB), was recently approved 
for treatment of hypertension 45. It has a superior ability to control systolic blood pressure (BP) 
relative to other widely used ARBs. Greater antihypertensive effects of AZL might be due in part 
to its unusually potent and persistent ability to inhibit binding of angiotensin II to AT1 receptors 
46. Preclinical studies have indicated that AZL may also beneficially affect cellular mechanisms 
of cardio-metabolic disease and insulin sensitizing activity 47. There is only one reported method 
44 for determination of AZL alone and it was applied to analysis in plasma. Chlorthalidone 
(CLT), (2-chloro-5- (1-hydroxy-3-oxoiso-indolin-1-yl) benzenesulfonamide), (Fig. 1.2.1b), is an 
orally taken thiazide-like diuretic for controlling hypertension and edema, including that 
associated with heart failure 48. CLT has been determined in different matrices either alone or in 
combination with other medications using LC 49, 50, LC/MS/MS 51, HPTLC 52, 53, 
chemiluminometry 54, spectrophotometry 55 and CE 56 techniques.  Binary combination therapies 
of AZL and CLT proved to induce significant reductions in systolic and diastolic BP in patients 
with mild to severe hypertension 57. Accordingly, it is desirable to develop validated simple 
analytical methods for assay of AZL in its combination with CLT either in their synthetic 
mixtures or in their combined pharmaceutical preparations. Regarding simultaneous 
determination of CLT and AZL, there is only one LC reported method  58, done on a symmetry 
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C18 column with a mobile phase consisting of methanol: Water: Acetonitrile : 0.1% Ortho 
phosphoric acid (30:35:15:5, v/v/v/v) at λ of 251 nm. To the best of our knowledge there is no 
spectrophotometric or spectrofluorimetric methods developed for determination of AZL either 
alone or in its combination with CLT. Hence, the aim of these studies was to develop and 
validate simple, rapid and inexpensive analytical methods using spectrophotometric and 
spectrofluorimetric techniques for determination of AZL in its combination with CLT to be 
applied to their determination in pharmaceuticals. These newly developed and validated methods 
can be used for routine analysis and quality control of the cited medications either separately or 
in combinations without pre-separation. 
3.3.2 Experimental 
3.2.2.1 Materials and reagents 
All the chemicals used in the present studies were of analytical reagent grade and the solvents 
were of HPLC grade.  
CLT (certified to contain 98%) was supplied by Ark Pharm. Inc., IL 60048 USA. AZL 
(certified to contain 98%) was supplied by D-L Chiral Chemicals, LLC., NJ 08540 USA.    
Edarbcyclor® 40-25 mg tablets; batch # NDC 64764-0994-30 (Takeda Pharmaceutical Company 
Limited, Tokyo, Japan) each labeled to contain 42.68 mg of azilsartan kamedoxomil (equivalent to 
40 mg AZL) and 25 mg CLT were purchased from commercial sources in local market. Methanol, 
Sodium dodecyl sulphate (SDS), cetyl trimethyl ammonium bromide (CTAB), and hydroxymethyl 
cellulose (HMC) were obtained from Sigma-Aldrich, MO, USA. β-Cyclodextrin (β-CD) (TCI, 
Tokyo Kasei, Japan). O-phosphoric acid 85% and hydrochloric acid (Fisher Scientific, NJ, USA) 
were used. Sodium hydroxide and sodium dihydrogen phosphate were purchased from J.T. Baker, 
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NJ, USA. Phosphate buffer solutions (PBS) (0.02 M) were freshly prepared. SDS, CTAB, β-CD and 
HMC were prepared as 1% w/v aqueous solutions. Also, 0.1N NaOH and 0.1N HCl were prepared. 
3.3.2.2 Instruments 
A Lambda 20 UV/VIS spectrometer (Perkin Elmer, Massachusetts, USA) was used for 
the spectrophotometric measurements whereas a LS 55 Fluorescence spectrometer, 120V (Perkin 
Elmer, Massachusetts, USA) was used for the spectrofluorimetric measurements. 
Spectrophotometric measurements and data handling were performed using UV WinLab 1.22 
software whereas fluorescence spectra measurements and data handling were performed using 
FL WinLab™ software. Quartz cells (1 cm) were used. A VRW SympHoly (SB20) pH-meter 
(Thermo Orion. Beverly, MA, USA) was used for pH measurements. Deionized water was 
prepared using a Barnstead NANO pure Dlamond Analytical ultrapure water system (Thermo 
Fischer Scientific, Waltham, MA, USA). 
3.3.2.3 Standard solutions 
10 mg of AZL and CLT were accurately weighed and transferred separately into 10 mL 
volumetric flasks. Then, they were dissolved and made up to volume with methanol to give 
concentrations of 1000 g mL-1 for each. Further dilutions were made separately using the same 
solvent to prepare 1 g mL-1 solutions for each. 
3.3.2.4 Procedures 
3.3.2.4.1 Linearity and construction of calibration graphs for the spectrophotometric technique 
Aliquots of AZL and CLT standard stock solutions (1000 g mL-1) were separately 
transferred into two series of 10 mL Fisherbrand disposable tubes to give final concentrations of 
8–50 and 2–20 µg mL-1 for AZL and CLT, respectively, then completed to 5 mL with methanol 
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and the contents were mixed well. The absorbance spectra were recorded against a methanol 
blank and then the first derivative spectra were obtained (number of points = 18), (Fig. 3.3.1). 
The amplitudes at 286 nm and 257 nm for AZL and CLT, respectively, were measured then 
plotted versus the corresponding final drug concentration of AZL and CLT (µg mL-1) to obtain 
the calibration graphs and the regression equations. Figures (3.3.2 & 3.3.3) show linear 
relationships which were established by plotting first derivative of the spectra for AZL or CLT at 
286 nm and 257 nm against AZL and CLT concentrations in µg mL-1. Linear regression analysis 
of the data gave the following equations:         
1DAZL = 0.0075C + 0.0064            (r=0.9998);                                                        eq. (1) 
1DCLT = 0.0224C - 0.0154              (r=0.9999);                                                       eq. (2) 
Where: 1D is the first derivative of the spectra for AZL or CLT at 286 nm and 257 nm, 
respectively. C is the concentration of AZL or CLT in µg mL-1 and r is the correlation 
coefficient. 
3.3.2.4.2 Linearity and construction of calibration graphs for the spectrofluorimetric technique 
Aliquots of AZL standard stock solution (1 g mL-1) were transferred into a series of 10 
ml Fisherbrand disposable tubes to give final concentrations in the range of 0.01-0.08 µg mL-1. 
Then, completed to 5 mL with methanol and the contents were mixed well. Relative fluorescence 
intensity (RFI) of the synchronous spectrofluorimetric spectra were recorded against a solvent 
blank using (Δλ= 110 nm, slit width for excitation and emission= 10 nm) and then the fourth 
derivatives were obtained (number of points = 90), (Fig. 3.3.4).  The amplitudes of the fourth 
derivative of the synchronous spectra at 298 nm were measured and plotted versus the 
corresponding final drug concentration of AZL (µg mL-1) to obtain the calibration graphs and 
regression equations. Figures (3.3.5 – 3.3.7) show linear relationships which were established by 
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plotting the RFI of AZL or CLT against their concentrations in µg mL-1. Linear regression 
analysis of the data gave the following equations:         
4DAZL = 789.1C + 0.7876             (r=0.9998); (Synchronous method)                  eq. (3) 
RFIAZL = 6289.8C+ 41.996           (r=0.9991); (Conventional method)                  eq. (4) 
RFIAML = 3922.4C + 3.534            (r=0.9996); (Conventional method)                 eq. (5) 
Where: 4D is the fourth derivative of the synchronous fluorescence for AZL, RFI is the 
relative fluorescence intensity, C is the concentration of AZL or CLT in µg mL-1 and r is the 
correlation coefficient. 
3.3.2.4.3 Preparation of AZL and CLT laboratory prepared mixtures 
For the spectrophotometric method, aliquots of AZL and CLT standard stock solutions 
(1000 g mL-1) were accurately transferred into a series of 10 ml Fisherbrand disposable tubes to 
give final concentrations of 9.6, 16.0, 24.0 g mL-1 for AZL and 6.0, 10.0, 15.0 g mL-1 for 
CLT. The procedure described under "section 2.2.4.2" was then applied. For the 
spectrofluorimetric method, aliquots of AZL and CLT standard stock solutions (1 g mL-1) were 
accurately transferred into a series of 10 ml Fisherbrand disposable tubes to give final 
concentrations of 0.0384, 0.0576, 0.0768 g mL-1 for AZL and 0.0240, 0.0360, 0.0480 g mL-1 
for CLT. The procedure described under "section 2.2.4.3" was then applied. For both methods, 
the percentage recoveries were calculated using the corresponding regression equation. Table 
(3.3.1) shows the mean percentage recoveries ± S.D. of AZL and CLT using the proposed 
methods. 
3.3.2.4.4 Sample preparation and application to dosage form 
Ten tablets of Edarbcyclor were weighed and finely powdered after removal of the coat 
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using a tissue moistened with methanol. A portion of the powder equivalent to AZL (40 mg) and 
CLT (25 mg) was introduced into a 25 mL volumetric flask and completed to volume with 
methanol. The solutions were sonicated for 30 min then filtered through a Whatman filter paper 
and then filtered again using 0.2 µm a Whatman inorganic membrane filter. For 
spectrophotometric analyses, different aliquots from the prepared sample solutions were scanned 
and manipulated using the same procedure described under section “2.2.4.2”. For the 
spectrofluorimetric analyses, further dilutions were prepared and different aliquots from the 
prepared sample solutions were scanned and manipulated using the same procedure described 
under section “2.2.4.3”. The percentage recoveries were calculated by referring to the 
corresponding regression equations. Table (3.3.1) shows that the mean percentage recoveries ± 
S.D. of ALS and AML using the proposed methods. 
3.3.2.5 Validation 
The suggested analytical methods were validated according to ICH guidelines with 
respect to certain parameters such as linearity, LOD and LOQ, accuracy, precision, specificity 
and stability. 
3.3.3 Results and discussion 
 The goal of the present investigations was to perform spectrophotometric and 
spectrophotometric studies on AZL and CLT in order to develop validated, rapid, sensitive, 
simple, inexpensive and selective spectrophotometric and specrofluorimetric methods for 
quantification of AZL in its combination with CLT. These studies focused on factors that 
enhance the absorbance or the intensities of the emission bands of each analyte separately and in 
their combination.  
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3.3.3.1 Optimization of experimental conditions for the spectrophotometric technique 
For the spectrophotometric technique, the effect of different diluting solvents such as 
methanol, 0.1N HCl and 0.1N NaOH on absorbance was studied. 0.1N NaOH showed a slightly 
higher response for both drugs, (Fig. 3.3.8). This solvent can be used for ordinary UV 
measurements of AZL or CLT separately at 260 nm and 232 nm, respectively.  Methanol was 
used as a convenient diluting solvent with satisfactory linearities in the range 8-50 and 2-20 µg 
mL-1 for AZL and CLT at 242 nm and 266 nm, respectively, (Fig. 3.3.1). The spectra of AZL 
and CLT in all the studied solvents showed severe overlap, (Fig. 3.3.1).  Obtaining the first 
derivative for the absorbance spectra of the analyzed drugs was able to resolve such overlapping 
between AZL and CLT, only in methanol, to be utilized for their simultaneous quantitative 
determination at 286 nm and 257 nm, respectively, (Fig.3.3.9). 
3.3.3.2 Optimization of experimental conditions for the spectrofluorimetric technique 
3.3.3.2.1. Effect of diluting solvent 
AZL is freely soluble in methanol so it was added to the solvent media in at least 10% of 
the final volume then either methanol, 0.1N HCl, 0.1N NaOH or PBS was added to complete the 
volume. The influence of these different diluting solvents on the relative fluorescence intensity 
(RFI) of AZL and CLT was studied and methanol was chosen as it showed the highest RFI, (Fig. 
3.3.10).  
3.3.3.2.2 Effect of pH 
The effect of pH on RFI of AZL and CLT was investigated and pH 7.5 was found to give 
slightly higher RFI for AZL as its pKa values is 6.1 and it will have higher ionization percentage 
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at that pH, (Fig. 3.3.11). For CLT (pKa = 9.4), it is highly ionized at all the studied pHs so the 
effect of the studied pH values was not significant, (Fig. 3.3.11).  
3.3.3.2.3 Effect of different organized media 
The fluorescence properties of AZL and CLT in various micellar media were studied 
using anionic surfactant (SDS), cationic surfactant (CTAB) and different macromolecules; (β-
CD) and (HMC). Micelles or reversed micelles are able to stabilize the exited singlet state and 
delay the decay process and thus may enhance the intensity of the emission bands 59. PBS of pH 
7.5 was used in this study to allow proper ionization of both analytes. None of the examined 
surfactants showed significant enhancement in RFI of AZL and CLT, (Fig. 3.3.12). 
3.3.3.2.4 Techniques and parameters settings 
Satisfactory linearities were obtained for AZL and CLT in methanol at 381 nm and 330 
nm, upon excitation at 260 nm, respectively, at slit width of excitation and emission of 10 nm, 
(Fig. 3.3.13), (Table 3.3.1). However, the spectra of AZL and CLT in all of the studied solvents 
showed severe overlap so they cannot be used for their simultaneous determination, (Fig. 3.3.13).  
Also, synchronous fluorescence was not able to resolve such overlap at (λ= 10 – 300 nm, slit 
width for excitation and emission= 5 - 10 nm), (Fig. 3.3.4). Obtaining the fourth derivative for 
the synchronous fluorescence spectra (λ=110 nm, slit width for excitation and emission= 10 nm) 
of the analyzed drugs was able to resolve such overlap between AZL and CLT, only in methanol, 
to be utilized for quantitative determination of AZL in presence of CLT at 298 nm in their 
medicinally recommended ratio of (1.6: 1), respectively, (Fig. 3.3.14). 
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3.3.3.3 Validation of the proposed methods  
3.3.3.3.1 Linearity and range 
Linear relationships between the responses of AZL or CLT and their corresponding 
concentrations were obtained. The regression equation y = bC ± a for each drug was also 
computed. In these studies, five concentrations for AZL or CLT were used. The linearity of the 
calibration curves was validated by the high value of correlation coefficients (r) of the regression 
equation, small values of the standard deviation of residuals (Sy/x) and small value of the 
percentage relative error (Table 3.3.1). The analytical data of the calibration curves including 
standard deviations for the slope and intercept (Sb, Sa) are summarized in (Table 3.3.1). These 
data indicate the linearity of the calibration graphs. 
3.3.3.3.2 Limit of detection and limit of quantification 
LOQ and LOD were calculated according to ICH recommendations 51. LOD was 
considered as the minimum concentration with a signal to noise ratio of at least three (S/N˜3), 
while LOQ was taken as a minimum concentration with a signal to noise ratio of at least ten 
(S/N˜10). Results are given in (Table 3.3.1).  
3.3.3.3.3 Accuracy and precision 
The satisfactory recovery results for the assay of AZL and/with CLT in their synthetic 
mixtures indicate the accuracy of the method, (Table, 3.3.2). Repeatability (intra-day) and 
intermediate precision (inter-day) were assessed using three concentrations and three replicates 
of each concentration. The relative standard deviations were found to be very small indicating 
reasonable repeatability and intermediate precision of the proposed method (Table 3.3.3).   
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3.3.3.3.4 Specificity 
The specificity of the method was investigated by observing any interference encountered 
from common tablet excipients and it was confirmed that the signals measured was caused only 
by the analytes. The inactive ingredients in Edarbcylor® are: mannitol, microcrystalline cellulose, 
fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crospovidone, magnesium stearate, 
hypromellose 2910, talc, titanium dioxide, ferric oxide red, polyethylene glycol 8000, and 
printing ink gray F1. It was found that the excipients did not interfere with the results, (Table 
3.3.2). For the spectrophotometric method, it was found that AZL and CLT can be determined 
simultaneously either in their laboratory prepared mixtures or in their co-formulated tablets, 
(Table 3.3.2). On the other hand, the spectrofluorimetric method was only able to determine AZL 
in presence of CLT in methanol, (Table 3.3.2).  
3.3.3.3.5 Stability 
Stabilities of the standard stock solutions of AZL and CLT, stored at 2 – 8 °C, were 
evaluated at various time points over 1 month. The concentrations of freshly prepared solutions 
and those aged for 1 month were calculated by the methods developed and the difference 
between them was found to be less than 2%. Also, the prepared solutions for analysis were found 
to be stable for at least 3 days at 2 – 8 °C and for a day at room temperature. These solutions can 
therefore be used during this interval of time without the results being affected. 
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Figure 3.3.1 Zero order UV-absorbance spectra of (a) 8, 12, 20, 30, 50 µg mL-1 AZL and (b) 2, 
4, 8, 12, 20 µg mL-1 CLT against (c) methanol blank 
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Figure 3.3.2 Standard calibration curve for determination of AZL by the proposed 
spectrophotometric method 
 
 
 
 
Figure 3.3.3 Standard calibration curve for determination of CLT by the proposed 
spectrophotometric method 
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Figure 3.3.4 Synchronous fluorescence spectra for 0.06 µg mL-1 of (a) AZL and (b) CLT upon 
excitation at 260 nm against (c) methanol blank using the described parameters 
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Figure 3.3.5 Standard calibration curve for determination of AZL by the proposed synchronous 
spectrofluorimetric method 
 
 
Figure 3.3.6 Standard calibration curve for determination of AZL by the proposed Conventional 
spectrofluorimetric method 
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Figure 3.3.7 Standard calibration curve for determination of CLT by the proposed Conventional 
spectrofluorimetric method 
 
 
 
Figure 3.3.8 Effect of different diluting solvents on the Zero order UV-absorbance spectra of (a) 
20 µg mL-1 of AZL at 260 nm and (b) 8 µg mL-1 of CLT at 232 nm 
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Figure 3.3.9 First derivative for the spectra of (a) 8, 12, 20, 30, 50 µg mL-1 of AZL and (b) 2, 4, 
8, 12, 20 µg mL-1 CLT against (c) methanol blank 
  
256 
 
 
Figure 3.3.10 Effect of different diluting solvents on the relative conventional fluorescence 
intensities for 0.02 µg mL-1 of AZL and CLT at 381 nm upon excitation at 260 nm using the 
described parameters 
 
  
257 
 
 
Figure 3.3.11 Effect of pH of PBS on the relative conventional fluorescence intensities for 0.02 
µg mL-1 of AZL and CLT at 381 nm upon excitation at 260 nm using the described parameters 
 
 
Figure 3.3.12 Effect of different surfactants (1 mL of 1% solution for each) on the relative 
conventional fluorescence intensities for 0.02 µg mL-1 of AZL and CLT at 381 nm upon 
excitation at 260 nm using the described parameters 
 
258 
 
 
 
Figure 3.3.13 Conventional emission spectra for 0.06 µg mL-1 of (a) AZL and (b) CLT upon 
excitation at 260 nm against (c) methanol blank using the described parameters 
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Table 3.3.1 Performance data and results of the proposed spectroscopic methods 
 
 
  
Item 
Spectrophotometric 
technique 
Spectrofluorimetric  
technique 
AZL 
(1D) 
CLT 
(1D) 
AZL 
(4D) 
AZL 
(381 nm) 
CLT 
(330 nm) 
Limit of detection, LOD  
(µg mL-1) 
0.977 0.296 0.001 0.001 0.002 
Limit of quantitation, LOQ  
(µg mL-1) 
2.960 0.897 0.003 0.004 0.005 
Intercept (a) 0.0064 -0.0154 0.7876 41.996 3.5339 
Slope (b) 0.0075 0.0224 789.1 6289.8 3922.4 
Correlation coefficient (r) 0.9998 0.9999 0.9998 0.9991 0.9996 
S.D. of residuals (Sy/x) 0.003 0.003 0.478 4.396 2.576 
S.D. of intercept (Sa) 0.002 0.002 0.267 2.469 2.043 
S.D. of slope (Sb) 0.001 0.001 8.048 74.453 61.598 
Percentage relative error, % 
Error 
0.75 0.55 0.76 0.94 1.23 
Linearity range (µg mL-1) 8.00-50.00 2.00-20.00 0.01-0.08 0.01-0.08 0.01-0.06 
Mean recovery ± %R.S.D. 
99.55± 
1.69 
100.62± 
1.24 
99.94± 
0.80 
99.54± 
2.09 
100.61± 
2.75 
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Table 3.3.2 Intra-and inter-day validation for the spectroscopic methods  
 Medication 
Concentration 
(µg mL-1) 
Intra-day assay Inter-day assay 
Found ±  
%R.S.D a 
Found ±  
%R.S.D a 
Spectrophotometric 
Technique 
AZL 
12.000 12.619 ± 0.63 12.124 ± 1.68 
20.000 20.124 ± 2.02 20.258 ± 1.01 
30.000 29.813 ± 1.23 29.457 ± 1.19 
    
CLT 
4.000 4.028 ± 0.32 4.051 ± 0.64 
8.000 7.905 ± 1.63 8.054 ± 1.66 
12.000 11.923 ± 1.08 11.789 ± 1.58 
Spectrofluorimetric 
Technique 
AZL 
   
0.015 0.015 ± 2.09 0.015 ± 2.92 
0.030 0.030 ± 2.22 0.030 ± 2.77 
0.050 0.050 ± 1.36 0.050 ± 2.88 
a Mean and standard deviation of three determinations 
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Figure 3.3.14 Fourth derivative of the synchronous fluorescence spectra for (a) 0.01, 0.02, 0.04, 
0.06, 0.08 µg mL-1 of AZL and (b) 0.01, 0.02, 0.03 0.04, 0.06 µg mL-1 of CLT against (c) 
methanol blank using the described parameters 
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Table 3.3.3 Assay results for the determination of the studied drugs in their laboratory prepared 
mixtures and dosage form 
 
Compound 
Synthetic mixtures (CLT: 
AZL) (1.0: 1.6) 
Dosage form 
 (Edarbcyclor® tablets) 
 
Amount 
taken 
(g mL-1) 
Amount 
found 
(g mL-1) 
% 
Found 
 
Amount 
taken 
(g mL-1) 
Amount 
found 
(g mL-1) 
% 
Found 
S
p
ec
tr
o
p
h
o
to
m
et
ri
c
 
 t
ec
h
n
iq
u
e 
CLT 6.000 6.045 100.74 6.000 6.045 97.95 
 10.000 9.839 98.39 10.000 10.286 99.10 
 18.000 17.875 99.31 18.000 17.875 101.71 
Mean 
recovery% 
  99.48   99.59 
± %R.S.D.   1.19   1.93 
 9.600 9.813 102.22 9.600 9.813 100.45 
AZL 16.000 15.813 98.83 16.000 16.480 101.17 
 28.800 28.480 98.89 28.800 28.480 100.48 
Mean 
recovery% 
  99.98   100.70 
± %R.S.D.   1.94   0.40 
       
S
p
ec
tr
o
fl
u
o
ri
m
e
tr
ic
 
te
ch
n
iq
u
e
 
AZL 0.0384 0.039 101.26 0.0384 0.037 97.40 
 0.0576 0.058 100.12 0.0576 0.057 99.30 
 0.0768 0.077 100.47 0.0768 0.076 98.80 
Mean 
recovery% 
  100.62   98.50 
± %R.S.D.   0.58   1.00 
Each result is the average of three separate determinations.  
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3.4 Conclusions 
In section 3.2, rapid, sensitive, and simple spectrofluorimetric methods were developed 
and validated for simultaneous determination of ALS and AML in bulk and in dosage forms. The 
proposed methods have many advantages regarding analysis time, sensitivity and cost compared 
with those of the previously reported methods. Also, the proposed methods are less pollutant to 
far extent as no harmful reagents are used. Moreover, lower values for LOD and LOQ could be 
obtained easily by controlling the slit width of excitation and emission which could allow 
determination of these drugs separately in plasma using the steady state spectrofluorimetric 
method. Moreover, the direct steady state method showed good tolerance and could be applied 
for the determination of ALS and AML in their co-formulated tablets with HCZ.  
In section 3.3, rapid, sensitive, inexpensive and simple spectrophotometric and 
spectrofluorimetric methods were developed and validated for determination of AZL in its 
combination with CLT either in their laboratory prepared mixtures or in their combined 
pharmaceutical formulation. The proposed methods have many advantages regarding analysis 
time, sensitivity and cost.  
Finally, the proposed methods can be used for the quality control of the cited drugs in 
ordinary laboratories. 
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4 FUNCTIONALIZED SILICA NANOPARTICLES FOR ENHANCED 
ELECTROPHORETIC SEPARARTION OF SOME ACIDIC AND BASIC DRUGS  
 
This chapter provides a systematic comparison of five functionalized silica nanoparticles 
(SNPs) that can be used as pseudo-stationary phases (PSPs) in capillary electrochromatography. 
Monoamine-modified SNPs (MA-SNPs), L-lysine-modified SNPs (L-SNPs), and linear poly L-
lysine (LPL-SNPs) were prepared using the proper organosilane coupling agents to render a 
positive charge on the surface of the SNPs, whereas, cysteine-modified SNPs (CYS-SNPs) and 
Glutamic acid-modified SNPs (GLU-SNPs) were prepared using amino acids-based organosilane 
conjugate moieties to render a zwitter ionic nature and a negative charge on the surface of the 
SNPs at the proper pH, respectively.  The SNPs were prepared using the reverse microemulsion 
approach with mean diameters in the range of 53.4 ± 5.9 nm to 82.7 ± 4.7 nm as shown by the 
TEM measurements. The differences in the electrophoretic behavior, and the ability to separate 
mixtures of acidic and basic drugs using these PSPs were evaluated by analyzing a mixture of 
ibuprofen, ketoprofen, and valsartan as well as a mixture of atenolol and propranolol as examples 
of acidic and basic compounds, respectively. An enhanced separation of the acidic or basic drug 
mixtures was achieved using LPL-SNPs. Also, MA-SNPs resulted in fast and enhanced 
separation of the acidic drugs mixture using the reversed polarity mode. Both CYS-SNPs and 
GLU-SNPs did not show any significant change in the electroosmotic flow with non-negligible 
improvement in the separation of the acidic drugs mixture at pH 4 using the reversed polarity 
mode. These amino acids or peptides-modified SNPs can significantly help in achieving fast and 
efficient separation of challenging mixtures of compounds of different charges.  
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4.1 Introduction 
The use of silica nanoparticles (SNPs) with surface modifications in different 
applications is a topic of growing interest. Nanochemistry has been widely used in recent years 
in various fields, including chemistry, physics, biology, material science, etc., because of their 
advantageous features 1. The interest in nanoparticles (NPs) comes from their unique mechanical, 
magnetic, catalytic, electronic, optical, and biological characteristics. Size of NPs can range from 
1 to 1,000 nm and can consist of biodegradable polymers, metals, inorganic, or lipid constituents 
2. The applications of NPs include catalysis, electronics, biosensors, medicines, cosmetics, 
imaging, bioanalysis and bio-related applications 3.   For instance, NP-based drug delivery 
systems have been utilized to improve human health by illuminating tumors, brain, and other 
cellular functions while using medical imaging 4. 
Breakthroughs in the synthesis of SNPs are beneficial when designing and developing 
nanosized probes.  SNPs can be modified with various organic groups and conjugated to 
molecules, which include monoclonal antibodies, DNA, or other moieties 5.  
The SNPs usually consist of a polymeric structure consisting of siloxan (-Si-O-Si-O-) and 
high concentrations of silanol (Si-OH) groups on the outer surface and are a type of colloidal 
metal oxide, which can be easily modified.  There are two major classes of SNPs: solid SNPs 
(SSNPs) and mesoporous SNPs (MSNPs). The MSNPs have many pores with a silica matrix, 
and SSNPs have no pores.  The MSNPs, with its empty pores and channels, can be filled with 
various amounts of biomolecules and drugs as well as filling the gaps of molecules 6. Controlled 
release of drugs from MSNPs pores is an excellent feature and can also prolong drug efficiency 
6.  
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Functionalized SNPs also have some useful applications in the field of separation of 
organic molecules either by using liquid chromatography or capillary electrophoresis (CE) as 
they can be used as pseudostationary phases (PSP) or as additives to the mobile phase to enhance 
the separation performance and get better resolutions 7.  
NP capillary electrophoresis is the combination of NPs and CE technology in which NPs 
are used as stationary or PSP to alter the electroosmotic flow (EOF), increase column capacity, 
and improve separation selectivity and column efficiency. The technique combines the high 
efficiency of CE with the high selectivity of HPLC that can be used for the separation of 
different types of analytes. The use of NPs-based PSPs in capillary electrochromatography 
(CEC) 8 has attracted the interest of many researchers because of its several merits, such as no 
packing or frits, fast regeneration of the column, and the absence of stationary phase carry-over 
effects. When NPs are used as PSPs, they are suspended in the background electrolyte and are 
continuously pumped through the capillary. Compared with other CEC types, NPs are much 
smaller than the particles used in packed columns, and improved separation efficiency is 
expected due to their high surface-to-volume ratio 9. And compared with traditional micelles, 
NPs have higher stability and larger surface area, which make them powerful buffer additives for 
achieving more efficient separations 7.  
NPs used in CEC usually include polymer nanoparticles, gold nanoparticles, molecularly 
imprinted polymer NPs, dendrimers, and SNPs. Nilsson 7 and Palmer 4 reviewed the research in 
the field of NPs in detail, including SNPs as well. SNPs own many advantages over other types 
of NPs, such as good biocompatibility, no swelling in aqueous and organic solvents, and easy 
post-modifications with different functional groups, etc. 10 
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In the past decade, functionalized SNPs have received considerable attention and had 
been successfully used as PSPs for the enhanced separation of organic acids and bases, drugs and 
proteins 11. SNPs used in CEC, contain hydroxyl functional groups with different binding sites 
on the surface. In many cases, the SNPs have to be surface coated or are derived using specific 
functional groups to provide additional interaction sites 12. Achieving controlled localization of 
two or more different molecular functionalities on the surface of NPs would offer several 
profound advantages. For example, Bachmann and Gottlicher covalently modified commercially 
available SNPs with a combination of reversed-phase groups and negatively charged groups 13. 
Also, Neiman et al. prepared one neutrally charged and two positively charged modified silica 
solutions for the CEC separation of aromatic acids and their structural isomers 14. Accordingly, 
the development of synthetically tailored SNPs is of great significance in separation science.  
EOF is a very important factor in CEC separation because analytes move through the 
capillary by EOF drive, as well as self-electrophoretic mobility if they are charged 15. Knowing 
the direction and magnitude of the EOF will be helpful to understand the separation behavior.  
Since the structures of amino acids can be easily modified, amino acids and their 
derivatives would be candidates to act as precursors for modifying the surface of SNPs. Also, 
due to their weak UV absorption and low cost, it is meaningful to use native amino acids -
functionalized SNPs as additives for enhanced electrophoretic separation of chiral and achiral 
drugs 16. Therefore, the design and synthesis of amino acid-functionalized SNPs could prove 
useful for separation and determination of pharmaceutical compounds especially for 
enantiomeric drugs and metabolites either alone or in combination with other chiral selectors 
such as cyclodextrins, antibiotics or carbohydrates. 
Synthesis of SNPs is usually carried out through two sol–gel methods: the Stöber method 
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17 and the water in oil reverse microemulsion (WORM) method 18. The particles prepared by 
Stöber methods usually are not uniform. To overcome these shortcomings, WORM method is 
preferred as it results in SNPs with better monodispersity. However, a high amount of surfactants 
is needed in the synthesis process which necessitates extensive subsequent cleaning steps 19. This 
article provides a systematic comparison of five functionalized SNPs using the WORM method; 
Monoamine-modified SNPs (MA-SNPs), L-lysine-modified SNPs (L-SNPs), and linear poly L-
lysine (LPL-SNPs) were prepared using the proper organosilane coupling agents to render a 
positive charge on the surface of the SNPs, whereas, cysteine-modified SNPs (CYS-SNPs) and 
Glutamic acid-modified SNPs (GLU-SNPs) were prepared using amino acids-based organosilane 
conjugate moieties to render a zwitterionic nature and a negative charge on the surface of the 
SNPs at the proper pH, respectively, Fig. 4.1. 
The separation of acidic compounds in unmodified capillaries is often unsatisfactory and 
requires higher pH buffer solutions (∼neutral or alkaline) in order to produce higher cathodic 
EOF to surpass the anodic electrophoretic mobility of analytes.  The poor separation of the acidic 
analytes in bare capillary can be caused by the migration of the acidic compounds in reverse 
direction with the EOF. Hence, the five proposed modified SNPs were explored as background 
electrolyte additive to investigate their effect on the EOF, and hence on the separation of two 
separate mixtures of acidic and basic drugs. The mixture of acidic drugs consisted of ibuprofen 
(IBU), Ketoprofen (KET), and Valsartan (VAL) whereas the mixture of basic drugs consisted of 
propranolol (PRP) and atenolol (ATN), Fig. 4.2. 
These amino acids or peptides-modified SNPs can significantly help in achieving fast and 
efficient separation of challenging mixtures of achiral and chiral compounds of different charges.  
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Figure 4.1 The structural formulae of the proposed amino acid-based functionalized SNPs; (a) 
MA-SNPs, (b) L-SNPs, (c) LPL-SNPs, (d) CYS-SNPs, and (c) GLU-SNPs 
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Figure 4.2 The structure formulae for (a) ibuprofen, (b) ketoprofen, (c) valsartan, (d) atenolol, 
and (e) propranolol 
 
4.2 Experimental 
4.2.1 Reagents and materials 
All chemicals were analytical-grade unless noted otherwise. All the following chemicals 
were produced by Sigma-Aldrich, MO, USA: 1-heptanol (anhydrous, ≥99%), 3-aminopropyl 
triethoxysilane (APTES) (≥98%), tetraethyl orthosilicate (TEOS) (99.99% trace metal basis), 3-
(Triethoxysilyl)propyl isocyanate (95%), Ethyl acetate, anhydrous (99.8%), tert-butyl alcohol 
(99.5%), (±)-propranolol hydrochloride (99%), (±)-atenolol (98%), (±)-ketoprofen (98%), 
sodium hydroxide (pellets, 97+%, A.C.S. reagent), cyclohexane (anhydrous, 99.5%), di-tert-
butyl dicarbonate (98%), L-cysteine (97%), poly-L-lysine hydrobromide (P2636), ethanol 
(99.7%), dichloromethane, sodium phosphate, dibasic (98+%), potassium phosphate monobasic 
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(>95%), TRIS-HCl buffer, magnesium sulfate anhydrous (99.5%), potassium hydrogen sulfate 
(99%), sodium bicarbonate, trifluoroacetic acid (TFA), hydrochloric acid (37%), and Triton™ X-
100 (laboratory grade). Fisher Scientific, Fair Lawn, NJ, produced ammonium hydroxide 
solution (28%). Alfa Aesar, Ward Hill, MA, produced L-glutamic acid, 99+%. Aldrich 
Pharmaceutical Company Inc., Milwaukee, WI, USA produced DMAP (4-
Dimethylaminopyridine) (99%), 1,3-dicyclohexyl-carbodiimide (DCC) (99%), sodium hydrogen 
carbonate (99%), and glutaric dialdehyde (50 wt.%) solution in water. AK Scientific, Inc., Union 
City, CA, USA produced ±ibuprofen (98%), and L(+)-glutamic acid (99%). Pharmaceutical 
grade VAL USP was supplied by Zydus, batch No.: VSK1MK A02B (certified to contain 
99.4%).   
4.2.2 Instrumentation 
Regarding instrumentation, separations were performed using a Beckman Coulter P/ACE 
MDQ (144001) Capillary Electrophoresis System (Fullerton, CA, USA) equipped with an 
autosampler and a UV detector for the CE technique. Beckman Coulter's 32 Karat™ Software 
3.0 was used for the instrument control, data acquisition, and analysis. Electrophoretic analyses 
were performed in a fused silica capillary (Polymicro Technologies, Phoenix, AZ, USA) of 53.2 
cm long (42.5 cm effective length) and 50 μm id. Prior to the first use, the capillary was 
successively rinsed with methanol, DI water, 1 M NaOH, DI water, 1 M NaOH, DI water, 0.1 M 
HCl, DI water, and 25 mM phosphate buffer (pH 5) for 20 min each. Afterwards, the capillaries 
were flushed with a 5 mg/mL SNPs suspension for 5 min and left to stand for 10 min, and this 
step was repeated three times. Nano pure water was prepared using a Barnstead NANO pure 
DIamond Analytical ultrapure water system (Fischer Scientific, NJ, USA). A SympHonly 
(SB20) pH-meter (Thermo Orion, MA, USA) was used for pH adjustment. Transmission 
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electron microscopy micrographs were conducted by the Zeiss LEO 912AB (Zeiss, Thornwood, 
NY). Scanning electron microscopy micrographs were conducted by the Tescan Vega3 LMU 
scanning electron microscope (TESCAN, Kohoutovice, Czech Republic) and Denton Desk II 
sputter coated with a gold target (Denton Vacuum, NJ, USA). 0.2 mg/mL SNPs suspensions 
dispersed in ethanol or water were subjected to particle size determination analysis using a 
Malvern Mastersizer (Malvern Instruments Ltd., Malvern, UK. The polydispersity index (PDI), 
and standard deviation were obtained from three independent measurements of the dispersions of 
SNPs. The zeta potential of particles dispersions in water was measured. NPs separation required 
an Allegra 64R Centrifuge (Beckman Coulter Inc., Brea, CA).  
4.2.3 Synthesis of the amino acid-based conjugate moieties (ACM) 
The reaction progress was monitored using silica gel 60 F254 thin layer chromatography 
plates (Merck EMD Millipore, Darmstadt, Germany). Open column chromatography was 
utilized for the purification of all final compounds using 60−200 μm, 60A classic column silica 
gel (Dynamic Adsorbents, Norcross, GA). The nuclear magnetic resonance spectra were 
obtained using high quality Kontes NMR tubes (Kimble Chase, Vineland, NJ) rated to 500 MHz 
and were recorded on a Bruker Avance 400 MHz spectrometer interfaced to a PC using Topspin 
3.1. High-resolution accurate mass spectra were obtained at the Georgia State University Mass 
Spectrometry Facility using a Waters Q-TOF micro (ESI-Q-TOF) mass spectrometer. 
4.2.3.1 Synthesis of L-ACM 
The synthesis included three steps, (Scheme 4.1). In the first step, a 50 mL flask was 
charged with a solution of NaOH (0.454 g, 0.011 moles) in water (12.5 mL). Then, L-lysine 
(1.503 g, 0.010 moles) was added followed by tert-butyl alcohol (10 mL). The solution was 
cooled in an ice bath, and subsequently, di-tert-butyl dicarbonate (5.462 g, 0.025 moles) was 
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added in three portions over a one hour period. After the addition was completed, the reaction 
mixture was stirred for another hour. Then, the ice bath was removed and the reaction mixture 
was stirred overnight at room temperature. After that, the reaction mixture was diluted with an 
equal volume of ethyl acetate and acidified by the addition of a solution of KHSO4 (2.3 g, 0.017 
mole) in water (15 mL). The ethyl acetate layer was separated, and the aqueous phase was 
extracted once more with ethyl acetate. The combined ethyl acetate fractions were washed with 
water, separated, dried over MgSO4, filtered, and evaporated under reduced pressure. Upon 
drying under vacuum, the resulting yellow oil turned into yellowish white foam (di-BOC-lysine). 
Yield was 2.88 g (81%). In the second step, 4 0.533 g (488 μL, 1.54 mmoles) of di-BOC-lysine 
free acid, 167 μl (0.77 mmoles) of APTES, 36.6 mg (0.324 mmoles) of DMAP (4-
Dimethylaminopyridine), and 0.32 g (1.53 mmoles) of DCC were dissolved in 15 mL of 
methylene chloride and stirred for 20 h at room temperature. The reaction mixture was filtered to 
remove N,N'-dicyclohexyl urea (DCU), washed four times with 15 mL 0.5 M sodium 
bicarbonate, 15 mL 0.2 N HCl, and 15 mL saturated NaCl solution, and dried over MgSO4. The 
solution was then concentrated under reduced pressure to obtain di-BOC-L-ACM. In the third 
step, the precipitate then obtained (0.5 g) was collected and was subjected for further reaction 
preceded by its deprotection with 1:1 trifluoroacetic acid (TFA): dichloromethane (DCM) (2 mL) 
and stirred for 8 hours at room temperature. The solution was then concentrated overnight under 
reduced pressure. Materials were recrystallized in a 3:1 acetone/methanol mixture and dried to 
obtain yellowish white crystals of L-ACM. Yield was 0.122 g (34% yield). MS (ESI): 478 (M+). 
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Scheme 4.1 Synthesis of L-ACM 
 
4.2.3.2 Synthesis of the zwitter ionic L-cysteine-based conjugate moieties (CYS-ACM) 
A 50-mL flask was charged with L-Cysteine (0.315 g, 2.0 mmole) in DMF (4.0 mL). 
Then, 3-(Triethoxysilyl)propyl isocyanate (0.519 mL, 2.10 mmole) was added. After the addition 
was completed, the reaction mixture was stirred for three days at room temperature. The product 
was filtered and washed several times with DMF. The solid was dried under reduced pressure to 
obtain CYS-ACM. Yield was 0.681 g (92% yield), Scheme 4.2.  
 
 
Scheme 4.2 Synthesis of CYS-ACM 
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4.2.4 Preparation of the functionalized SNPs 
To obtain spherical SNPs with small size and narrow size distribution patterns, modified 
Stöber methods were used in the beginning for the synthesis of bare SNPs, MA-SNPs, L-SNPs, 
and CYS-SNPs then a WORM method was used for the preparation of bare SNPs, MA-SNPs, L-
SNPs, LPL-SNPs, CYS-SNPs, and GLU-SNPs, (Fig. 4.3). The amounts of all reagents for each 
preparation method were adjusted carefully. 
4.2.4.1 Preparation of bare SNPs and MA-SNPs by a modified Stöber method 
MA-SNPs were prepared by modifying the Stöber method, Fig. 4.3.  The first solution 
was a mixture of 0.930 mL TEOS and 7.50 mL ethanol, and the second solution was a mixture of 
0.230 mL 28% (w/w) ammonia, 2.30 mL DI water, and 5.870 mL ethanol.  With stirring, the first 
solution was added to the second solution. After reaction for 24 h at room temperature, APTES 
acting as surface functionality was added with TEOS, with the volume ratio of APTES to TEOS 
equals 1:1 for particle co-condensation. The total amount of functionalized trialkoxysilane 
reagents added corresponds to 5% of the initial amount of TEOS. The mixture was further 
reacted for 24 h, and the particles thus formed were centrifuged and washed with ethanol and DI 
water for several times, then vacuum-dried at 80 °C for 6 h. If no functionalization was intended, 
the reaction mixture of TEOS, ethanol, and ammonia was stirred overnight at room temperature 
in a similar way, and the bare SNPs thus formed were centrifuged and washed with ethanol and 
DI water for several times and then vacuum-dried at 80 °C for 6 h. 
4.2.4.2 Synthesis of L-SNPs by a modified Stöber method 
L-SNPs were prepared by modifying the Stöber method 20, Fig. 4.3. A total amount of 1 
mL of TEOS (∼4.5 mmol) was added to a conical flask in the presence of 12.5 mL of ethanol 
and 1 mL DI water. The solution was sonicated for 10 minutes, and then 0.4 mL of ammonia was 
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added gradually. After 24 h of reaction under stirring at room temperature (200 rpm), 0.23 
mmoles (107 mg) of L-ACM was dissolved in 0.5 mL ethanol and added with extra TEOS (0.23 
mmoles, 50 μL) gradually. The reaction of the obtained mixture continued for another 24 h (120 
rpm), and the particles thus formed were centrifuged and washed with ethanol and DI water 
repeatedly, then the residue was left to dry completely at 80 °C. 
4.2.4.3 Synthesis of CYS-SNPs by a modified Stöber method 
CYS-SNPs were prepared by modifying the Stöber method 20, Fig. 4.3. A total amount of 
0.625 mL of TEOS (∼2.8 mmol) was added to a conical flask in the presence of 1 mL of 
methanol, 0.36 mL DI water, and 0.08 mL NH4OH. The solution was stirred at room temperature 
for 24 h, and then 0.09 mmol CYS-ACM were added, and stirred for another 24 h at room 
temperature, and the particles thus formed were centrifuged and washed with methanol and DI 
water repeatedly, then the residue was left to dry completely at 80 °C. 
4.2.4.4 Synthesis of bare SNPs and MA-SNPs by WORM method 
Bare SNPs were prepared by modifying the WORM method.  The micelles were prepared 
using 15.0 mL cyclohexane, 2.60 mL 1-heptanol, 3.55 mL Triton™ X-100, and 1.13 mL DI H2O 
which were stirred for 10 min to generate the microemulsion. After time elapsed, 3.0 mL TEOS, 
and 0.12 mL ammonium hydroxide were added and the solution was stirred at low speed for 24 
h. In order to modify the surface of the SNPs to prepare MA-SNPs, 0.075 mL from each of 
TEOS and APTES were added gradually to the reaction mixture and stirred at low speed for 
another 24 h at room temperature. Afterward, 5.0 mL acetone were added, and the NPs were 
collected by centrifugation and washed 5 times with absolute ethanol and two times with water 
to remove any unreacted chemicals, Fig. 4.3, then the residue was left to dry completely at 80 °C. 
286 
 
4.2.4.5 Synthesis of L-SNPs, and CYS-SNPs by WORM method 
75.0 mg bare SNPs prepared as described in the previous section were added to a conical 
flask, and suspended in 7.5 mL 50 mM TRIS-HCl buffer (pH 8.0) with stirring at low speed. 
Afterwards, 7.5 mg L-ACM in the case of L-SNPs or 7.5 mg CYS-ACM in the case of CYS-
SNPs were dissolved in 2.0 mL 90% ethanol, and added dropwise to the reaction mixture. Then, 
15.0 μL TEOS and 40.0 μL ammonium hydroxide were added, and the reaction mixture was 
stirred for 18 h at room temperature. The NPs were collected by centrifugation and washed 3 
times with each of 50 mM TRIS-HCl buffer (pH 8.0), ethanol and water to remove any unreacted 
chemicals, Fig. 4.3, then the residue was left to dry completely at 80 °C. 
 
 
Figure 4.3 Modifying the surface of bare SNPs to prepare MA-SNPs, L-SNPs, and CYS-SNPs 
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4.2.4.6 Immobilization of linear poly-L-lysine or glutamic acid on the surface of MA-SNPs 
The primary amino groups on the MA-SNPs carrier were modified with glutaric acid 
dialdehyde molecules to effectively combine with the linear poly-L-lysine (LPL) or L-glutamic 
acid (GLU), Fig. 4.4. In detail, 60 mg of MA-SNPs prepared by WORM method were dispersed 
in 5.0 mL 50 mM ammonium acetate buffer solution of pH 7.0, and then 1 mL of 50 (Wt.%) 
glutaric acid dialdehyde solution in water was then added to the dispersion solution, which was 
stirred overnight at room temperature. Samples were then centrifuged and washed with DI water 
four times to remove the excess reagent. Finally, the solid was dried at 60 °C in a vacuum drying 
oven. For the immobilizing procedure, 50 mg of carrier (Glut-MA-SNPs) were added into 2 mL 
of 10.0 mg/mL LPL or 7.5 mg/mL L-glutamic acid solutions prepared in 50 mM ammonium 
acetate buffer, pH 5. Afterwards, the mixtures were stirred gently for 12 h in an ice bath, 
followed by centrifugation. The collected NPs were rinsed alternately three times with the same 
buffer and DI water, then the residue was left to dry completely at 60 °C. 
4.2.5 Characterization of the functionalized SNPs 
The developed functionalized SNPs were characterized in detail by one or more of the 
following techniques: TEM, SEM, dynamic light scattering (DLS), zeta potential measurements, 
and FT-IR.  
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Figure 4.4 Immobilization of linear poly-L-lysine or L-glutamic acid on the surface of MA-
SNPs 
 
4.2.6 Standard and working solutions 
72 mM of IBU, KET, 48 mM of ATN, PRP and 24 mM of VAL stock solutions were 
prepared separately in methanol. The mixture of the acidic drugs consisted of 3.6 mM IBU, 3.6 
mM KET, and 1.2 mM VAL whereas the mixture of the basic drugs consisted of 2.4 mM PRP 
and 3.6 mM ATN which were prepared by transferring the proper aliquots from the 
corresponding stock solutions, and completing the volume with methanol and water to reach a 
final ratio of 25% methanol in DI water. The solutions were stable for one month when kept in 
the refrigerator at 2 oC. 
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4.3 Results and discussion 
4.3.1 Characterization of the functionalized SNPs 
The physical nature and dimensions of the particles were derived from the SEM, TEM, 
and DLS scans. Two sol-gel methods were used in preparing the functionalized SNPs. The NP 
diameter obtained from TEM images, the mean hydrodynamic particle sizes by DLS, PDI, and 
zeta potential values are summarized in Table 4.1 and 4.2. The NPs prepared by Stöber method 
had relatively larger diameters with a poor control on the monodispersity of the size and shape as 
shown in Fig. 4.5 and Table 4.1. SEM and TEM micrographs showed that the SNPs prepared by 
WORM method had a spherical shape and a narrow size distribution as can be seen in Fig.4.6 
and Table 4.2. Although having different surface functional groups, the five functionalized SNPs 
had nearly the same shape and size morphology. The five materials were sphere-like and uniform 
in shape, with an average size of approximately 79 nm.  
As shown in Table 4.2, the zeta potential of both the bare SNPs 21 and GLU-SNPs 
colloidal SNPs showed a highly negative charge of about -44 mV whereas CYS-SNPs and L-
SNPs showed a relatively lower negative charge of about -37 and -35 mM, respectively. MA-
SNPs showed a positive charge of +14.7 ± 4.37 mV while LPL-SNPs showed a wide range of 
charge deviation between -48.0 to + 60.0 mV which can be attributed to the ionization nature of 
the poly L-lysine protein at the neutral pH of the used dispersant.  
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Figure 4.5 TEM photographs for SNPs prepared by Stöber method for (a) bare SNPs, (b) MA-
SNPs, (c) L-SNPs, and (d) CYS-SNPs 
 
 
Figure 4.6 SEM and TEM photographs for SNPs prepared by WORM method. (a) SEM 
photographs of bare SNPs, TEM photographs for: (b) bare SNPs, (c) LPL-SNPs, (d) MA-SNPs, 
(e) L-SNPs, (f) CYS-SNPs, and (g) GLU-SNPs 
291 
 
Table 4.1 Diameter determined by TEM and DLS, polydispersity index (PDI), zeta potential of 
0.1 mg/ml SNPs in ethanol (prepared by Stӧber method) 
SNPs 
Diameter (TEM) 
(nm) 
Diameter (DLS) 
(nm) 
PDI 
Zeta potential 
(mV) 
Bare SNPs 343.2 ± 40.4 145.3 ± 36.45 0.402 -25.0 ± 14.9 
MA-SNPs 119.8 ± 9.9 299.6 ± 119.3 0.217 +6.7 ± 5.2 
L-SNPs 123.3 ± 6.3 275.4 ± 105.8 0.190 -12.3 ± 9.1 
CYS-SNPs 347.7 ± 38.3 387.5 ± 41.2 0.285 -32.0 ± 5.6 
 
 
 
 
 
 
Table 4.2 Diameter determined by TEM and DLS, polydispersity index (PDI), zeta potential of 
0.1 mg/ml SNPs in DI water (prepared by WORM method). 
SNPs 
Diameter (TEM) 
(nm) 
Diameter (DLS) 
(nm) 
PDI 
Zeta potential 
(mV) 
Bare SNPs 58.8 ± 6.6 189.8 ± 81.7 0.242 -44.1.0 ± 11.3 
MA-SNPs 77.1 ± 4.6 384.2 ± 126.6 0.254 +14.7 ± 4.37 
LPL-SNPs 79.9 ± 6.3 164.2 ± 0.01 0.974 -0.36 ± 31.5 
L-SNPs 77.9 ± 4.9 342.4 ± 78.1 0.656 -35.7 ± 6.31 
CYS-SNPs 82.7 ± 4.7 328.3 ± 180.8 0.531 -37.2 ± 3.78 
GLU-SNPs 78.1 ± 5.0 439.3 ± 51.9 0.542 -44.3 ± 3.46 
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FT-IR spectra of bare SNPs and amine-modified SNPs (Fig. 4.7) showed the presence of 
organic groups. In comparison with pure SNPs, several new absorption bands appeared in the 
spectrum of MA-SNPs. The peak between 3,300 and 3,500 cm-1 are assigned to the stretching 
vibration of the amino group (m-NH2), and the peaks at 1,650 and 624 cm-1 are the bending 
vibrations of the amino group (d-NH2 and s-NH2). These results confirmed the presence of 
functional groups on the surface of SNPs.  
 
 
Figure 4.7 The IR spectra of bare SNPs (a), and MA-SNPs (b) 
 
4.3.2 EOF Characteristics 
EOF is a very important factor in CE separation because analytes are driven through the 
capillary both by the EOF and as a result of self-electrophoretic mobility if they are charged. 
When the amine-functionalized NPs such as MA-SNPs, L-SNPs, and LPL-SNPs are suspended 
in the acidic background electrolyte, they are positively charged, because of the amino groups on 
their surface. Thus they were adsorbed on the inner wall of the negatively charged capillary to 
600110016002100260031003600
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form a dynamic coating under acidic buffer solutions. As a result, reversed anodic EOF was 
obtained. Fig. 4.8 depicts the dependence of the EOF mobility of the used SNPs-based PSPs on 
buffer solution pH. Considering that the silica-based materials tend to dissolve in strongly 
alkaline solutions, the pH range of 3–8 was selected for this investigation.  
From Fig. 4.8 it can be observed that only cathodic EOF can be detected by varying the 
pH of the running electrolyte because no suitable functional groups exist on the surface of the 
bare SNPs and GLU-SNPs to reverse the EOF. Moreover, bare SNPs, CYS-SNPs, L-SNPs, and 
GLU-SNPs did not show in significant difference in EOF from the unmodified capillary 
columns. With MA-SNPs and LPL-SNPs the anodic EOF velocity decreased when the buffer pH 
increased from 3 to 5 whereas the cathodic EOF velocity increased when the buffer pH increased 
from 6.5 to 8. At pH 3, the amine groups of the functionalized SNPs were protonated strongly 
and residual silanol groups on the capillary were partly suppressed. With increasing pH, the 
anodic EOF velocity decreased as the ionization of the amine groups became weaker. At pH 6.0, 
no EOF was observed because the net charge between the positively charged functionalized 
SNPs and the negatively charged capillary wall was nearly zero. Moreover, from this plot, it can 
be observed that an increased reversed anodic EOF can be obtained from LPL-SNPs compared 
with MA-SNPs at very low pH values. The amine-modified SNPs that can generate a reversed 
EOF should have a positive effect on the separation of charged analytes especially the acidic 
compounds.  
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Figure 4.8 Effect of buffer pH on EOF. Experimental conditions: capillary, total length 53.2 cm, 
effective length 42.5 cm; buffer, 25 mmol/L KH2PO4 buffer without additives (a), with 0.5 
mg/mL bare SNPs (b), with 0.5 mg/mL functionalized SNPs (c-g); detection wavelength, 214 
nm; separation voltage, 20 kV or – 20 kV; hydrodynamic injection for 6 s 
 
4.3.3 Electrophoretic Separation 
4.3.3.1 Effect of modified SNPs 
The separation of acidic compounds in unmodified capillary columns is often 
unsatisfactory because acidic compounds migrate in the reverse direction to the EOF, resulting in 
longer separation time 22. For fast and efficient separation of acidic compounds, it is preferred 
that the analytes migrate in the same direction as the EOF (co-EOF). Because the direction of the 
EOF is from cathode to anode under low pH conditions in the case of MA-SNPs and LPL-SNPs 
(Fig. 4.8), it is expected that fast separation can be obtained for acidic compounds. Taking into 
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account all those aspects, three acidic drugs IBU, KET, and VAL and two basic drugs PRP and 
ATN were chosen as target analytes to evaluate the performance of five functionalized SNPs as 
buffer additives in CE. First, no NPs were added to the running buffer. However, it was difficult 
to observe resolved peaks of the three acidic drugs or the two basic drugs using normal polarity 
mode over the pH range 3.0 to 8.0 as can be seen in Fig. 4.9 and 4.10, respectively.  Hence, the 
organically functionalized SNPs were evaluated as buffer additives to improve the separation 
where five different functionalized SNPs were separately added to the running buffer as PSP in 
the concentration of 0.5 mg/mL. A background electrolyte of pH 4 and negative polarity were 
used in the case of analyzing the acidic drugs, Fig. 4.11, whereas pH 3 and positive polarity were 
used in the case of analyzing the basic drugs, Fig. 4.12. As it can be observed in Fig. 4.11 and 
Table 4.3, only MA-SNPs and LPL- SNPs additives were able to resolve the three acidic 
analytes in less than 15 min with acceptable peak shapes. Also, only LPL-SNPs were able to 
resolve the two analyzed basic drugs but with a prolonged run time and poor peak shapes, Fig. 
4.12, Table 4.3.  
The fast and successful separation of the acidic analytes is based on the fact that the 
direction of EOF is from cathode to anode under lower pH conditions in the tested separation 
system, that is, to say that the analytes migrate in the same direction with the EOF (co-EOF).  
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Figure 4.9 The effect of pH on the separation of the three acidic drugs without SNPs. 
Experimental conditions: Applied voltage 20 kV at pH 3, 4, 5, 6.5 or 8. The other conditions are 
the same as given in Fig. 4.8. Peak identities: 1 VAL; 2 KET; 3 IBU. 
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Figure 4.10 The effect of pH on the separation of the two basic drugs without SNPs. 
Experimental conditions: Applied voltage 20 kV at pH 3, 4, 5, 6.5 or 8. The other conditions are 
the same as given in Fig. 4.8. Peak identities: 1 PRP; 2 ATN 
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Figure 4.11 Electropherograms obtained from the three acidic drugs in the absence of SNPs (a), 
in the presence of MA-SNPs (b), LPL-SNPs (c), L-SNPs (d), GLU-SNPs (e), and CYS-SNPs (f). 
Experimental conditions: buffer, 25 mM phosphate buffer (pH 4) with (or without) 0.5 mg/mL 
SNPs added; applied voltage -20 kV; injection, 1psi for 6 s. The other conditions are the same as 
for Fig. 4.8. 
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Figure 4.12 Electropherograms obtained from the three acidic drugs in the absence of SNPs (a), 
in the presence of MA-SNPs (b), LPL-SNPs (c), L-SNPs (d), GLU-SNPs (e), and CYS-SNPs (f). 
Experimental conditions: buffer, 25 mM phosphate buffer (pH 3) with (or without) 0.5 mg/mL 
SNPs added; applied voltage 20 kV; injection, 1psi for 6 s. The other conditions are the same as 
for Fig. 4.8.  
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Table 4.3 Comparison of migration times and resolution using the proposed modified SNPs  as 
PSPs 
    VAL KET IBU ATN PRP 
Unmodified capillary Migration time (min) 14.4 19.5 32.6 7.2 7.6 
Resolution       1.07   1.68 ---- 
MA-SNPs Migration time (min) 9.5 11.2 13.0 11.4 13.1 
Resolution       1.43   1.18 ----- 
LPL-SNPs Migration time (min) 8.5 9.5 10.6 23.5 29.1 
Resolution       0.91    1.0 1.55 
L-SNPs Migration time (min) 14.6 ------ 25.7 9.6 11.1 
Resolution 10.9 ----- 
GLU-SNPs Migration time (min) 15.1 19.2 15.9 7.4 8.2 
Resolution     -----   0.97 ----- 
CYS-SNPs Migration time (min) 16.8 21.3 24.2 6.7 7.3 
Resolution     0.95   0.78 ----- 
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4.3.3.2 Effect of pH  
Running buffer pH is often important in achieving separations with high resolution in CE 
[26]. In this investigation, MA-SNPs and LPL-SNPs were used as PSPs and added to the running 
buffer using a pH ranging from 3 to 8 to evaluate any enhancement in the separation of the 
selected mixtures of the acidic and basic drugs. It is clear that separation efficiency can be 
readily tuned by adjusting the running buffer pH. For MA-SNPs (Fig. 4.13) and LPL-SNPs (Fig. 
4.14), it was observed that at pH 3 the three acidic analytes were not resolved and at pH 8 only 
VAL appeared. The pH range of 4 to 6.5 was suitable for the separation of the three acidic 
analytes within a reasonable time where pH 4 showed the best separation efficiency for the three 
analytes using both amine-based PSPs as presented in Table 4.3. Regarding the separation of the 
two basic analytes, MA-SNPs did not show any obvious resolution of the two peaks over the 
tested pH range (Fig. 4.15) whereas LPL-SNPs at pH 3 showed separation of the two peaks but 
with poor peak shapes and prolonged migration times, (Fig. 4.16). 
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Figure 4.13 The effect of pH on the separation of the three acidic drugs using 0.5 mg/mL MA-
SNPs. Experimental conditions: 25 mM phosphate buffer at pH 3, 4, 5, 6.5 or 8. The other 
conditions are the same as given in Fig. 4.11. 
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Figure 4.14 The effect of pH on the separation of the three acidic drugs using 0.5 mg/mL LPL-
SNPs. Experimental conditions: 25 mM phosphate buffer at pH 3, 4, 5, 6.5 or 8. The other 
conditions are the same as given in Fig. 4.11. 
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Figure 4.15 The effect of pH on the separation of the two basic drugs using 0.5 mg/mL MA-
SNPs. Experimental conditions: 25 mM phosphate buffer at pH 3, 4, 5, 6.5 or 8. The other 
conditions are the same as given in Fig. 4.12. 
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Figure 4.16 The effect of pH on the separation of the two basic drugs using 0.5 mg/mL MA-
SNPs. Experimental conditions: 25 mM phosphate buffer at pH 3, 4, 5, 6.5 or 8. The other 
conditions are the same as given in Fig. 4.12. 
 
4.3.3.3 Effect of applied voltage and SNPs concentration 
In order to enhance the peak shapes, optimize the separation efficiency, and shorten the 
run time while separating PRP and ATN using LPL-SNPs as PSPs, the effect of the applied 
voltage was investigated. As can be observed in Fig. 4.17, increasing the voltage to +25 KV did 
not show a significant enhancement in the separation efficiency of the two basic analytes. On the 
other hand, the effect of changing the concentration of LPL-SNPs on the separation of the 
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selected analytes was also investigated. As shown in Fig. 4.18, decreasing the concentration of 
LPL-SNPs from 0.5 mg/mL to 0.2 mg/mL decreased the resolution and the migration times in 
the case of the basic drugs and increased the migration times with a better resolution and poor 
peak shapes in the case of the acidic drugs. 
 
 
 
 
Figure 4.17 The effect of voltage on the separation of the two basic drugs without SNPs. 
Experimental conditions: 25 mM phosphate buffer at pH 3. The other conditions are the same as 
given in Fig. 4.12. 
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Figure 4.18 The effect of LPL-SNPs concentration on the separation of the two basic drugs 
using 0.5 mg/mL LPL-SNPs (a) and 0.2 mg/mL LPL-SNPs (b), and on the three acidic analytes 
using 0.5 mg/mL LPL-SNPs (c) and 0.2 mg/mL LPL-SNPs (d). The other conditions are the 
same as given in Fig. 4.11 and 4.12. 
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4.4 Conclusions 
Five functionalized-SNPs were successfully prepared by using Stöber or reverse 
microemulsion methods. Under optimum experimental conditions, the obtained functionalized 
SNPs were tested as PSPs which can be used to enhance the electrophoretic separation of 
challenging mixtures of acidic or basic drugs.  Four of these modifications were based on amino 
acids to form suitable conjugate moieties to be copolymerized and grafted on the surface of 
SNPs and render them different charges and ionization patterns based on the nature of the added 
functional groups and the pH of the used background electrolyte. Furthermore, the 
electrophoretic properties of bare SNPs and the functionalized SNPs, determined by their 
different surface properties, were systematically investigated. The effects of running buffer pH, 
applied voltage and concentrations of the PSPs on separation efficiency were also evaluated.  It 
was found that bare SNPs, L-SNPs, CYS-SNPs, and GLU-SNPs did not result in any significant 
enhancement in the separation of the selected acidic or basic drugs` mixtures. However, MA-
SNPs and LPL-SNPs showed obvious enhancement in the separation of the acidic drugs VAL, 
KET, and IBU in the pH range of 4-6.5 in terms of migration times, peak shapes, and separation 
efficiency especially at pH 4. The fast and successful separation of the acidic analytes can be 
attributed to the anodic co-EOF caused by the positive charge of the amino groups on the surface 
of these modified SNPs at low pH. Regarding PRP and ATN binary mixtures, LPL-SNPs at pH 3 
provided the most suitable conditions to resolve these two analytes but with prolonged migration 
times and poor peak shapes. Finally, the introduced functionalized SNPs could be tested either 
alone or in combination with other chiral selectors for their ability to enhance the separation of 
some enantiomeric drug mixtures using the CE technique. 
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5 FLUORESCENTLY LABELED SILICA NANOPARTICLES FOR SOME 
FORENSIC AND BIO-RELATED APPLICATIONS 
5.1 Introduction 
Silica nanoparticles (SNPs) have proven to be useful in many applications in the areas of 
chemistry, forensics, nanomedicine and related technologies. Combining the properties of SNPs 
and fluorescent dyes that can serve as chemical probes is relatively easy by synthesizing 
fluorophore-encapsulated core-shell silica nanoparticles (FLSNPs), a process that results in the 
fluorescent dye covalently or non-covalently attached to the structure of the silica matrix. 
Moreover, this platform can enhance both the brightness and photostability of the dyes, 
compared to the free dye 1.  
Several approaches have been reported for the encapsulation of organic fluorophores into 
SNPs 2, 3. To meet certain applications` requirements, FLSNPs must possess high quantum yield, 
good photostability, size uniformity as well as minimized dye leakage. Synthesis of FLSNPs is 
usually carried out through two sol–gel methods: the Stöber method 4 and the water in oil reverse 
microemulsion (WORM) method 5. The particles prepared by Stöber methods usually are not 
uniform. To overcome these shortcomings, WORM method is preferred as it results in SNPs 
with better monodispersity. However, a high amount of surfactants is needed in the synthesis 
process which necessitates extensive subsequent cleaning steps 6. Recently, an approach via an 
amino acid-catalyzed seeds regrowth technique (ACSRT) using L-arginine as a catalyst to 
prepare nanoparticles of tunable sizes as well as minimized dye leakage without covalent 
copolymerization has been developed 7. The new technique can overcome the limitations of the 
other two methods by obtaining less polydisperse SNPs without the use of surfactants. 
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The formation mechanism of SNPs affects the rate of dye leaching. Toshiyuki Yokoi et 
al. 8, reported that silica nanoparticles were synthesized under weakly basic conditions where the 
basic amino acid, L-arginine was used as a catalyst. The pH of the reaction medium during the 
seeds formation step is about 9-10 in the basic amino acids based approach whereas the 
hydrolysis reaction of TEOS in the other methods is conducted under much more basic 
conditions (pH 12-13). Moreover, a slight change in the pH was observed in the ACSRT system. 
This is probably due to consumption of the hydroxyl species as well as the formation of a large 
number of weakly acidic silanol groups. The presence of arginine with a buffering action might 
cause the slight reduction in the pH during the synthesis to achieve a slow hydrolysis of TEOS 
which allows particle growth through complete hydrolysis. Thus, the FLSNPs synthesized with 
the amino acid approach are less vulnerable to dissolution and dye leakage 8, 9.  
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5.2  A Comparative Study of Fluorescein Isothiocyanate-Encapsulated Silica 
Nanoparticles Prepared in Seven Different Routes for Developing Fingerprints 
 
Preparation of fluorescein isothiocyanate (FITC)-encapsulated silica nanoparticles (F-
SNPs) with seven different approaches to be used as developing agents for fingerprints detection 
is presented in this report. In this study, the suitability of each synthesis route toward 
incorporation of the selected fluorophore into silica matrix and its efficiency in fingerprints 
detection were systematically studied. The composition of the particles was designed to examine 
the hydrophobic and/or ionic interactions between the silicate backbone and both of the 
fluorescent reporter molecule and the fingerprint residues. F-SNPs were prepared using two 
conventional approaches; Stöber method and water in oil reverse microemulsion (WORM) 
method.  The alkoxysilane precursor, tetraethoxyorthosilicate (TEOS) and its binary mixtures 
with phenyltriethoxysilane (PTEOS) or 3-aminopropyl triethoxysilane (APTES) have been used 
in preparing the F-SNPs to study the effect of nanoparticles composition on fingerprints 
development. In addition, FITC was conjugated with APTES so it can be covalently bonded to 
the silica matrix and to be compared with the non-covalently FITC-doped SNPs. Moreover, the 
enhancement effect of introducing polyvinylpyrrolidone (PVP) onto the surface of the less 
hydrophobic F-SNPs on fingerprints detection was also investigated. The mean diameters of the 
F-SNPs were between 4.1±0.6 and 110.4±31.1 nm as shown by TEM size analysis for the 
nanoparticles prepared by WORM and Stöber methods, respectively. The obtained results clearly 
highlight the advantages of using a mixture of TEOS and PTEOS alkoxysilane precursors in 
preparing F-SNPs with remarkable encapsulation efficiency and clear detection of fingerprints 
due to the efficient embedding of the fluorophore inside the silica network even without 
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conjugation. It was also observed that both Stöber and WORM methods gave comparable results 
and that PVP coated particles did not show any significant enhancement in fingerprints 
visualization. This systematic investigation can be followed to determine the appropriate 
preparation route of silica nanoparticles loaded with any other small molecules to be utilized in 
forensic or biomedical applications.  
5.2.1 Introduction 
Detection of fingerprints at a crime scene is of great interest in forensic investigation 
mainly for collecting physical evidences. Fingerprints visualization requires a specific reaction of 
the developing agent with the fingerprint residue to obtain a clear contrast from the underlying 
substrate. This residue is a complex mixture of organic compounds such as proteins, amino 
acids, and lipids and some inorganic substances. Development of fingerprint can be achieved 
either through a chemical interaction between the reagent and the components found in the 
fingerprint deposit or via physical adhesion of a developing agent to the sticky fingerprint 
residue 10, 11.  
Various methods such as powder dusting, cyanoacrylate fuming, and ninhydrin have been 
developed for fingerprint visualization. However, there is still a need for selective and sensitive 
reagents for fingerprint development.  Recently, there have been increased interests in using 
nanoparticles (NPs) for fingerprints detection due to their unique properties. First, their small 
particle size enhances detection of fingerprints due to increased resolution because small 
particles have the ability to adhere with high affinity to the fingerprint residue 12. Second, the 
optical properties of fluorescent NPs allow detecting fingerprints with improved overall 
sensitivity 13. Finally, surface modification can be achieved by the incorporation of functional 
groups possessing the potential interactions with certain components in the fingerprint residue, 
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and thus increase the selectivity. Leggett et al. reported the use of antibody-functionalized gold 
NPs to detect specifically cotinine, a metabolite of nicotine, only present in fingerprints left by 
smokers 14. Many types of NPs such as gold NPs 15, quantum dots 16, 17, nanostructured powders 
18, and silica nanoparticles (SNPs) 19-21, have been used as developing agents for fingerprints. 
Despite all advantages of nanoparticles for fingerprint detection, there are still concerns 
regarding their toxicity, cost, and laborious procedures. SNPs are a favorable candidate for 
fingerprints detection due to their great surface-to-volume ratio, biocompatibility and high 
photochemical stability 19. Furthermore, modification of SNPs surface can be easily achieved by 
introducing several types of silicate monomer to target various compounds in the fingerprint 
residue. For example, amphiphilic SNPs were synthetized and used as a developing agent where 
the hydrophobic and hydrophilic nature of the used monomers made the surface of these particles 
sensitive to the amino acids present in the fingerprint residue 20. Moreover, fluorophores such as 
organic dye molecules can be incorporated within the silica matrix during the synthesis process, 
providing superior optical properties and low background interference as presented in Theaker et 
al. work where they developed hydrophobic silica micro- and NPs encapsulating fluorescent 
dyes as developing agents for fingerprints detection 21.  
Synthesis of SNPs is typically carried out through two commonly used sol–gel methods: 
the Stöber method 4 and the water in oil reverse microemulsion (WORM) method 5. The 
modified Stöber process is used in synthesizing silica colloids by means of hydrolysis and 
condensation of the organosilicate monomers such as tetraethyl orthosilicate (TEOS), 3-
aminopropyl triethoxysilane (APTES) and phenyltriethoxysilane (PTEOS) in alcoholic alkaline 
solutions (pH 11–12) where ammonia acts as a catalyst. On the other hand, the NPs prepared by 
WORM show less polydispersity with better control of particle size allowed 5, 22. However, a 
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high amount of surfactants and co-surfactants are needed in the synthesis process making tedious 
subsequent washing steps necessary 23. Regardless of the synthesis route, several approaches 
have been suggested for coupling of organic fluorophores into the SNPs platform 2, 3. The 
simplest approach is the non-covalent encapsulation of dyes into the silica matrix. Nevertheless, 
the absence of a stable covalent attachment between the fluorophores and the silica matrix 
implies that the dye molecules can leak out of the NPs over time, resulting in decrease in the 
brightness of the NPs, increase in the background signal and exposition of the fluorophores to the 
surrounding environment making them less suitable for fingerprints detection 24. On the contrary, 
the dye leakage can be effectively avoided by covalent dye encapsulation. The covalent 
incorporation of dyes into silica can be achieved by using an amine-containing organosilane as 
the crosslinker such as APTES which can form a covalent binding between its amine group and 
cyanate of the dye leading to the formation of thiourea linkage 25. It is obvious that the covalent 
bonding approach is the best method for incorporation of a dye into SNPs. However, the dye 
should have the necessary functional groups towards modification and conjugation with the 
silicate precursors. This concept might increase considerably the difficulty of dye selection and 
pre-modification. 
To the best of our knowledge, most of the reports dealing with the application of 
fluorescent SNPs in fingerprints development concentrated on the incorporation of fluorophores 
into the colloidal silica spheres and on the nature of these fluorophores 26-28. Nevertheless, very 
few studies have been carried out that focus on the core and surface properties of the NPs used 
for fluorophore encapsulation and their effects on the efficiency of fingerprints detection in a 
systematic manner. It was suggested that for effective dye doping and fingerprints visualization, 
mixtures of TEOS and PTEOS have to be used in synthesizing the NPs, hence it was concluded 
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that analogous hydrophobic and electrostatic interactions occur within these hydrophobic NPs 
between compatible groups within the fluorescein isothiocyanate (FITC) dye molecules or any 
other dye of a related structure and the silica matrix 21. Moreover, it was reported that the dye is 
not subject to photo-bleaching under exposure to high intensity UV illumination. Hence, these 
NPs can be utilized as agents for developing fingerprints, including aged prints where the 
residues mainly consist of hydrophobic endogenous chemicals secreted by the donor, due to the 
hydrophobic nature of some of the proposed FITC-encapsulated silica nanoparticles (F-SNPs) 21. 
It should also be noted that as the proportion of PTEOS increases, the hydrophobicity of the 
resulting sol–gel also increases 29.  
In this study, a systematic investigation of several factors that may influence the 
efficiency of developing fingerprints is presented. These factors include (i) method of SNPs 
preparation, (ii) the method of fluorophore encapsulation into the NPs matrix, and (iii) nature of 
the used organosilicate precursors and (iv) surface modification of the dye encapsulated SNPs 
using adhesive agents such as polyvinylpyrrolidone (PVP) and its enhancing effect on the 
binding affinity to fingerprints. In order to study these factors, F-SNPs were prepared using 
seven different approaches and tested as developing agents for some forensic applications such 
as fingerprints detection.  
5.2.2 Experimental 
5.2.2.1 Materials and reagents 
All the chemicals used were of Analytical Reagent grade, and the solvents were of HPLC 
grade. All the following chemicals were produced by Sigma-Aldrich, MO, USA: fluorescein 
isothiocyanate (FITC) (isomer I, 90%), 1-hexanol (anhydrous, ≥99%), 3-aminopropyl 
triethoxysilane (APTES) (≥98%), tetraethyl orthosilicate (TEOS) (99.99% trace metal basis), 
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sodium hydroxide (pellets, 97+%, A.C.S. reagent), cyclohexane (anhydrous, 99.5%), Ethanol 
(99.7%), and Triton™ X-100 (laboratory grade). Fisher Scientific, Fair Lawn, NJ, produced 
ammonium hydroxide solution (28%). Phenyltriethoxysilane (PTEOS) was supplied by Chem-
Impex Int`l Inc., IL, USA whereas polyvinylpyrrolidone (PVP) was supplied by Alfa Aesar, MA, 
USA.  
5.2.2.2 Pre-modification of FITC 
In order to covalently incorporate FITC in the silica matrix, it was modified by inducing a 
reaction between the isothiocyanate group of FITC and the amine group of APTES and forming 
a thiourea linkage. A known amount of FITC was added to 1-hexanol to make a 1.0 mM 
solution. 10 molar equivalents of APTES were added and allowed to stir for 24 h in a round-
bottom flask to get the FITC conjugated with APTES (FCA), (Scheme 5.2.1). The reagents are 
air sensitive and the reaction needs to be completed in a closed container in the dark.  
5.2.2.3 Preparation of F-SNPs 
To obtain F-SNPs with narrow size distribution patterns, the amounts of all reagents for 
each preparation method were adjusted carefully in preliminary experiments. Seven synthesis 
routes are schematically illustrated in Scheme 5.2.1. 
5.2.2.3.1 Preparation of FITC doped (non-covalently) into the TEOS/PTEOS-based SNPs 
(FDTPS) 
FDTPS were prepared using the Stöber method where 0.30 mL 10 mM solution of FITC 
in ethanol was transferred into a 25 mL round flask containing 2.7 mL ethanol and mixed with 
0.25 mL PTEOS. 0.20 mL ammonium hydroxide was added to the resulting solution to start the 
hydrolysis of the alkoxysilane precursor. The solution was stirred at low speed for 24 hours at 
room temperature. 0.5 mL TEOS and 0.25 mL PTEOS, dissolved in 5.0 mL ethanol were added 
320 
 
to the hydrolyzed solution and further reacted with 0.10 mL ammonium hydroxide solution via 
the Stöber process. The reaction was carried out for an hour at 0°C with continuous sonication 
and frequent vortexing then stirred for another 24 hours at room temperature. The formed 
particles were centrifuged and washed 3 times with a solution composed of ethanol and DI water 
(1:1, v/v), then the residue was left to dry completely. 
5.2.2.3.2 Preparation of FITC three covalently bonded-SNPs (FCTS, FCTPS, and FCTAS) 
FCTS, FCTPS, and FCTAS were also prepared by the Stöber method where 0.50 mL of 
the FCA conjugate solution were dissolved in 20.0 mL ethanol, followed by the sequential 
addition of the proper volume of the alkoxysilane precursor(s), 1.60 mL DI H2O, and 1.60 mL 
ammonium hydroxide solution. 1.00 mL TEOS was used in the case of FCTS preparation while 
0.5 mL TEOS and 0.5 mL PTEOS were used in the case of FCTPS preparation. Similarly, 0.5 
mL TEOS and 0.5 mL APTES were used in the case of FCTAS. The mixture was stirred at 400 
rpm for 24 hours at room temperature. The formed particles were centrifuged and washed 3 
times with ethanol and water, then the residue was left to dry completely, (Scheme 5.2.1).  
5.2.2.3.3 Preparation of FITC covalently encapsulated SNPs using WORM method (FCTPS-
RM) 
The micelles were prepared using 15.0 mL cyclohexane, 2.60 mL 1-hexanol, 3.55 mL 
Triton™ X-100, and 1.13 mL DI H2O which were stirred for 10 min to generate the 
microemulsion. After time elapsed, 0.50 mL of the FCA conjugate solution was slowly added to 
the microemulsion and stirred for 30 min at 120 rpm. Finally, 0.50 mL TEOS, 0.50 mL PTEOS, 
and 0.12 mL ammonium hydroxide were added and the solution was stirred for 24 h. Afterward, 
5.0 mL acetone were added and the NPs were collected by centrifugation and washed 5 times 
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with absolute ethanol and two times with water to remove any unreacted chemicals and free dye 
conjugates, (Scheme 5.2.1). 
5.2.2.3.4 Surface Modification of F-SNPs with PVP  
60 mg PVP were dissolved in a solution containing 30 mg of either FCTS or FCTAS in 
5.0 mL ethanol, and the mixture was stirred for 24 hours at room temperature and then 
centrifuged for 20 min at 3800 rpm. The precipitate was re-dispersed in ethanol, and the 
dispersion was centrifuged again then the residue was left to dry completely to obtain the 
corresponding PVP coated F-SNPs, FCTS-PVP and FCTAS-PVP, respectively (Scheme 5.2.1).  
5.2.2.4 Instruments and particles characterization 
0.1 mg/mL F-SNPs suspensions dispersed in ethanol were subjected to particle size 
determination analysis using a Malvern Mastersizer (Malvern Instruments Ltd., Malvern, UK. 
Polydispersity index (PDI), and standard deviation were obtained from three independent 
measurements of the dispersions of NPs. Zeta potential of NPs dispersions in ethanol was also 
measured. Transmission electron microscopy micrographs were conducted by the Zeiss LEO 
912AB (Zeiss, Thornwood, NY). NPs separation required an Allegra 64R Centrifuge (Beckman 
Coulter Inc., Brea, CA). A SympHonly (SB20) pH-meter (Thermo Orion, MA, USA) was used 
for pH adjustment. Nano pure water was prepared using a Barnstead NANO pure DIamond 
Analytical ultrapure water system (Fischer Scientific, NJ, USA). All fluorescence spectra were 
performed on ISS K2 multifrequency cross-correlation phase and modulation fluorimeter (ISS™ 
Focus and Discover, Champaign, IL, USA), equipped with a 300W xenon arc lamp. A 1.0 cm 
disposable plastic was used for all fluorescence measurements. To investigate the fluorescence 
properties of the F-SNPs, they were dispersed in a 1:1 (v/v) water/ethanol solvent and their 
emission spectra were recorded. 
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5.2.2.5 Use of F-SNPs as developing agents for fingerprints:  
Fingerprints were collected from a 26-year-old male donor and then developed after 24 
hours of deposition. Fingerprints were obtained by requesting the donor to rub his finger with his 
nose immediately prior to fingerprints deposition. The donor was instructed not to wash his 
hands within the last two hours. Fingerprints were deposited onto glass microscope slides (Fisher 
Scientific, Fair Lawn, NJ) which were used as received.  A specific concentration of 5.0 mg/mL 
suspensions for each of the F-SNPs in a solvent composed of 1:1 (v/v) DI water: ethanol were 
prepared, then the they were sonicated for 10 min to ensure sufficient particles dispersion. About 
0.5-1.0 mL of the suspension was pipetted onto the sample using a transfer pipette. After 5 
minutes, the excess solution was removed, and the sample was gently washed with a mixture of 
1:1 (v/v) DI water: ethanol. After that the developed fingerprint sample was left to dry at room 
temperature. The photographs were recorded with luminescence mode using the forensic light 
source (FLS), Mini-CrimeScope 400 MCS-400 (Spex Forensics, Edison, NJ) at excitation 
wavelength of 445 nm and crime scene search (CSS) settings. The fingerprint image was 
photographed using a digital camera (Nikon D3300) with a 520 nm long-pass filter. The sample 
was placed on a black surface to enhance the contrast of fingerprint image during illumination 
and taking pictures. 
5.2.3 Results and discussion 
To achieve stable incorporation of small molecules such as dyes, either covalent 
copolymerization of the dye conjugate or strong non-covalent binding interactions between the 
added dye molecules and the backbone of the cross-linked silicate matrix is needed. These 
interactions are likely to arise from hydrophobic and hydrophilic groups in the dye molecules 
and the silicate backbone. To identify the factors leading to stable incorporation of the 
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fluorogenic molecules into the SNPs and efficient visualization of fingerprints, seven different 
routes for preparing F-SNPs have been examined in this report. The produced SNPs have 
embedded within them either FITC or its conjugate with APTES, FCA. Two of the most 
commonly used sol-gel methods for SNPs preparation namely Stöber method and WORM 
method were used. Moreover, covalent encapsulation of the FCA dye conjugate versus 
encapsulation of the FITC dye itself non-covalently into the SNPs has been examined. In 
addition, three organosilicate monomers namely TEOS, PTEOS, APTES and their binary 
combinations were used to prepare the NPs. Finally, the adhesive agent, PVP was introduced 
onto the surface of the less hydrophobic F-SNPs to investigate the enhancement effect on the 
binding affinity of PVP-coated F-SNPs towards fingerprints residue.  
5.2.3.1 Particle characterization 
The physical nature and dimensions of the particles were derived from the DLS and TEM 
scans for FCTPS and FCTPS-RM, (Fig. 5.2.1). The NPs are composed of discrete 
monodispersed spherical particles with an average diameter of 110.4±31.1 and 4.1±0.6 for the 
NPs prepared by WORM and Stöber methods, respectively. The NP diameter obtained from 
TEM images, the mean hydrodynamic particle sizes by DLS, PDI, and zeta potential values are 
summarized in Table 5.2.1.  
TEM micrographs showed that the labeled F-SNPs prepared by WORM method had a 
spherical shape and a narrow size distribution of 4.1±0.6 which was confirmed by the DLS 
measurements. On the other hand, NPs prepared by Stöber method had a relatively larger 
diameter of about 110.4±31.1 with lower control on the monodispersity of the size and shape. 
The zeta potentials of FCTPS and SCTPS-RM in ethanol were ranging from -12.8 to -26.7 mV, 
respectively, Table 5.2.1.  
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Table 5.2.1 Diameter determined by TEM and DLS, polydispersity index (PDI), zeta potential of 
0.1 mg/ml labeled SNPs in ethanol 
 
F-SNPs 
Diameter (TEM) 
(nm) 
Diameter (DLS) 
(nm) 
PDI Zeta potential (mV) 
FCTPS 110.4 ± 31.1 605.7 ± 131.5 0.48 -26.7 ± 14.3 
FCTPS-RM 4.1 ± 0.6 5.3 ± 0.4 1.00 -12.8 ± 14.2 
 
5.2.3.2 Preparation method of the F-SNPs 
Two different F-SNPs, FCTPS and FCTPS-RM, were prepared to be used in this 
investigation. Both of them were prepared using a mixture of TEOS and PTEOS alkoxysilane 
precursors 21. FCTPS were prepared using the Stöber method 4 whereas FCTPS-RM were 
prepared using the WORM method 5. The Stöber method has the advantages of simplicity 
besides avoiding using surfactants which requires extensive cleaning steps. However, controlling 
the particle size is easily achieved using the WORM method, as nanoreactors of water droplets in 
the oil phase define the particles dimension 28. As expected, WORM method resulted in NPs 
with smaller size of about 4.1±0.6 nm and better monodispersity in comparison with the Stöber 
method as can be revealed from the SEM and DLS measurements. Due to the simplicity and cost 
effectiveness of the Stöber method, it was chosen as the method of F-SNPs preparation to 
investigate the other factors affecting fingerprints visualization.  
5.2.3.3 Covalent versus non-covalent fluorophore encapsulation into the SNPs matrix 
Two different F-SNPs, FDTPS and FCTPS, were prepared to be used in this 
investigation. Both of them were prepared using the Stöber method with equal volumes of TEOS 
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and PTEOS alkoxysilane precursors 21. FITC (logP 5.03) was non-covalently doped into a 
hydrophobic core composed of PTEOS (logP 3.25) then entrapped in a shell composed of TEOS 
(LogP 1.68) and PTEOS in the case of FDTPS. The composition of the core and the shell of 
FDTPS allowed stable non-covalent encapsulation of the hydrophobic FITC dye molecules with 
minimal leakage under the used experimental conditions. For FCTPS, APTES was used for 
crosslinking the FITC dye molecules with the silica matrix, where the binding between cyanate 
groups of the dye and amine groups of APTES results in the formation of thiourea linkage 30. 
The formed FITC conjugate with APTES, FCA, was covalently copolymerized into the SNPs to 
form FCTPS. Investigation of the emission spectra of these NPs, confirmed the successful 
encapsulation of the hydrophobic FITC dye, (Fig 5.2.2). The fluorescence maximum for all the 
NPs is within the same range of the pure dye.  Different patterns were observed due to the 
differences in the composition of the NPs. 
It is reported that the incorporation yield of non-covalently bound fluorophores is poor, as 
it is only based on physical adsorption forces 31. Nevertheless, non-covalent incorporation of 
FITC was made suitable using the hydrophobic alkoxysilane precursor, PTEOS, and this 
observation is consistent with other reports 6, 21, 32, 33. It was also noted that the intensity of 
FDTPS fluorescence increased as the proportion of PTEOS in the initial monomer mixture 
increased 21. A ratio of 1:1 (v/v) was used thereafter in all incorporation experiments. However, 
the dye is prone to leaking from FDTPS under exposure to the used solvent for longer time so the 
more stable FCTPS was found to be more suitable for developing fingerprints.  
5.2.3.4 Type of the alkoxysilane precursor(s) 
Three different organosilicate monomers have been used in this investigation, namely 
TEOS (logP 1.68), PTEOS (logP 3.25), and APTES (logP -1.83) to incorporate FCA covalently 
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into the silica platform.  It is hypothesized that the planar aromatic phenyl groups of PTEOS 
would form hydrophobic interactions with the planar rings of FITC and that negatively charged 
Si–O groups present in the alkoxysilane precursors would form strong interaction with the polar 
functional groups of FITC, and thus producing a highly fluorescent and stable complex on 
encapsulation can be obtained [7]. Nevertheless, the nature of organosilicate monomers will not 
have a significant effect on the dye loading and its leaking from the NPs as the dye was 
covalently bonded into the silica matrix to form highly stable F-SNPs. Thus, the nature of the 
organosilicate monomers is expected to influence mainly the binding affinity to the fingerprints 
residue as it will be discussed in details in the following section. 
5.2.3.5 Use of dye-encapsulated SNPs suspensions as developing agents for fingerprints  
To investigate the binding affinity of F-SNPs to fingerprints, suspensions of these 
particles were applied on a glass substrate as shown in Fig 5.2.3. The nature of the precursor 
plays an important role in fingerprint detection. When the binary mixture of TEOS and PTEOS 
used in three different preparation routes of F-SNPs namely FCTPS, FCTPS-RM, and FDTPS, 
clear luminescent fingerprint ridges were obtained for the three F-SNPs suspensions at CSS 
setting of the FLS viewed through a 520 nm long pass filter as shown in Fingers 3a, b, and c 
(first row). The surface of NPs has been decorated with PTEOS which increases the hydrophobic 
interaction between the phenyl group of PTEOS and the sebaceous secretion in the fingerprint 
residue resulting in enhanced binding and detection of fingerprints. Despite the differences in the 
preparation methods, the efficiency of these hydrophobic NPs as developing agents able to 
produce clear luminescent fingerprints with high contrast was observed and attributed to the 
PTEOS-modified hydrophobic surface. However, a more distinct definition in fingerprint 
detection was noticed using another setting of FLS at excitation wavelength of 445 nm viewed 
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through the same filter as shown in Fig. 5.2.3a, b, and c (second row). Fingerprints developed 
with FDTPS appeared luminescent with clear ridge pattern. The luminescence intensity of 
fingerprints decreased with FCTPS-RM and FCTPS, and the latter appeared more as dotted 
marks. It was found that CSS setting of the crimescope was the best choice for fingerprints 
visualization. When TEOS was used solely for the preparation of FCTS, weak luminescence and 
poor contrast were obtained as shown in Fig. 5.2.3d in both settings of the FLS. Therefore, using 
these particles as developing agents for fingerprint detection is not practical. On the other hand, 
the binary mixture of TEOS and APTES used in preparing FCTAS resulted in highly 
luminescent ridges with obvious background noise as shown in Fig. 5.2.3e using both CSS and 
445 nm settings. The observed background noise could be due to undesirable interactions 
between the polar APTES with the glass substrate. The presence of amine group in APTES 
promotes interaction with any compounds bearing carboxyl groups in fingerprint residue to 
produce amide linkage. The formation of this linkage was confirmed by the work of Moret et al. 
in understanding the mechanism of fingerprint development using SNPs 34. 
Friction ridge features of a fingerprint have been classified into three levels of detail 35.  
First- level detail describes the overall ridge pattern such as fingerprint orientation and ridge flow 
direction. The general information obtained from the first-level detail are not decisive. Thus, it 
cannot be used for personal identification. Second-level detail involves ridge formations and 
pattern minutiae such as ridge ending, bifurcation, and dots. Third-level detail includes the 
morphology of a ridge such as width, shape, and pores. Both second and third- level details 
enable identification and fingerprint matching due to the unique individual features. The typical 
features of second-level detail of fingerprint friction ridge of FCTPS, FCTPS-RM, and FDTPS 
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are shown in Fig. 5.2.4. Such features including bifurcations and ridge endings were slightly 
clear in fingerprints developed by FCTPS-RM, and FDTPS compared with FCTPS.  
5.2.3.6 Surface modification of fluorescent SNPs with PVP 
In order to enhance the fingerprints detection, the less hydrophobic FCTS and FCTAS 
were coated with the adhesive agent, PVP to improve their binding affinity to the hydrophobic 
components present in the fingerprint residue. PVP has been used as adhesive agent or binder in 
pharmaceutical industry because of its binding affinity to polar and nonpolar molecules 
contributed to intrinsic amphiphilic property of PVP 36, 37. Thus, compared to uncoated NPs, their 
PVP-modified counterparts, FCTS-PVP and FCTAS-PVP should show much higher contrast 
fingerprints images on glass because of their high binding affinity 12. Fingerprints detection using 
PVP-coated SNPs as fluorescent labeling markers should be well-defined in terms of finger ridge 
details without background staining, resulting in a good definition of enhanced detection. 
However, it was observed that the PVP-coated SNPs did not result in any enhanced visualization 
as shown in Fig. 5.2.3f and g. 
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Scheme 5.2.1 Preparation routes for F-SNPs 
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Figure 5.2.1 TEM micrographs of (a) FCTPS and (b) FCTPS-RM 
 
 
Figure 5.2.2 Normalized emission spectra of (a) FITC (b) FCTPS, (c) FCTPS-RM, (d) FDTPS, 
(e) FCTS, and (f) FCTAS in water: ethanol (1:1, v/v) at excitation wavelength of 455 nm 
(a) (b) 
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Figure 5.2.3 Fluorescence images of the fingerprints developed using 5.0 mg/mL F-SNPs 
suspensions in water: ethanol (1:1, v/v) of (a) FCTPS, (b) FCTPS-RM, (c) FDTPS, (d) FCTS, (e) 
FCTAS, (f) FCTS-PVP, and (g) FCTAS-PVP at different FLS settings 
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Figure 5.2.4 Fluorescence images of fingerprints of (a) FCTPS, (b) FCTPS-RM, and (c) FDTPS, 
at CSS setting of FLS, showing second-level detail of fingerprint friction ridge (i) bifurcation 
and (ii) ridge ending 
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5.3  Preparation of Fluorescently Labeled Silica Nanoparticles Using an Amino Acid-
catalyzed Seeds Regrowth Technique: Application to Latent Fingerprints Detection 
and Hemocompatibility Studies 
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The efficiency of an amino acid catalyzed seed regrowth technique (ACSRT) in 
synthesizing twelve fluorescently labeled core-shell silica nanoparticles (FLSNPs) with tunable 
sizes, tailored hydrophobicity, low polydispersity as well as high labeling efficiency and 
minimized dye leakage using different organosilicate monomers and fluorophores have been 
systematically investigated in this report. The utilization of some of these FLSNPs in some 
applications that are facilitated by hydrophobicity such as developing and visualizing latent 
fingerprints (LFPs) on different surfaces was also investigated. The non-specific binding affinity 
of the developed nanoparticles to human serum albumin (HSA) and immunoglobulin G (IgG) 
has also been studied. Fluorescein, fluorescein isothiocyanate and its more hydrophilic 
butenamine derivative (WA6) have been used in this study. Also, the alkoxysilane precursor, 
tetraethoxyorthosilicate (TEOS) and its binary mixture with phenyltriethoxysilane (PTEOS) or 3-
aminopropyl triethoxysilane (APTES) have been used in preparing the FLSNPs with tailored 
compositions for the core and shell of the nanoparticles.  The mean diameters of the PTEOS-
coated FLSNPs were between 33.4±5.9 and 42.2±10.8 nm as shown by the SEM measurements. 
The obtained results highlight the advantages of having a hydrophobic surface along with proper 
selection of the monomers forming the core to match the properties of the fluorescent reporters 
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for clear detection of LFPs even using dyes of low hydrophobicity such as fluorescein and WA6. 
Furthermore, some of the developed FLSNPs were compared with bare silica nanoparticles in 
terms of nonspecific protein adsorption and hemolysis. The obtained results proved that the 
selected FLSNPs had a superior hemocompatibility in comparison with bare silica nanoparticles. 
These FLSNPs could also be used in some bio-related and diagnostic studies such as 
immunoassays and cell imaging purposes. 
5.3.1 Introduction 
Using APTES-based organosilane chemistry is the common approach to achieve proper 
dye encapsulation via Stöber and WORM methods. Shakiba Shahabi et al. 6 reported that the 
poor incorporation efficiency of non-covalently bound fluorophores could be enhanced using 
ACSRT 31. The synthesis pathway of ACSRT eliminates the need for covalent crosslinking step 
such as APTES-conjugation of dyes. Furthermore, enhanced dye stability and a higher labeling 
efficiency can be obtained with ACSRT, even without using APTES. The use of L-arginine as a 
catalyst also induces a stable crosslinking of some dyes into the silica matrix through a thiourea 
linkage 6, 38.  
In this report, the synthesis of twelve fluorophore-encapsulated SNPs with well-
controllable size and tunable hydrophobicity for the core and shell of the particles based on the 
ACSRT is presented, (Fig. 5.3.1, Table 5.3.1). Besides L-arginine, water, and the proper 
organosilicate precursors, the fluorophore molecules were introduced in the nucleation step, to 
form the fluorescent silica. The water-soluble organic fluorophore, fluorescein, or its more 
hydrophobic derivative, fluorescein isothiocyanate (FITC) or the more hydrophilic butenamine 
derivative of FITC (WA6) were directly incorporated into the seeds without covalent binding. 
The structure formulae of the three dyes are presented in Fig. 5.3.1.  
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Based on Shakiba Shahabi et al., work 6, particle size can be adjusted by controlling the 
reaction parameters and the proportion of seeds and organosilicate precursors in the regrowth 
step. The obtained fluorescent SNPs were characterized using scanning electron microscopy 
(SEM), dynamic light scattering (DLS), and fluorescence spectrometry. In addition, the labeling 
efficiency, dye leakage and colloidal stability were evaluated. The utilization of these particles in 
some hydrophobicity-based detection applications such as developing latent fingerprints (LFPs) 
39 was systematically investigated. Furthermore, the suitability of these FLSNPs for biological 
studies was assessed by testing their non-specific binding to plasma proteins and by assessing 
their hemocompatibility. SNPs have been successfully used in such applications because of their 
unique advantages. Firstly, excellent physicochemical stability and cost-effective fabrication. 
Secondly, SNPs have tunable structural properties such as particle shape, particle sizes, pore 
structures, pore volumes, specific surface areas, hydrophobicity and so on. Thirdly, efficient 
loading of a wide range of hydrophilic or hydrophobic organic molecules such as organic dyes. 
Fourthly, SNPs are not toxic with great biocompatibility and biodegradability. Finally, facile 
multi-functionalization on the abundant -Si-OH, where their surfaces can be modified to satisfy 
the required purpose 39, 40.  
The developed hydrophobic FLSNPs can be used for LFPs detection which is useful for 
personal identification in forensic investigations. The common form of fingerprint evidence left 
at the scenes of crime is LFPs, which is generally invisible to the naked eyes. Therefore, it needs 
to be developed to enable its visualization 10. This can be achieved by obtaining an obvious 
contrast between the secretion residues of the LFPs pattern and the underlying substrates 41. 
Many micro- or nanometer-sized particles with various compositions, such as gold nanoparticles, 
semiconductor quantum dots, magnetic particles, rare earth nanomaterials, silica particles, 
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composites, have been exploited as the developing agents using the powdering method 19. 
Among various compositions, the hydrophobic SNPs, which were doped with dyes, metals, 
metal oxides or carbon, were used in developing clear LFPs 42.  
Some reports concentrated on the incorporation of fluorophores into the colloidal silica 
spheres and on the nature of these fluorophores 26-28. Nevertheless, very few studies have been 
carried out that focus on the nature of the SNPs core and shell composition used for dye 
encapsulation and their effects on the efficiency of LFPs detection in a systematic manner. 
Theaker et al reported that for effective dye doping mixtures of TEOS and PTEOS have to be 
used in synthesizing the SNPs, hence it was concluded that analogous hydrophobic and 
electrostatic interactions occur within these hydrophobic SNPs between compatible groups 
within the fluorescein isothiocyanate (FITC) dye molecules or any other dye of a related 
structure and the silica matrix 39. Moreover, it was found that this dye was not subjected to 
photo-bleaching under exposure to high intensity UV illumination. Hence, these FLSNPs can be 
utilized as agents for developing LFPs, including aged prints where the residues mainly consist 
of hydrophobic endogenous chemicals secreted by the donor, due to their hydrophobic nature 39. 
It should also be noted that as the proportion of PTEOS increases, the hydrophobicity of the 
resulting sol–gel also increases 29.  
To the best of our knowledge, this is the first report that describes the synthesis of 
fluorescent SNPs based on a basic amino acid-catalyzed approach for developing LFPs using 
different combinations of hydrophilic and hydrophobic organosilicate precursors for modifying 
the core and shell of the SNPs. Moreover, the efficiency of embedding three fluorescent reporters 
with different LogP values in the core of theses SNPs has also been investigated. It was 
attempted in this study to enhance the loading efficiency of the used dyes and decrease their 
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leakage from the silica matrix just through non-covalent interactions between the dye and the 
alkoxysilane molecules in the core of the SNPs as well as encapsulating the dye molecules 
insides a shell with the suitable composition. Also, this is the first time to systematically study 
the effect of organosilane precursors on the size and colloidal stability of the ACSRT-made silica 
nanoparticles. Moreover, the scalable synthesis of silica nanoparticles from ultra-small size (13.9 
nm) to large size (hundreds nm) with varying the nature of the core and shell compositions can 
provide a great benefit to study the effect of these factors, which have been considered to play a 
major role in the interaction with different surfaces, in vivo pharmacokinetics, and other bio-
relevant issues. 
On the other hand, it is reported that bare SNPs exhibit a noticeable hemolytic behavior, 
besides, their nonspecific binding to human serum albumin (HSA) and immunoglobulin G (IgG) 
43. In this report, some of the proposed hydrophobic FLSNPs were compared with bare silica 
nanoparticles in terms of nonspecific protein adsorption and percentage of hemolysis. 
Different requirements should characterize those SNPs to achieve the desired properties. 
Therefore, hydrophobicity, labeling efficiency, dye leakage, monodispersity, colloidal stability as 
well as hemocompatibility of the synthesized FLSNPs were carefully considered.  
5.3.2 Experimental 
5.3.2.1 Materials and reagents 
All the chemicals used were of Analytical Reagent grade, and the solvents were of HPLC 
grade. All the following chemicals were produced by Sigma-Aldrich, MO, USA: fluorescein 
isothiocyanate (FITC) (isomer I, 90%), 1-heptanol (anhydrous, ≥99%), 3-aminopropyl 
triethoxysilane (APTES) (≥98%), tetraethyl orthosilicate (TEOS) (99.99% trace metal basis), 
sodium hydroxide (pellets, 97+%, A.C.S. reagent), cyclohexane (anhydrous, 99.5%), albumin 
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from human serum (>96%), purified human immunoglobulin G (IgG), sodium phosphate, 
dibasic (98+%), potassium phosphate monobasic (>95%), hydrochloric acid (37%), and Triton™ 
X-100 (laboratory grade). Fisher Scientific, Fair Lawn, NJ, produced ammonium hydroxide 
solution (28%) and sodium chloride crystals (certified A.C.S). Phenyltriethoxysilane (PTEOS) 
was supplied by Chem-Impex Int`l Inc., IL, USA. Ethanol (200 proof) was obtained from Decon 
labs Inc (King of Prussia, PA USA) while KCl was obtained from J.T.Backer Inc. (NJ, USA). 3-
Buten-1-amine (97%) was purchased from Alfa Aesar (MA, USA).   
5.3.2.2 Pre-modification of WA6 
1-(but-3-en-1-yl)-3-(3',6'-dihydroxy-3-oxo-4a',9a'-dihydro-3H-spiro[isobenzofuran-1,9'-
xanthen]-5-yl)thiourea (WA6) was prepared by inducing a reaction between the isothiocyanate 
groups in FITC with the amine group of 3-butene-1-amine. 0.22 mmole of FITC was added to 
0.32 mmole of 3-butene-1-amine and refluxed for 24 h in a round-bottom containing 2 mL 
ethanol, (Scheme 5.3.1). The residue was filtered and washed several times with methanol and 
then dried under reduced pressure to obtain the pure form.  
5.3.2.3 Synthesis of FLSNPs using ACSRT  
All FLSNPs were synthesized by slightly modifying previous methods 6, 7.  
5.3.2.3.1 Preparation of labeled seeds 
One mmole L-arginine was dissolved in 16.9 ml DI H2O and stirred thoroughly at room 
temperature. Afterward, 0.02 mmoles of the corresponding fluorescent dye dissolved in 500 μL 
ethanol was added to the L-arginine solution. The mixture was stirred for 10 min and then heated 
up to 70 °C, before the addition of 0.001 mmoles of TEOS. In the case of using a binary mixture 
of the organosilicate monomer, 0.0005 mmoles from each monomer were used instead.  The 
mixture was stirred for 24 h at 70 °C in an oil bath. Finally, the dispersion containing the labeled 
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seeds was used as stock for the regrowth step. The synthesis was carried out in the dark to 
minimize photo-bleaching of the fluorescent dye.  
5.3.2.3.2 Regrowth of labeled seeds  
4.47 mmole L-arginine were dissolved in 1 mL water and 4 mL ethanol. Subsequently, 1 
mL of the labeled seeds was added to the L-arginine solution. The mixture was stirred for 10 min 
before heating up to 70 °C. Thereafter, 1 mL of TEOS was added. In the case of using a binary 
mixture of the organosilicate monomer, 0.5 mL from each monomer was used instead. The 
suspension was then stirred at 70 °C for 24 h in the dark. Twelve different types of FLSNPs with 
different sizes were prepared only by varying the fluorophore and/or the organosilicate precursor 
(Table 5.3.1), while the other parameters were kept constant. Then, the particles were collected 
by centrifugation, washed with ethanol and water twice and left to dry at 60°C. A different set of 
the SNPs namely; T-T, T-TP, TP-TP, TA-T, and TA-TP, was prepared for colloidal stability and 
characterization studies according to the same procedure without labeling with any fluorophores 
in the seeds preparation step. The effect of the amount of L-arginine on the size of the silica 
nanoparticles was investigated by varying the concentration of the amino acid catalyst in the 
regrowth step to be 0.0, 1.0, and 4.47 mmoles in the prepared particles; T-T-0, T-T-1, and T-T, 
respectively. 
5.3.2.4. Instruments and particle characterization 
0.2 mg/mL FLSNPs suspensions dispersed in ethanol were subjected to particle size 
determination analysis using a Malvern Mastersizer (Malvern Instruments Ltd., Malvern, UK. 
Polydispersity index (PDI), and standard deviation were obtained from three independent 
measurements of the dispersions of SNPs. Zeta potential of particles dispersions in ethanol and 
water were also measured. Scanning electron microscopy micrographs were conducted by the 
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Tescan Vega3 LMU scanning electron microscope (TESCAN, Kohoutovice, Czech Republic) 
and Denton Desk II sputter coated with a gold target (Denton Vacuum, NJ, USA). Nanoparticle 
separation required an Allegra 64R Centrifuge (Beckman Coulter Inc., Brea, CA). A SympHonly 
(SB20) pH-meter (Thermo Orion, MA, USA) was used for pH adjustment. Nano pure water was 
prepared using a Barnstead NANO pure DIamond Analytical ultrapure water system (Fischer 
Scientific, NJ, USA). All fluorescence spectra were performed on ISS K2 multifrequency cross-
correlation phase and modulation fluorimeter (ISS™ Focus and Discover, Champaign, IL, USA), 
equipped with a 300W xenon arc lamp. A 1.0 cm disposable plastic was used for all fluorescence 
measurements. The nuclear magnetic resonance spectra were obtained using high quality Kontes 
NMR tubes (Kimble Chase, Vineland, NJ) rated to 500 MHz and were recorded on a Bruker 
Avance 400 MHz spectrometer interfaced to a PC using Topspin 3.1. High-resolution accurate 
mass spectra were obtained at the Georgia State University Mass Spectrometry Facility using a 
Waters Q-TOF micro (ESI-Q-TOF) mass spectrometer or utilizing a Waters Micromass LCT 
TOF ES+ Premier mass spectrometer. 
5.3.2.5 Solvatochromic effect 
The solvatochromic effect was studied by measuring the emission spectra of 5 mg/mL 
WA6-TA-T as well as the free WA6 dye (3.3 x 10-7 M) in different solvents including water, 
ethanol, and 0.1 M HCl using the ISS K2 fluorimeter.  
5.3.2.6 Labeling efficiencies and dye leakage studies for the prepared FLSNPs 
Labeling efficiencies are the fraction of added dye molecules actually incorporated in the 
SNPs 44 by comparing the fluorescence intensities of the remained free dyes with standard 
samples. For the dye leakage study, seven of the FLSNPs, sets of three samples of 22.5 mg for 
each type of the FLSNPs dispersed by sonication in 3 mL of a dispersant composed of ethanol 
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and water mixture (1:1, v/v) or (1:9, v/v) were prepared. After measuring the initial fluorescence, 
the samples were kept in the dark at room temperature. After 1 hour, the SNPs were centrifuged 
at 3200 rpm for 5 min. The supernatant was discarded, and the pellet of FLSNPs was 
resuspended in the corresponding dispersant. Then, the fluorescence signal of the FLSNPs 
suspensions was measured. This procedure was repeated with a different set of samples after 24 
hours using a solvent composed of ethanol and water with a ratio of (1:9, v/v) 45. 
5.3.2.7 LFPs detection using FLSNPs 
Two methods for applying the resulting particles to latent prints were used; one used an 
aqueous suspension which consisted of discrete nanoparticles, and the second used the 
nanoparticles powder for dusting the LFPs. Fingerprints were collected from the same donor, a 
26-year-old male and then developed after 24 hours of deposition. Fingerprints were obtained by 
requesting the donor firstly; to wash his hands thoroughly with the soap then rub his finger with 
his nose immediately prior to fingerprints deposition onto the tested surfaces. The photographs 
were recorded with luminescence mode using the forensic light source (FLS), Mini-CrimeScope 
400 MCS-400 (Spex Forensics, Edison, NJ, USA) at excitation wavelength of 445 nm or crime 
scene search (CSS) settings. The fingerprint image was photographed using a digital camera 
(Nikon D3300) with a 540 nm long-pass filter. The sample was placed on a black surface to 
enhance the contrast of fingerprint image during illumination and taking pictures. 
5.3.2.7.1 Use of FLSNPs suspensions as developing agents for LFPs 
The particle suspension method was carried out with the glass slides substrates only as 
follows: a specific concentration of 2.5 mg/mL suspensions for each of the twelve FLSNPs in 9:1 
(v/v) DI water: ethanol dispersant was prepared as the working suspension, then they were 
sonicated for 10 min to ensure sufficient particles dispersion. About 0.5-1.0 mL of the 
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suspension was pipetted onto the sample using a transfer pipette. After 5 minutes, the excess 
solution was removed, and the sample was gently washed with a mixture of 9:1 (v/v) DI water: 
ethanol. After that, the developed fingerprint sample was left to dry at room temperature.  
5.3.2.7.2 Use of FLSNPs powders as developing agents for LFPs on various substrates 
Five different substrate surfaces were tested in this investigation, namely; glass slide, 
petri dish (polystyrene), aluminum foil, common white paper, and the white area of paper 
currency. F-TA-TP was selected as representative hydrophobic FLSNPs in this investigation. 
The powder method was performed as follows: a commercial Lightning Powder Zephyr 
Fiberglass Fingerprint Brush was used to pick up some F-TA-TP powder, and then carefully 
applied to the surface of LFPs with a light brushing action. The excess powder was removed by 
using a hair dryer for 90 seconds. 
5.3.2.8 Protein adsorption  
WA6-T-T particles were selected as a representative for FLSNPs without surface 
hydrophobization whereas WA6-T-TP particles were selected as representative hydrophobic 
FLSNPs in this investigation to be compared with bare SNPs in terms of non-specific protein 
binding. HSA and IgG were used in this investigation where 1.5 mL of 10 mg/mL of IgG 
solution and 72 mg of HSA were dissolved in 10 and 18 mL pure water to get a 1.5 and 4.0 
mg/mL stock solutions, respectively. WA6-T-T, WA6-T-TP and bare SNPs were dispersed in 10 
mM isotonic PBS (pH = 7.4) buffer with a concentration of 5 mg/mL. Then 2 mL of each of the 
SNPs suspension were mixed with 2 mL of the corresponding protein solution and shook at 37 
°C for 6 h at 100 rpm in the incubator. Finally, the mixture was centrifuged and the supernatant 
was measured using a UV spectrophotometer, the adsorbed protein was presented as adsorption 
efficiency (AE(wt.%)) and calculated. The absorption efficiency was calculated using the 
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following formula: AE (wt.%) = (Ci−Cf)/Cn × 100% Ci and Cf represents the initial and final 
protein concentration in the solution, respectively, Cn represent the concentration of the 
nanoparticles 46. 
5.3.2.9 Hemolysis study 
A hematology-3, sample hem-02, American proficiency institute (manufactured by 
Streck, LaVista, NE, USA) was used in this study. Red blood cells (RBCs) were isolated from a 
2-mL sample by centrifugation for 10 min, and washed three times with sterile isotonic PBS 
solution. Following the last wash, RBCs were diluted 1:5 in sterile isotonic PBS solution. The 
RBCs suspension from the diluted sample (0.4 mL) was added into 1.2 mL of nanoparticles 
isotonic PBS suspension to reach a final concentration of 2 mg/mL. Bare SNPs, WA6-T-T, 
WA6-T-TP, WA6-TP-TP, WA6-TA-T, and WA6-TA-TP were used. The RBCs incubated with 
pure water and isotonic PBS solution were set as positive and negative controls, separately. The 
mixtures were shaken before being incubated for 1.5 h at 37 °C. Finally; the mixtures were 
centrifuged for 10 min, then the absorbance of the clear upper solutions at 538 nm were recorded 
by a UV spectrophotometer. 
5.3.3 Results and discussion 
5.3.3.1 Preparation method of the FLSNPs and labeling efficiency 
The labeling efficiency and photophysical properties of FLSNPs intrinsically depend on 
the applied synthesis method. In this investigation, an amino acid-catalyzed seed regrowth 
method was used for the synthesis of twelve FLSNPs and tested for efficient control on the core 
and shell composition of the SNPs in order to achieve proper non-covalent embedding of the 
fluorescent reporters. The Stöber method has the advantages of simplicity besides avoiding using 
surfactants which requires extensive washing steps whereas controlling the particle size is easily 
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achieved using the WORM method, as nanoreactors of water droplets in the oil phase define the 
particles dimension 28. Unlike the conventional methods such as Stöber 4 and WORM 5, ACSRT 
permits the synthesis of fluorescent SNPs in a water-based system, without the use of any 
surfactants or co-surfactants. By this approach, additional linkers for covalent coupling of the 
fluorophore to silica matrix were omitted, while a remarkable doping efficiency was achieved, 
Table 5.3.1 7. L-arginine was applied as a catalyst while the dye molecules were incorporated 
into the particle nuclei formed by hydrolysis and recondensation of three different organosilane 
monomers, namely; TEOS (logP 1.68), PTEOS (logP 3.25) and APTES (logP -1.83). Particle 
regrowth was achieved in the second stage due to the polymerization of either TEOS or its binary 
mixture with the more hydrophobic organosilicate precursor, PTEOS, or the polar oeganosilicate 
precursor, APTES, Table 5.3.1. Fluorescein (logP 3.4), Fluorescein isothiocyanate (logP 4.8) and 
WA6 (logP -1.1) have been used in this study. The logP of the novel WA6 dye was determined 
using the shake flask method based on the distribution between equal volumes of chloroform and 
water. Twelve different FLSNPs were prepared with tailored compositions for the core and the 
shell of the SNPs. From the results presented in Table 5.3.1, it was found that using TEOS as the 
sole organosilane precursor in the core and shell of F-T-T, FITC-T-T and WA6-T-T resulted in 
poor labeling efficiency of 15.8, 8.0, and 16.3 %, respectively, due to absence of efficient non-
covalent interactions between the used dyes and the silica matrix. However, a labeling efficiency 
of 37.4% was obtained in the case of WA6-TA-T due to strong hydrogen bonding between the 
amino groups in APTES and the thiourea and hydroxyl groups in WA6. On the other hand, in 
case of F-T-TP and F-TP-TP, the incorporation of the hydrophobic PTEOS either in the shell 
only or both in the core and in the shell resulted in intermediate labeling efficiency of 44.9 and 
52.6%, respectively, which can be attributed to the reasonable interactions between fluorescein 
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and the core as well as the successful encapsulation of the dye inside the hydrophobic silica 
shell. For F-TA-TP and WA6-TA-TP, the use of a mixture of TEOS and the polar APTES in the 
core of the SNPs allowed proper embedding of fluorescein and WA6 dye molecules with high 
labelling efficiency of 79.2% and 78.4%, respectively, through strong non-covalent interactions 
which were then entrapped by a hydrophobic shell composed of a mixture of TEOS and the 
hydrophobic PTEOS. Furthermore, FITC-T-TP should higher labeling efficiency than FITC-TP-
TP of 74.5 and 53.6%, respectively.  This can be attributed to the use of L-arginine that induces 
the stable incorporation of FITC into the TEOS based silica matrix in the core of FITC-T-TP. As 
the thiocyanate groups of FITC are reactive that they can bind to the amine groups of L-arginine 
forming a stable thiourea linkage. It is suggested that L-arginine, used as the catalyst in ACSRT, 
also plays a crosslinking role to bind the dye molecules to the silica matrix 6. Finally, WA6-T-TP 
and WA6-TP-TP showed satisfactory labeling efficiencies of 63.9 and 72.4%, respectively which 
highlights the virtue of using a hydrophobic shell in achieving a successful encapsulation of dye 
molecules even the ones of low lipophilicity such as WA6 and fluorescein. It is worth noting 
that, APTES was not used for encapsulating FITC to avoid any interferences in the obtained 
labeling efficiency results as APTES can form a covalent thiourea linkage with FITC 38.  
5.3.3.2 Particle characterization 
The synthesized FLSNPs were characterized via different methods prior to the 
application to LFPs detection and hemocompatibility studies. The physical nature and 
dimensions of the particles were derived from the SEM scans and DLS for WA6-T-T, WA6-T-
TP, WA6-TP-TP, WA6-TA-T and WA6-TA-TP, (Fig. 5.3.2, Table 5.3.2). Also, the mean 
hydrodynamic particle sizes and PDI measurements in deionized water by DLS for the used three 
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unlabeled seeds T, TP, and TP as well as for the unlabeled particles; T-T, T-TP, TP-TP, TA-T, 
and TA-TP were summarized in Table 5.3.3.  
SEM micrographs showed that the labeled FLSNPs prepared using PTEOS had a smaller 
diameter and narrow size distribution in comparison with WA6-T-T and WA6-TA-T which were 
prepared under the same conditions, Table 5.3.2. The hydrophobic SNPs were composed of 
discrete monodispersed globular particles with an average diameter (SEM) of 33.4.6±5.9, 
42.2±10.8, and 39.8±3.0 nm, for WA6-T-TP, WA6-TP-TP, and WA6-TA-TP, respectively, 
whereas the WA6-T-T and WA6-TA-T had an average diameter (SEM) of 1511.0±354.8 and 
1428.26±116.3, respectively. The bigger size of the particles that don`t have PTEOS in their 
shell composition may be attributed to the higher rate of hydrolysis and recondensation of TEOS 
in comparison with PTEOS.  
The hydrodynamic diameters for the seeds; T, TP, and TA as well as for the SNPs; T-T, 
T-T-1, T-TP, TP-TP, TA-T, and TA-TP were characterized using DLS, Table 5.3.3. The 
obtained hydrodynamic size data for the seeds and for the core-shell nanoparticles reflect the size 
of the regrowth shell which proved to be dependent on the nature of the used organosilane 
precursors and on the amount of the L-arginine catalyst in the regrowth step. When TEOS was 
used solely in the regrowth step, bigger particles was obtained.  
The effect of the amount of L-arginine on the size of the prepared unmodified silica 
nanoparticles was investigated by varying the concentration of the amino acid catalyst in the 
regrowth step to be 0.0, 1.0, and 4.47 mmoles. As a control, no silica product was obtained at 
x=0, likely because of the lack of catalysis for the hydrolysis of TEOS followed by condensation 
of the resultant products. The DLS hydrodynamic diameter measurements with the composition 
of arginine varied are shown in Table 5.3.3. When the concentration of the basic amino acid was 
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decreased from 4.47 mmoles in the case of T-T to 1.0 mmoles in the case of T-T-1, the 
hydrodynamic dimeter decreased. 
The zeta potential measurements for five unlabeled SNPs; T-T, T-TP, TP-TP, TA-T, and 
TA-TP were presented in Table 5.3.3 and Fig. 5.3.3. The obtained results showed that zeta 
potentials of the PTEOS-modified particles, T-TP, TP-TP and TA-TP, were less negative than 
the unmodified particles. 
5.3.3.4 Dye leakage 
The leakage of fluorescein, FITC and WA6 dye molecules from SNPs was also examined 
in this report. Fig. 5.3.4a shows the changes in fluorescence intensities from nine FLSNPs kept 
for 1 hour at room temperature in two different solvents composed of ethanol and water in the 
ratio of (1:1, v/v) or (1:9, v/v). The obtained results clearly highlight the advantage of using a 
lower ratio of ethanol to avoid a significant dye leakage as hydrophobicity of the dye plays an 
important role in this process. In Fig. 5.3.4b, the experiment was repeated for the seven FLSNPs 
in a solvent composed of ethanol and water in the ratio of (1:9, v/v) for 24 hours.  
The obtained results show the virtue of using the polar APTES in the core of WA6-TA-T 
and F-TA-TP in achieving a stable non-covalent encapsulation of WA6 and fluorescein with 
only 21% and 33% decrease in fluorescence intensity after 1 hour in comparison with 72% 
decrease for WA6-TP-TP and F-T-TP and 69% for F-TP-TP, respectively. For FITC-T-TP and 
FITC-TP-TP, decreases of 45% and 43%, respectively, were obtained after 1 hour indicating the 
importance of having a core with a hydrophobic nature in minimizing the leakage of the 
relatively hydrophobic FITC dye molecules. On the other hands, WA6-TA-TP and WA6-T-TP 
showed average leakage results with decreases of 54% and 47% after an hour, respectively.  
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It is worth noting that using 10% ethanol in water was necessary to help the dispersion of 
the FLSNPs for the LFPs detection application. Moreover, it can be concluded that using the 
hydrophilic dye molecules in this study, WA6 and fluorescein along with keeping a 
nonhydrophobic composition for the core are extremely important in minimizing the dye leakage 
under the prescribed experimental conditions for developing LFPs using the pipetting method 
which is just a 20 min process.   
5.3.3.5 Solvatochromic effect 
Solvatochromic characteristics were studied for WA6-TA-T, which showed minimal dye 
leakage (Fig. 5.3.4), and compared to WA6 free dye by measuring their fluorescent spectra in 
three different solvents namely water, ethanol and 0.1M HCl, (Fig. 5.3.5 a&b). The normalized 
absorbance spectra of WA6-TA-T and the free dye were measured in water and ethanol, (Fig. 
5.3.5 c &d). Free WA6 showed different fluorescence behaviors in the selected solvents, (Fig. 
5.3.5a, Fig. 5.3.6). 
This solvatochromic shift indicated the changes in the excited state energies of WA6 
depending on solvents polarity 47. According to previous reports 6, 48, the response profiles of 
SNPs prepared by Stöber and WORM show obvious solvent-dependent characteristics. This 
suggests that dye molecules are randomly localized near the SNP surface. As a consequence, the 
solvatochromic characteristics of these SNPs are the outcome of the behaviors of dye molecules 
with inhomogeneous localizations which can be minimized by using the ACSRT due to the 
protective architecture of silica in these FLSNPs 6. A dense localization of fluorophores in the 
seeds can be reached before they get completely covered with silica in the regrowth step using 
ACSRT.  
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It was observed that WA6 showed no fluorescence at all in 0.1M HCl due to protonation 
of the carboxylic group in the presence of an acidic medium, (Fig. 5.3.5a). However, when the 
dye molecules were properly embedded in the seeds of WA6-TA-T, the fluorescence was 
retained, (Fig. 5.3.5b). Also, the normalized fluorescence spectra of the free WA6 dye in ethanol 
and water showed obvious stokes shift of about 18 nm (Fig. 5.3.5c) which was minimized to less 
than 9 nm in the case of WA6-TA-T, (Fig. 5.3.5d). These observations confirm that the 
incorporated dye molecules are inside the silica matrix and can be shielded effectively from the 
outside exposure featuring a higher photo-stability. 
5.3.3.6 LFPs detection using FLSNPs 
Two methods; dusting and SNPs suspensions pipetting were investigated to develop the 
resultant LFPs. 
5.3.3.6.1 Use of FLSNPs suspensions as developing agents for LFPs 
To investigate the binding affinity of FLSNPs to LFPs, suspensions of these particles 
were applied on a glass substrate as shown in Fig. 5.3.7 and Fig. 5.3.8. The nature of the 
precursors in the shell of the SNPs plays an important role in fingerprint detection. Also, the 
photographs for the developed fingerprints using white light source were presented in Fig. 5.3.9. 
When a binary mixture of TEOS and PTEOS used in eight different FLSNPs, clear 
luminescent fingerprint ridges were obtained using CSS setting of the FLS viewed through a 540 
nm long pass filter. The surface of the FLSNPs has been decorated with PTEOS which increases 
the hydrophobic interaction between the phenyl group of PTEOS and the sebaceous secretion in 
the fingerprint residue resulting in enhanced binding and detection of fingerprints. Despite the 
differences in hydrophobicity in the used fluorescent reporter, the efficiency of these 
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hydrophobic FLNPs as developing agents able to produce clear luminescent fingerprints with 
high contrast was observed and attributed to the PTEOS-modified hydrophobic surface.  
When the surface was not coated with PTEOS in the case of F-T-T, FITC-T-T, WA6-T-T 
and WA6-TA-T, weak luminescence and poor contrast were obtained as shown in Fig. 5.3.8 a&e 
and Fig. 5.3.7a&e, respectively. Therefore, using these particles as developing agents for 
fingerprint detection is not practical.  
Friction ridge features of a fingerprint have been classified into three levels of detail 35.  
First- level detail describes the overall ridge pattern such as fingerprint orientation and ridge flow 
direction. The general information obtained from the first-level detail are not decisive. Thus, it 
cannot be used for personal identification. Second-level detail involves ridge formations and 
pattern minutiae such as ridge ending, bifurcation, and dots. Third-level detail includes the 
morphology of a ridge such as width, shape, and pores. Both second and third- level details 
enable identification and fingerprint matching due to the unique individual features. 
The typical features of second-level detail of fingerprint friction ridge developed using 
WA6-TP-TP are shown in Fig. 5.3.7c, where well-defined ridges of fingerprint were observed 
displaying the sweat pores of the fingerprint, which is the typical feature of tertiary structure of 
fingerprint.  
5.3.3.6.2 Use of FLSNPs powders as developing agents for LFPs on various substrates 
The colloidal particle suspension method is not very suitable to be used in actual crime 
scenes due to its tedious procedure and low efficiency 19. Subsequently, powder method was 
examined using F-TA-TP as developing agents to test the contrast and selectivity in LFPs 
detection. Five different substrate surfaces were tested in this investigation, namely; glass slide, 
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petri dish (polystyrene), aluminum foil, common white paper, and the white area of currency 
paper and the results are presented in Fig. 5.3.10 (CSS) and Fig. 5.3.11 (CSS and white light).  
As shown in Fig. 5.3.10 and Fig. 5.3.12, F-TA-TP as developing agents can realize the 
LFPs development on the surface of nonporous substrates such as glass slides (Fig. 5.3.10a), 
common transparent polystyrene petri-dish (Fig. 5.3.10b), regular aluminum foil (Fig. 5.3.10c) as 
well as a porous surface such regular white papers (Fig. 5.3.10d). No clear contrast was obtained 
when F-TA-TP was tried to detect the details of LFPs on the surface of currency paper, (Fig. 
5.3.10e). However, the margins of the LFPs and some details can still be observed. 
5.3.3.7 Colloidal Stability 
The aqueous dispersion stability of five SNPs namely; T-T, T-TP, TP-TP, TA-T, and TA-
TP, has been investigated over seven days. 0.5 mg/mL suspensions in deionized water from each 
SNPs type were used in this study. As shown in Fig. 5.3.13a&b, the five SNPs showed good 
suspension stability for 1 and 3 hours, respectively. After two days (Fig. 5.3.13c) and seven days 
(Fig. 5.3.13d), only the hydrophobic NPs; T-TP, TP-TP, and TA-TP remained as one phase 
showing a good colloidal stability whereas T-T and TA-T, which were not modified with 
PTEOS, started to show phase separation. Moreover, the DLS measurements of the 
hydrodynamic diameter of the PTEOS-modified SNPs did not show any significant increase in 
size after seven days whereas T-T and TA-T showed an obvious increase in size, Table 5.3.3. 
These results suggest the potential of using these hydrophobic NPs at low concentrations for bio-
related applications 49. 
5.3.3.8 Protein adsorption 
The adsorption of proteins to surfaces involves electrostatic interactions and Van der 
Waals binding forces 50. Therefore proteins tend to adsorb more strongly to nonpolar than to 
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polar, and to charged than to neutral substrates 51. Bare unmodified SNPs with rich surface 
silanol groups possess negatively charged surface potential is expected to show nonspecific 
binding to HSA and IgG. Hence, in this study, WA6-T-T (-34.1 ± 8.1 mV) with comparable 
charge to bare SNPs (Table 5.3.3) and WA6-T-TP (-26.1 ± 7.5 mV) with the surface coated with 
PTEOS of a lower charge were tested for reducing nonspecific protein adsorption. To evaluate 
the efficiency of this modification in minimizing nonspecific protein adsorption, the amount of 
HSA or IgG adsorbed on the surface of WA6-T-T, WA6-T-TP and bare SNPs were quantified. 
The adsorption efficiency (%) of HSA decreased from 2.64 wt.% for bare SNPs to 0.0 wt.% for 
WA6-T-T and WA6-T-TP whereas for IgG it dropped from 7.55 wt.% of bare SNPs to 1.36% 
and 3.77% wt.% for WA6-T-T and WA6-T-TP, respectively (Fig. 5.3.14). These results indicate 
the reduced non-specific protein binding of the tested FLSNPs and promising potential for 
biological applications. 
5.3.3.9 Hemolysis study 
In-vivo applications of bare SNPs for drug delivery are highly limited by their 
nonnegligible hemolytic effect 46 which is caused by the generation of reactive oxygen species 
induced by the surface of silica, denaturation of membrane proteins, and the high binding affinity 
of the tetra-alkyl ammonium groups that are abundant in the membranes of RBCs for the silanol 
groups 52. To assess the effect of surface modification and hydrophobization on the 
hemocompatibility of FLSNPs, hemolytic effect of samples to RBCs was investigated. Five 
SNPs with different composition namely, WA6-T-T, WA6-T-TP, WA6-TP-TP, WA6-TA-T, and 
WA6-TA-TP were compared with the same concentration of unmodified bare SNPs in this study. 
In addition, to quantify the extent of hemolysis, concentration of hemoglobin released in the 
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supernatant was measured by UV absorbance of the supernatant at 538 nm. As shown in Fig. 
5.3.15.  
In the chosen concentration 2 mg/mL, none of the selected FLSNPs suspension showed 
obvious hemolysis after 1.5 h in comparison with the bare SNPs, which caused a hemolysis of 
14.02%, where the three hydrophobic FLSNPs WA6-T-TP, WA6-TP-TP and WA6-TA-TP 
resulted in very low hemolysis of 1.29, 1.02, and 1.13%, respectively. Also, WA6-T-T and 
WA6-TA-T resulted in a low hemolysis of 2.06 and 1.61%, respectively. The obtained results 
indicated that increasing the surface hydrophobicity of the FLSNPs resulted in very good 
hemocompatibility at concentrations up to 2mg/mL. For FLSNPs modified with PTEOS, the 
interactions between the exposed silanol groups and the membrane surface of RBCs are 
minimized, thereby reducing hemolytic effects.  
 
 
 
Scheme 5.3.1 Synthesis of WA6 
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Table 5.3.1 Used fluorophores and composition for the core and shell of the labeled SNPs and 
their labeling efficiencies 
FLSNPs Fluorophore Core composition Shell composition 
Labelling  
efficiencies (%) 
F-T-T Fluorescein TEOS TEOS 15.8 
F-T-TP Fluorescein TEOS TEOS + PTEOS 44.9 
F-TP-TP Fluorescein TEOS + PTEOS TEOS + PTEOS 77.6 
F-TA-TP Fluorescein TEOS + APTES TEOS + PTEOS 79.2 
FITC-T-T FITC TEOS TEOS 8.0 
FITC-T-TP FITC TEOS TEOS + PTEOS 74.5 
FITC-TP-TP FITC TEOS + PTEOS TEOS + PTEOS 53.6 
WA6-T-T WA6 TEOS TEOS 16.3 
WA6-T-TP WA6 TEOS TEOS + PTEOS 63.9 
WA6-TP-TP WA6 TEOS + PTEOS TEOS + PTEOS 72.4 
WA6-TA-T WA6 TEOS + APTES TEOS  37.4 
WA6-TA-TP WA6 TEOS + APTES TEOS + PTEOS 78.4 
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Table 5.3.2 Diameter determined by TEM and DLS, polydispersity index (PDI), zeta potential of 
0.1 mg/ml labeled SNPs in ethanol 
FLSNPs 
Diameter (SEM) 
(nm) 
Diameter (DLS) 
(nm) 
PDI 
WA6-T-T 1511.0 ± 354.8* 1096.0 ± 40.9 0.999 
WA6-T-TP 33.4 ± 5.9* 217.1 ± 34.9 0.903 
WA6-TP-TP 42.2 ± 10.8* 138.2 ± 11.4 0.774 
WA6-TA-T 1428.26 ± 116.3* 994.2 ± 177.2 0.449 
WA6-TA-TP 39.8 ± 9.4* 196.6± 28.5 0.724 
                     * SD where n=21 
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Table 5.3.3 Diameter determined by DLS, polydispersity index (PDI), zeta potential of 0.1 
mg/ml unlabeled SNPs in water 
 FLSNPs Diameter (DLS) (nm) PDI Zeta potential (mV) 
 T seeds 13.1 ± 2.3 0.317  
TP seeds 219.5 ± 68.4 0.557  
TA seeds 396.1 ± 55.5 1.000  
F
re
sh
 s
a
m
p
le
s 
T-T 911.9 ± 177.6 0.672 -34.1 ± 8.1 
T-TP 385.2 ± 146.6 0.328 -26.1 ± 7.5 
TP-TP 471.8 ± 280.6 0.291 -28.6 ± 6.0 
TA-T 1051 ± 373.6 0.365 -21.9 ± 6.6 
TA-TP 465.1 ± 284.5 0.363 -24.2 ± 8.2 
T-T-1 178.8 ± 49.7 0.473  
A
ft
er
 s
ev
en
 d
a
y
s 
T-T 1239.0 ± 341.7 0.278  
T-TP 333.3 ± 135.4 0.281  
TP-TP 392.3 ± 178.7 0.375  
TA-T 1438.0 ± 546.3 0.233  
TA-TP 343.2 ± 155.3 0.430  
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Figure 5.3.1 The structure formulae for (a) fluorescein, (b) FITC, and (c) WA6 as well as (d) 
illustration of core and shell composition of the proposed FLSNP 
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Figure 5.3.2 SEM micrographs of (a) WA6-T-T, (b) WA6-T-TP, (c) WA6-TP-TP, WA6-TA-T 
and (e) WA6-TA-TP 
  
 (a) (b) (c) 
   
(d) (e)  
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Figure 5.3.3 Zeta potential measurements of 0.1 mg/ml SNPs dispersions in deionized water; (a) 
T-T, (b) T-TP, (c) TP-TP, (d) TA-T, and (e) TA-TP 
 
  
360 
 
 
Figure 5.3.4 Dye leakage from nine of the FLSNPs. Fluorescence intensity change of 7.5 mg/mL 
FLSNPs kept at room temperature in dark at λex of 485 nm (a) after 1 hour in a solvent 
composed of ethanol and water in the ratio of (1:1, v/v) or (1:9, v/v), (b) after 24 hours in a 
solvent composed of ethanol and water (1:9, v/v) 
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Figure 5.3.5 Fluorescence spectra for (a) free WA6 dye (b) WA6-TA-T in water, ethanol and 0.1 
M HCl and the normalized fluorescence spectra for (c) free WA6 dye (d) WA6-TA-T in water 
and ethanol, indicating the solvatochromic behavior 
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Figure 5.3.6 Fluorescence spectra for (a) free WA6 dye in water, ethanol, methanol, acetonitrile, 
0.1 M HCl, and 0.1 M NaOH (b) normalized fluorescence spectra for free WA6 dye in water, 
ethanol, methanol, acetonitrile and 0.1 M NaOH (c) normalized fluorescence spectra for free 
WA6 dye in water: ethanol (9:1, v/v) and 0.1M NaOH: ethanol (9:1, v/v), and (d) ) normalized 
fluorescence spectra for WA6-T-TP dye in water: ethanol (9:1, v/v) and 0.1M NaOH: ethanol 
(9:1, v/v), indicating solvatochromic behavior 
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Figure 5.3.7 Fluorescence images of the fingerprints on glass slides developed using 2.5 mg/mL 
FLSNPs suspensions in water: ethanol (9:1, v/v) of (a) WA6-T-T, (b) WA6-T-TP, (c) WA6-TP-
TP, (d) WA6-TA-TP, and (e) WA6-TA-T at CSS FLS setting and emission filter of 540 nm, (II)  
is the magnified part in (I) 
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Figure 5.3.8 Fluorescence images of the fingerprints on glass slides developed using 2.5 mg/mL 
FLSNPs suspensions in water: ethanol (9:1, v/v) of (a) F-T-T, (b) F-T-TP, (c) F-TP-TP, (d) F-
TA-TP, (e) FITC-T-T, (f) FITC-T-TP, (g) FITC-TP-TP, (h) WA6-TA-T, (i) WA6-T-T, (j) WA6-
T-TP, (k) WA6-TP-TP, and (l) WA6-TA-TP at CSS FLS setting and emission filter of 540 nm, 
(II)  is the magnified part in (I)  
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Figure 5.3.9 Images of the fingerprints on glass slides developed using 2.5 mg/mL FLSNPs 
suspensions in water: ethanol (9:1, v/v) for (a) WA6-T-T, (b) WA6-T-TP, (c) WA6-TP-TP, (d) 
WA6-TA-TP, and (e) WA6-TA-T at (I) CSS FLS setting and emission filter of 540 nm, and (II) 
white light source 
 
  
 (a) (b) (c) (d) (e) 
(I) 
     
(II) 
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Figure 5.3.10 Photographs LFPs developed with F-TA-TP powder on different substrates: (a) 
glass slide, (b) petri dish (polystyrene), (c) aluminum foil, (d) common white paper, and (e) the 
white area of currency paper, (II) is the magnified part in (I) 
  
 (a) (b) (c) (d) (e) 
(I) 
     
(II) 
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Figure 5.3.11 Photographs LFPs developed with F-TA-TP powder on different substrates: (a) 
glass slide, (b) petri dish (polystyrene), (c) aluminum foil, (d) common white paper, and (e) the 
white area of currency paper using (I) CSS FLS setting and emission filter of 540 nm, and (II) 
white light source 
 
 
 (a) (b) (c) (d) (e) 
(I) 
     
(II) 
     
 
368 
 
 
Figure 5.3.12 Photographs LFPs developed with F-TA-TP powder on different substrates: (a) 
glass slide, (b) polystyrene, (c) Aluminum foil, (d) common white paper, and (e) the white area 
of money paper, (II) is the magnified part in (I) 
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Figure 5.3.13 Photographs of sealed vials that show the phase behavior of 0.5 mg/ml SNPs 
dispersions in deionized water at (a) 1 h, (b) 3 h, (c) 2 days, and (d) 7 days 
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Figure 5.3.14 UV–Vis absorbance of (a) HSA and (b) IgG solutions after interaction with WA6-
T-T, WA6-T-TP and bare SNPs suspensions 
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Figure 5.3.15 Hemolysis test results after 1.5 h incubation with 2mg/mL from each of bare 
SNPs, WA6-T-T, WA6-T-TP, WA6-TP-TP, WA6-TA-T, and WA6-TA-TP suspensions: (a) 
optical images and (b) relative hemolysis (%) from measuring the UV absorbance at 538 nm 
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5.4 Conclusions 
Uniform F-SNPs with a small particle size with diameters in the range of 4.1-110.4 nm 
were fabricated using seven different routes and characterized by DLS and SEM and 
spectrofluorometric measurements in section 5.2. In this study, a systematic investigation of 
several factors affecting the efficiency of developing fingerprints was carried out. FITC as a 
representative dye was loaded into the NPs matrix in order to increase the contrast of the 
developed fingerprints while the nanometer-sized particles improve the resolution of the 
developed fingerprints. It was found that the most important factor affecting this application was 
the hydrophobic nature of the F-SNPs. This can be obtained by using a mixture of TEOS and 
PTEOS alkoxyilane precursors during the formation of the NPs. This allowed proper loading of 
the used hydrophobic fluorophore and at the same time increased the binding affinity to 
hydrophobic components of the fingerprints. The obtained results indicated that the developed 
NPs are effective in fingerprint detection when the surface is modified with functional groups 
have the potential to react particularly with the most abundant components present in the 
fingerprint residue and not with the substrate. Therefore, FCTPS, FCTPS-RM, and FDTPS are 
considered good fingerprints developing agents as they developed clear luminescent fingerprints 
with good contrast. Both Stöber and WORM methods can be used for F-SNPs synthesis. 
However, Stöber method is simpler and more cost-effective. Moreover, FITC can be non-
covalently or covalently encapsulated after being conjugated with APTES into the silica matrix 
with efficient fingerprints detection results obtained. However, the FCA covalently bonded-SNPs 
are more stable and show no dye leakage. In addition, although the less hydrophobic F-SNPs 
were coated on the surface with PVP to increase the binding affinity to fingerprints, they did not 
result in any enhancement effect on fingerprints development. Thus, these systematic 
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investigations demonstrate the features that the dye-encapsulated NPs should hold in order to be 
utilized as reliable developing agents for fingerprints forensic applications. This insight may be 
applied to the preparation of a range of stable dye covalently or non-covalently loaded-NPs. In 
addition, a major understanding of these factors will provide the elemental basis for the effective 
utilization of similar dye-encapsulated NPs in other fields such as nanomedicine, tissue imaging, 
drug delivery and theranostics.  
On the basis of the previously reported basic amino acids-catalyzed approaches for 
preparing silica nanoparticles 6-8, the work presented in section 5.3 has demonstrated that the dye 
encapsulation efficiency and other photophysical properties of the FLSNPs intrinsically depend 
on the applied synthesis route and on the composition of the core-shell structures. In this study, 
an amino acid-catalyzed seed regrowth method was used for the synthesis of twelve FLSNPs 
with controllable size and tunable hydrophobicity for both the core and shell of the SNPs. The 
mean diameters of the hydrophobic FLSNPs were between 33.4±5.9 and 42.2±10.8 nm as shown 
by the SEM measurements. The obtained results clearly highlight the advantages of surface 
hydrophobization for clear visualization of LFPs, broadly similar to what was observed from 
reported doped hydrophobic SNPs 39. With maximizing the non-covalent interactions between 
the core of the SNPs and dye molecules, as in the case of F-TA-TP, even dyes of low 
hydrophobicity such as fluorescein and WA6 were used successfully in developing LFPs. 
Moreover, high dye encapsulation efficiency, high fluorescence intensity, enhanced stability 
against dye leaking were obtained, for example, WA6-TA-T, where the composition of both the 
core and the shell of the FLSNPs was made suitable for achieving strong non-covalent 
interactions with the dye molecules. Furthermore, the selected FLSNPs had superior 
hemocompatibility in comparison with bare silica nanoparticles in terms of minimizing the non-
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specific binding with plasma proteins and decreasing the hemolysis rates. On the other hand, 
dyes with alkene side chain such as WA6 have the potential to be covalently copolymerized into 
the silica matrix in order to achieve higher stability instead of the commonly used APTES-
conjugation route, a feature similar to those reported about several other silane-modified organic 
dye molecules 53. Moreover, it is reported that the globular and less ordered hydrophobic 
materials have lower hemolytic effects compared with the ordered structures which match the 
obtained hemocompatibility results presented in this work 54.  
Finally, the modified hydrophobic nanoparticles developed here have a great potential to 
impact many bio-related and diagnostic applications such as immunoassays and cell imaging 
purposes 54. 
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APPENDIX 
1H NMR, and HRMS Spectra 
 
 
 
LC-MS ion chromatograms for (a) intact AZL (b) acid induced degradation products of AZL. 
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1HNMR spectra (400 MHz, DMSO-d6) for (a) intact AZL (b) acid induced degradation products 
of AZL. 
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LC-MS ion chromatograms for (a) intact CLT and (b) alkaline induced degradation products of 
CLT. 
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1HNMR spectra (400 MHz, DMSO-d6) for (a) intact CLT (b) alkaline induced degradation 
products of CLT. 
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1H NMR spectrum ((400 MHz, CDCl3) for L-ACM 
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MS for L-ACM 
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1H NMR spectrum for CYS-ACM in DMSO-d6 using a 400 MHz Bruker instrument  
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The 1H NMR spectra for (a) WA6 and (b) FITC in DMSO-d6 using a 400 MHz Bruker 
instrument. 1H NMR δ 1.22 (t, 2H), 1.35 (q, 2H), 5.1 (m, 1H), 5.77 (t, 2H), 6.55 (m, 9H), 6.87 (t, 
1H), 6.95 (m, 2H) and 10.12 (s, 1H). 77% yield 
 
 
